image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
9820065eda8d5d15b5cfa59ee2ad908759af16238671c9e8f42f052ed98c42c0.png
|
complex
|
<table><tr><td></td><td colspan="2">Age group, years</td></tr><tr><td>Demographics</td><td>< 65</td><td>≥65</td></tr><tr><td>Participants, <i>n</i></td><td>9,883</td><td>3,566</td></tr><tr><td>Person-years,</td><td>124,466</td><td>50,269</td></tr><tr><td>Deaths (all causes), <i>n</i></td><td>460</td><td>1,379</td></tr><tr><td>Deaths (CVD), <i>n </i>(% of all deaths)</td><td>119 (26)</td><td>592 (43)</td></tr><tr><td>Mean age at baseline, years (± SD)</td><td>45.8 (11.3)</td><td>73.1 (6.1)</td></tr><tr><td>Mean body mass index, kg/m<sup>2 </sup>(± SD)</td><td>29.5 (4.0)</td><td>29.0 (3.9)</td></tr><tr><td>Mean waist circumference, cm (± SD)</td><td>95.3 (10.0)</td><td>95.1 (10.3)</td></tr><tr><td>Mean SBP, mmHg (± SD)</td><td>142.5 (17.3)</td><td>160.9 (22.3)</td></tr><tr><td>Mean DBP, mmHg (± SD)</td><td>85.1 (11.0)</td><td>87.7 (12.9)</td></tr><tr><td>Mean serum triglycerides, mmol/L (± SD)</td><td>2.8 (1.4)</td><td>2.6 (1.1)</td></tr><tr><td>Mean serum glucose, mmol/L (± SD)</td><td>5.6 (1.7)</td><td>6.3 (2.4)</td></tr><tr><td>Mean serum HDL, mmol/L (± SD)</td><td>1.1 (0.3)</td><td>1.2 (0.3)</td></tr><tr><td>Mean percentage of people taking diabetes medication (± SD)</td><td>3.8 (0.04)</td><td>12.6 (0.1)</td></tr><tr><td>Mean percentage of people taking BP medication (± SD)</td><td>11.5 (0.1)</td><td>33 (0.3)</td></tr><tr><td>Mean percentage of current smokers (± SD)</td><td>32.2 (0.3)</td><td>15.9 (0.1)</td></tr><tr><td>Mean percentage of sedentary occupational work (± SD)</td><td>28 (0.2)</td><td>45 (0.3)</td></tr><tr><td>Mean percentage of college or university education (± SD)</td><td>18 (0.2)</td><td>5 (0.05)</td></tr><tr><td>Participants' PA levels<sup>b</sup>, %</td><td></td><td></td></tr><tr><td> Inactive</td><td>9</td><td>19</td></tr><tr><td> Low</td><td>38</td><td>39</td></tr><tr><td> Moderate</td><td>27</td><td>29</td></tr><tr><td> High</td><td>26</td><td>12</td></tr></table>
|
92a1cd8de1330547d0811534dcb39161ce76119ef085e101fb53a9b0057717b8.png
|
complex
|
<table><tr><td></td><td colspan="3">History of diagnosed diabetes</td><td>P-value*</td></tr><tr><td></td><td>Overall</td><td>No</td><td>Yes</td><td></td></tr><tr><td>N</td><td>1873</td><td>1587</td><td>286</td><td></td></tr><tr><td>Age (years; mean ± SE)</td><td>73.0 ± 0.14</td><td>73.0 ± 0.15</td><td>73.1 ± 0.36</td><td>0.943</td></tr><tr><td>Sex (% female)</td><td>48.7</td><td>48.7</td><td>48.6</td><td>0.973</td></tr><tr><td>Education (years; mean ± SE)</td><td>4.9 ± 0.11</td><td>4.9 ± 0.12</td><td>5.1 ± 0.30</td><td>0.535</td></tr><tr><td>Marital status (%married or living with partner)</td><td>66.8</td><td>67.2</td><td>64.3</td><td>0.338</td></tr><tr><td>Smoking status (%current)</td><td>19.4</td><td>19.7</td><td>17.8</td><td>0.454</td></tr><tr><td colspan="5">Functional status (%)</td></tr><tr><td>High</td><td>47.7</td><td>50.5</td><td>32.5</td><td>< 0.001</td></tr><tr><td>Middle</td><td>44.6</td><td>43.0</td><td>53.8</td><td></td></tr><tr><td>Low</td><td>7.6</td><td>6.6</td><td>13.6</td><td></td></tr><tr><td>Heart disease (% yes)</td><td>23.4</td><td>21.6</td><td>32.9</td><td>< 0.001</td></tr><tr><td>Hypertension (% yes)</td><td>39.6</td><td>37.3</td><td>52.3</td><td>< 0.001</td></tr><tr><td>Stroke (% yes)</td><td>7.6</td><td>6.4</td><td>14.4</td><td>< 0.001</td></tr><tr><td colspan="5">Number of other conditions<sup>† </sup>(%)</td></tr><tr><td>0</td><td>49.6</td><td>52.1</td><td>35.3</td><td>< 0.001</td></tr><tr><td>1</td><td>32.8</td><td>32.4</td><td>34.5</td><td></td></tr><tr><td>≥ 2</td><td>17.7</td><td>15.4</td><td>30.2</td><td></td></tr><tr><td>Duration of diabetes (years; mean ± SE)</td><td></td><td></td><td>10.0 ± 0.55</td><td>-</td></tr><tr><td>Use Insulin (% yes)</td><td></td><td></td><td>19.7</td><td>-</td></tr></table>
|
2b1018703d0ac4c59832b7632be2138f8d7ce8768efad00ffb94788c3662cd54.png
|
simple
|
<table><tr><td></td><td>Masamoto et al. [5]</td><td>Lee et al. [6]</td><td>Matsuda et al. [7]</td><td>Oswal and Agarwal [8]</td><td>Ville et al. [11]</td><td>Ville et al. [11]</td><td>Present case</td></tr><tr><td>Warfarin dose (mg/day)</td><td>3.5</td><td>6–7</td><td>NA</td><td>NA</td><td>3–6</td><td>5–6</td><td>3–4.5</td></tr><tr><td>Start of warfarin (weeks)</td><td>20</td><td>14</td><td>14</td><td>24</td><td>26</td><td>15</td><td>12</td></tr><tr><td>PT (INR)</td><td>2.7–2.9</td><td>2.2–3.0</td><td>NA</td><td>NA</td><td>1.7–2.5</td><td>0.7–1.9</td><td>1.5–2.0</td></tr><tr><td>GA at diagnosis (weeks)</td><td>23</td><td>23</td><td>31</td><td>24</td><td>32</td><td>29</td><td>31</td></tr><tr><td>Hemorrhage site</td><td>Subdural</td><td>Subdural</td><td>Subdural</td><td>Subdural</td><td>Intraventricular</td><td>Intraventricular</td><td>Subdural</td></tr><tr><td>Delivery (weeks)</td><td>23</td><td>25</td><td>31</td><td>24</td><td>36</td><td>29</td><td>36</td></tr><tr><td>Fetal outcome</td><td>Stillbirth</td><td>Neonatal death</td><td>Alive</td><td>Termination</td><td>Stillbirth</td><td>Stillbirth</td><td>Alive</td></tr></table>
|
dff4182080e903cd0468b20e263363ae25b95ea273975bc3e45eb8f30c36e274.png
|
complex
|
<table><tr><td></td><td>Crude immediate brush material [21]</td><td>2-step ALI [5, 8, 22, 23]</td><td>2-step suspension [2, 3, 24, 25]</td><td>3D-E spheroids [9, 13]</td></tr><tr><td colspan="5">Characteristics</td></tr><tr><td> Sampling of cells</td><td>Nasal brush biopsy</td><td>Nasal brush biopsy</td><td>Removal of nasal polyp or nasal forceps biopsy</td><td>Removal of nasal polyp/nasal brush biopsy</td></tr><tr><td> Anesthesia required</td><td>No</td><td>No</td><td>Yes</td><td>Yes (polyp removal)No (nasal brush)</td></tr><tr><td> Preparation steps</td><td>Cell collectionCell dispersion</td><td>Cell collectionCell dispersionCell proliferation Ciliary regeneration</td><td>Tissue washingEnzymatic tissue digestionCell dispersionCell proliferationCiliary regeneration</td><td>Cell collectionCell dispersionSpheroid formation</td></tr><tr><td> Longevity of cells/culture</td><td>1–3 days</td><td>>1 month</td><td>>1 month</td><td>At least 16 days</td></tr><tr><td> Time from sampling to analysis</td><td>Immediately</td><td>4 weeks</td><td>4–6 weeks</td><td>24 h</td></tr><tr><td> Materials and reagents</td><td>Falcon tubeNaClGlass slide</td><td>Falcon tubeCulture mediumT25/75 flask24-well plateTranswell insert filtersD-PBSTrypsin–EDTATrypsin-inhibitorCentrifugeCO<sub>2</sub> incubator</td><td>Falcon tubePronaseCulture mediumPlastic plateCollagen gelCollagenaseT25/75 flaskGyrotori shakerCO<sub>2</sub> incubator</td><td>Falcon tubeCulture medium24-well plateCO<sub>2</sub> incubator</td></tr><tr><td> Complexity</td><td>Simple</td><td>Complex</td><td>Complex</td><td>Simple</td></tr><tr><td> Terminally differentiated cells</td><td>Yes</td><td>No</td><td>No</td><td>Yes</td></tr><tr><td> Cell divisions</td><td>No</td><td>Yes</td><td>Yes</td><td>No</td></tr><tr><td> Ciliogenesis</td><td>No</td><td>Yes</td><td>Yes</td><td>No</td></tr><tr><td colspan="5">Known applications</td></tr><tr><td> Diagnostics</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td> Study of transport mechanisms</td><td>No</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td> Study of ciliary physiology</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td colspan="5">Potential applications</td></tr><tr><td> Study of drug effects</td><td>No</td><td>Yes</td><td>Yes</td><td>Yes</td></tr></table>
|
0b282c74f285f8b64504aa6137c41fc1e7810f7a20618213c7afc4d08e1fc8d3.png
|
simple
|
<table><tr><td>Analysis</td><td>Description of measurement of benefits/effects</td><td>Hypothetical example applied to simulation</td></tr><tr><td>Cost minimisation analysis (CMA)</td><td>A comparison of costs when the effects are considered equal in all respects</td><td>Measurement of the simulation education method versus an alternative education method produced equivalent learning outcomes within a meaningful threshold; however, the simulation method is less costly.</td></tr><tr><td>Cost-effectiveness analysis (CEA)</td><td>Benefits/effects are measured in natural units (e.g. students educated)</td><td>Measurement of the simulation education method resulted in less clinical errors by the learner than the alternative education method.</td></tr><tr><td>Cost utility analysis (CUA)</td><td>Benefits/effects measured in ‘utility’ units—e.g. a measure of satisfaction derived from consumption/attainment of benefit</td><td>Measurement of the simulation education method resulted in higher levels of patient satisfaction with their care compared to the alternative education method.</td></tr><tr><td>Cost benefit analysis (CBA)</td><td>Benefits monetized</td><td>The simulation education method was measured to be of higher value (willingness to pay) by the learners when compared to the alternative education method.</td></tr></table>
|
bbe9aaf176d13f713ba9904e9a6397ad65d6772bce6fae9b0e1b85c92fbe6e33.png
|
simple
|
<table><tr><td>nFiles</td><td>Total</td><td><i>gql</i> = 0</td><td><i>gql</i> = 3</td></tr><tr><td>2</td><td>706</td><td>378</td><td>92</td></tr><tr><td>4</td><td>1076</td><td>666</td><td>105</td></tr><tr><td>8</td><td>1708</td><td>1179</td><td>124</td></tr><tr><td>12</td><td>2270</td><td>1659</td><td>137</td></tr></table>
|
34635c3952b3d13117b23ce2b5c3bd5efaabe9e0a59c619b4913eeb97c1325db.png
|
complex
|
<table><tr><td>Variable</td><td colspan="6">Solutions for the fixed effects using the mixed effect model</td><td>p-value</td></tr><tr><td> </td><td>Intercept</td><td>cos FA</td><td>cos<sup>2</sup>FA</td><td>cos<sup>3</sup>FA</td><td>Flexion/ extension</td><td>Natural/ TKA</td><td>Natural/ TKA</td></tr><tr><td>Quadriceps load</td><td>52.88</td><td>−7.51</td><td>+0.23</td><td>−0.0011</td><td>+118.91</td><td>+3.79</td><td>0.28</td></tr><tr><td>Tibial rotation</td><td>−1.00</td><td>+0.067</td><td>−0.0011</td><td>+4.75e-6</td><td>−0.38</td><td>+2.66</td><td>0.001</td></tr><tr><td>Peak pressure</td><td>0.89</td><td>−0.058</td><td>0.0018</td><td>−8.83e-6</td><td>+0.45</td><td>+2.66</td><td>0.004</td></tr><tr><td>Peak pressure (ridge)</td><td>0.99</td><td>+0.063</td><td>0.0021</td><td>−0.00001</td><td>+0.48</td><td>−0.61</td><td>0.0001</td></tr><tr><td>Peak pressure (medial)</td><td>−0.10</td><td>−0.015</td><td>+0.00089</td><td>−4.00e-6</td><td>+0.27</td><td>−1.24</td><td>0.064</td></tr><tr><td>Peak pressure (lateral)</td><td>0.42</td><td>−0.032</td><td>+0.0011</td><td>−5.09e-6</td><td>+0.30</td><td>−0.16</td><td>0.011</td></tr><tr><td>Contact area</td><td>285.99</td><td>−0.30</td><td>+0.0097</td><td>-0.00014</td><td>+7.36</td><td>−0.14</td><td><0.0001</td></tr><tr><td>Proximalization</td><td>8.55</td><td>+0.31</td><td>−0.0058</td><td> + 0.000019</td><td>+2.51</td><td>+3.58</td><td><0.0001</td></tr></table>
|
b829f0df27ccf1e8ed67b1002bd922fa1ee02343036b82adb09397076116bd8b.png
|
simple
|
<table><tr><td>Preferred strategy</td><td>Patient characteristics</td></tr><tr><td>Invasive</td><td>Recurrent angina or ischaemia at rest or with low-level activities despite intensive medical therapy</td></tr><tr><td></td><td>Elevated cardiac biomarkers (troponin I or T)</td></tr><tr><td></td><td>New or presumably new ST-segment depression</td></tr><tr><td></td><td>Signs or symptoms of heart failure or new or worsening mitral regurgitation</td></tr><tr><td></td><td>High-risk findings from non-invasive testing</td></tr><tr><td></td><td>Haemodynamic instability</td></tr><tr><td></td><td>Sustained ventricular tachycardia</td></tr><tr><td></td><td>PCI within 6 months</td></tr><tr><td></td><td>Prior CABG</td></tr><tr><td></td><td>High-risk score (e.g. TIMI, GRACE)</td></tr><tr><td></td><td>Reduced left-ventricular function (LVEF < 40%)</td></tr><tr><td>Conservative</td><td>Low-risk score (e.g. TIMI, GRACE)</td></tr><tr><td></td><td>Patient or physician preference in the absence of high-risk features</td></tr></table>
|
8585424b33aa4af465be726a8a5225aebb337680a49edc92f94c707b057f3e11.png
|
complex
|
<table><tr><td>DemographicCharacteristics</td><td colspan="2">Insured (n = 2080)</td><td colspan="2">Uninsured (n = 2554)</td><td colspan="2">Total (n = 4634)</td></tr><tr><td></td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td></tr><tr><td>Sex</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Male</td><td>883</td><td>42.45</td><td>1005</td><td>39.35</td><td>1888</td><td>40.74</td></tr><tr><td>Female</td><td>1197</td><td>57.55</td><td>1549</td><td>60.65</td><td>2746</td><td>59.26</td></tr><tr><td><i>p </i>= 0.033 <i>χ</i><sup>2 </sup>= 4.569</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Age</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>18--24</td><td>889</td><td>42.74</td><td>1487</td><td>58.22</td><td>2376</td><td>51.27</td></tr><tr><td>25--34</td><td>872</td><td>41.92</td><td>784</td><td>30.70</td><td>1656</td><td>35.74</td></tr><tr><td>35+</td><td>319</td><td>15.34</td><td>283</td><td>11.08</td><td>598</td><td>12.99</td></tr><tr><td><i>p </i>= 0.000 <i>χ</i><sup>2 </sup>= 110.003</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Education</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Illiterate</td><td>8</td><td>0.38</td><td>25</td><td>0.98</td><td>33</td><td>0.71</td></tr><tr><td>Primary</td><td>66</td><td>3.17</td><td>94</td><td>3.68</td><td>160</td><td>3.43</td></tr><tr><td>Junior high school</td><td>1056</td><td>50.77</td><td>1568</td><td>61.39</td><td>2624</td><td>56.63</td></tr><tr><td>Senior high school</td><td>705</td><td>33.89</td><td>722</td><td>28.27</td><td>1427</td><td>30.79</td></tr><tr><td>College</td><td>192</td><td>9.23</td><td>116</td><td>4.54</td><td>276</td><td>6.65</td></tr><tr><td>University or above</td><td>53</td><td>2.55</td><td>29</td><td>1.14</td><td>82</td><td>1.77</td></tr><tr><td><i>p </i>= 0.000 <i>χ</i><sup>2 </sup>= 92.019</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Marital status</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Single</td><td>708</td><td>34.03</td><td>1349</td><td>52.81</td><td>1847</td><td>39.86</td></tr><tr><td>Married</td><td>1364</td><td>65.60</td><td>1081</td><td>42.33</td><td>2772</td><td>59.82</td></tr><tr><td>Others</td><td>19</td><td>0.91</td><td>124</td><td>4.86</td><td>15</td><td>0.32</td></tr><tr><td><i>p </i>= 0.000 <i>χ</i><sup>2 </sup>= 266.095</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Occupation</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Administrative</td><td>341</td><td>16.39</td><td>327</td><td>12.80</td><td>668</td><td>14.42</td></tr><tr><td>Clerk/technician</td><td>591</td><td>28.41</td><td>638</td><td>24.98</td><td>1229</td><td>26.52</td></tr><tr><td>General worker</td><td>1051</td><td>50.53</td><td>1390</td><td>54.42</td><td>2441</td><td>52.68</td></tr><tr><td>Others</td><td>97</td><td>4.66</td><td>199</td><td>7.79</td><td>296</td><td>6.39</td></tr><tr><td><i>p </i>= 0.000 <i>χ</i><sup>2 </sup>= 36.214</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Monthly Income (CNY)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>< 500</td><td>26</td><td>1.25</td><td>108</td><td>4.23</td><td>134</td><td>2.89</td></tr><tr><td>500--999</td><td>965</td><td>46.39</td><td>1433</td><td>56.11</td><td>2398</td><td>51.75</td></tr><tr><td>1000-1499</td><td>684</td><td>32.88</td><td>611</td><td>23.92</td><td>1295</td><td>27.95</td></tr><tr><td>1500-1999</td><td>206</td><td>9.90</td><td>202</td><td>7.91</td><td>408</td><td>8.80</td></tr><tr><td>2000+</td><td>199</td><td>9.57</td><td>200</td><td>7.83</td><td>399</td><td>8.61</td></tr><tr><td><i>p </i>= 0.000 <i>χ</i><sup>2 </sup>= 98.215</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
|
735f36fe2598ad5614060a44023577ed7871db4b1afc61e7a0d0c2c1813ac2c8.png
|
complex
|
<table><tr><td></td><td></td><td></td><td colspan="2">Nurses</td><td colspan="3">Midwives</td><td></td></tr><tr><td>Baseline inputs</td><td>Doctors</td><td>Clinical officers</td><td>registered</td><td>enrolled</td><td>registered</td><td>enrolled</td><td>direct entry</td><td>Total</td></tr><tr><td colspan="9">Number of staff</td></tr><tr><td> At baseline (2008)<sup>1</sup></td><td>806</td><td>1236</td><td>1453</td><td>5134</td><td>339</td><td>1711</td><td>0</td><td>10 679</td></tr><tr><td> Minimum level required to meet need (same for all years)<sup>2</sup></td><td>1778</td><td>3737</td><td colspan="2">14 053</td><td colspan="3">4751</td><td>24 319</td></tr><tr><td colspan="9">Inflow from training</td></tr><tr><td> Annual training enrolment (# of new students)<sup>3</sup></td><td>74</td><td>155</td><td>660</td><td>423</td><td>136</td><td>173</td><td>174</td><td>1795</td></tr><tr><td> Total years of training required<sup>3</sup></td><td>7</td><td>3</td><td>3</td><td>2</td><td>1</td><td>1</td><td>2</td><td>n/a</td></tr><tr><td> Graduation rate (% of students)<sup>3</sup></td><td>90.0%</td><td>90.0%</td><td>96.7%</td><td>94.3%</td><td>97.1%</td><td>90.7%</td><td>90.0%</td><td>n/a</td></tr><tr><td> Public sector entry rate from training schools (% of graduates)<sup>3,4</sup></td><td>85.3%</td><td>91.4%</td><td>75.5%</td><td>81.4%</td><td>81.4%</td><td>81.4%</td><td>81.4%</td><td>n/a</td></tr><tr><td> Inflow from immigration (# per year)<sup>4</sup></td><td>20</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>20</td></tr><tr><td colspan="9">Outflow from attrition</td></tr><tr><td> Training program requires other professional diploma/degree and work experience before enrolling; or enrols students who leave the public sector workforce before enrolling</td><td>No</td><td>No</td><td>Yes</td><td>No</td><td>Yes</td><td>Yes</td><td>no</td><td>n/a</td></tr><tr><td> If yes, which specific cadre is the feeder cadre for training programs</td><td>n/a</td><td>n/a</td><td>enrolled nurses</td><td>n/a</td><td>registered nurses</td><td>enrolled nurses</td><td>n/a</td><td>n/a</td></tr><tr><td> Percent of enrolling students to which entry barrier applies (% per year)</td><td>n/a</td><td>n/a</td><td>14.89%</td><td>n/a</td><td>100%</td><td>100%</td><td>n/a</td><td>n/a</td></tr><tr><td> Total attrition from cadre (% per year)</td><td>9.80%</td><td>4.48%</td><td>5.30%</td><td>4.48%</td><td>4.48%</td><td>4.48%</td><td>4.48%</td><td>n/a</td></tr><tr><td> <i>Involuntary attrition (% per year) </i>[24,26]</td><td>6.66%</td><td>3.05%</td><td>3.60%</td><td>3.05%</td><td>3.05%</td><td>3.05%</td><td>3.05%</td><td>n/a</td></tr><tr><td> <i>Voluntary attrition (% per year) </i>[25,26]</td><td>3.14%</td><td>1.43%</td><td>1.70%</td><td>1.43%</td><td>1.43%</td><td>1.43%</td><td>1.43%</td><td>n/a</td></tr></table>
|
4acd2668982cdbbf7b3104f65754ab4de03544ec77421516a76714ba1a1d6278.png
|
simple
|
<table><tr><td>Neural-Network Parameters</td><td>Levenberg-Marquardt</td></tr><tr><td>Number of input parameters</td><td>3</td></tr><tr><td>Number of hidden neurons</td><td>9</td></tr><tr><td>Number of output parameters</td><td>1</td></tr><tr><td>Hidden transfer function</td><td>Sigmoidal</td></tr><tr><td>Output transfer function</td><td>linear</td></tr><tr><td>Maximum number of epochs</td><td>1000</td></tr><tr><td>Learning rate</td><td>0.01</td></tr><tr><td>Momentum rate</td><td>0.9</td></tr><tr><td>Stopping gradient</td><td>5.5292 × 10<sup>−8</sup></td></tr><tr><td>MU (momentum )</td><td>1 × 10<sup>−8</sup></td></tr></table>
|
4d306060874f65502e7568065dbdf3453e04f189de58ef44982e5fea63a01f46.png
|
complex
|
<table><tr><td></td><td>OR (95% CI)</td><td>p</td></tr><tr><td>Age, y</td><td>1 (0.96,1.05)</td><td>.926</td></tr><tr><td colspan="3">Gender</td></tr><tr><td>Female</td><td>1</td><td></td></tr><tr><td>Male</td><td>0.3 (0.08,1.15)</td><td>.079</td></tr><tr><td>BMI, kg/m<sup>2</sup></td><td>1.22 (0.99,1.49)</td><td>.056</td></tr><tr><td colspan="3">Smoking</td></tr><tr><td>Never smoked</td><td>1</td><td></td></tr><tr><td>Light smokers</td><td>0.63 (0.12,3.3)</td><td>.589</td></tr><tr><td>Severe smokers</td><td>0.29 (0.05,1.57)</td><td>.150</td></tr><tr><td>Osteoporosis</td><td>NA</td><td></td></tr><tr><td colspan="3">Lumbar lordosis,</td></tr><tr><td><50</td><td>1</td><td></td></tr><tr><td>≥50</td><td>0.14(0.03,0.57)</td><td>.006*</td></tr><tr><td colspan="3">L4-5 spinous height</td></tr><tr><td>≤20</td><td>1</td><td></td></tr><tr><td>20-30</td><td>2.57 (0.25,26.24)</td><td>.426</td></tr><tr><td>30-40</td><td>0.36 (0.08,1.64)</td><td>.186</td></tr><tr><td>≥40</td><td>0.86 (0.12,6.01)</td><td>.877</td></tr><tr><td colspan="3">L4-5 interspinous height</td></tr><tr><td>≤25</td><td>1</td><td></td></tr><tr><td>25-30</td><td>0.38 (0.06,2.53)</td><td>.318</td></tr><tr><td>30-35</td><td>0.52 (0.08,3.36)</td><td>.496</td></tr><tr><td>≥35</td><td>0.86 (0.05,13.48)</td><td>.913</td></tr><tr><td>Operating time, h</td><td>1.46 (0.37,5.82)</td><td>.589</td></tr><tr><td>Blood loss, mL</td><td>1 (1,1.01)</td><td>.261</td></tr><tr><td>Hospital stay, d</td><td>1.25 (0.98,1.6)</td><td>.067</td></tr><tr><td colspan="3">Time wearing brace, mo</td></tr><tr><td>≤3</td><td>1</td><td></td></tr><tr><td>4-5</td><td>2.18 (0.19,25.01)</td><td>.531</td></tr><tr><td>≥6</td><td>1.82 (0.49,6.76)</td><td>.372</td></tr><tr><td colspan="3">Time performing low back muscle exercises, mo</td></tr><tr><td>0</td><td>1</td><td></td></tr><tr><td>≤3</td><td>NA</td><td></td></tr><tr><td>3-6</td><td>0.77 (0.16,3.74)</td><td>.745</td></tr><tr><td>≥7</td><td>1.03 (0.19,5.51)</td><td>.976</td></tr></table>
|
4d7a0b3f6365e9ab854d9f7a36b7f1699065b4be3acec86d74393e2eebca0ee0.png
|
complex
|
<table><tr><td>Variables</td><td>Cases/Controls</td><td colspan="4">Genotypes (Cases/Controls)</td><td><i>p</i><sup>a</sup></td><td>OR (95% CI) <sup>a</sup></td></tr><tr><td></td><td></td><td colspan="2">AA/AG</td><td colspan="2">GG</td><td></td><td></td></tr><tr><td></td><td></td><td><i>n</i></td><td>%</td><td><i>n</i></td><td>%</td><td></td><td></td></tr><tr><td>Total age</td><td>690/675</td><td>610/572</td><td>88.4/84.7</td><td>80/103</td><td>11.6/15.3</td><td>0.041</td><td>0.72 (0.52–0.99)</td></tr><tr><td><68</td><td>275/397</td><td>246/335</td><td>89.4/84.4</td><td>29/62</td><td>10.6/15.6</td><td>0.199</td><td>0.72 (0.43–1.19)</td></tr><tr><td>≥68</td><td>415/278</td><td>364/237</td><td>87.7/85.2</td><td>51/41</td><td>12.3/14.8</td><td>0.379</td><td>0.82 (0.52–1.28)</td></tr><tr><td>Exposure years</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><27</td><td>268/261</td><td>236/216</td><td>88.1/82.8</td><td>32/45</td><td>11.9/17.2</td><td>0.060</td><td>0.62 (0.38–1.02)</td></tr><tr><td>≥27</td><td>422/414</td><td>374/356</td><td>88.6/86.0</td><td>48/58</td><td>11.4/14.0</td><td>0.268</td><td>0.79 (0.52–1.20)</td></tr><tr><td>Smoking status</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Never</td><td>339/351</td><td>302/295</td><td>89.1/84.0</td><td>37/56</td><td>10.9/16.0</td><td>0.049</td><td>0.64 (0.41–1.00)</td></tr><tr><td>Ever</td><td>351/324</td><td>308/277</td><td>87.8/85.5</td><td>43/47</td><td>12.2/14.5</td><td>0.344</td><td>0.81(0.52–1.26)</td></tr><tr><td>Stage</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>I</td><td>413/675</td><td>368/572</td><td>89.1/84.7</td><td>45/103</td><td>10.9/15.3</td><td>0.032</td><td>0.66 (0.45–0.96)</td></tr><tr><td>II</td><td>216/675</td><td>193/572</td><td>89.4/84.7</td><td>23/103</td><td>10.6/15.3</td><td>0.213</td><td>0.73 (0.44–1.20)</td></tr><tr><td>III</td><td>61/675</td><td>49/572</td><td>80.3/84.7</td><td>12/103</td><td>19.7/15.3</td><td>0.188</td><td>1.59 (0.80–3.18)</td></tr></table>
|
4176f9824032af7a8bec747f64d7b5ef53381d41b0ef4eaadc01fb91004ec2b8.png
|
simple
|
<table><tr><td></td><td>Intervention</td><td>Control</td><td></td></tr><tr><td>(n, first year)</td><td>(n = 343)</td><td>(n = 350)</td><td></td></tr><tr><td>(n, second year)</td><td>(n = 330)</td><td>(n = 241)</td><td>P <sup>(2)</sup></td></tr><tr><td>(n, both years)</td><td>(n = 673)</td><td>(n = 591)</td><td></td></tr><tr><td>Received the study leaflet</td><td></td><td></td><td></td></tr><tr><td> First year</td><td>37.0</td><td>20.0</td><td>0.005</td></tr><tr><td> Second year</td><td>48.2</td><td>44.4</td><td>0.748</td></tr><tr><td> Both years</td><td>42.5</td><td>29.9</td><td>0.090</td></tr><tr><td>Seen the study poster</td><td></td><td></td><td></td></tr><tr><td> First year</td><td>27.7</td><td>12.6</td><td>0.016</td></tr><tr><td> Second year</td><td>50.6</td><td>34.4</td><td>0.142</td></tr><tr><td> Both years</td><td>38.9</td><td>21.5</td><td>0.014</td></tr><tr><td>Received the advice on maternal care from township midwives</td><td></td><td></td><td></td></tr><tr><td> First year</td><td>70.0</td><td>49.1</td><td>0.031</td></tr><tr><td> Second year</td><td>63.9</td><td>64.7</td><td>0.942</td></tr><tr><td> Both years</td><td>67.0</td><td>55.5</td><td>0.196</td></tr><tr><td>Received the advices on maternal care from FP worker</td><td></td><td></td><td></td></tr><tr><td> First year</td><td>16.0</td><td>17.4</td><td>0.797</td></tr><tr><td> Second year</td><td>33.3</td><td>37.8</td><td>0.698</td></tr><tr><td> Both years</td><td>24.5</td><td>25.7</td><td>0.858</td></tr></table>
|
7a17a7e5b8c4d3ce01817c7401210f2531f4aa2bd948666a1d8c5035086a9f0f.png
|
complex
|
<table><tr><td>Strain</td><td>Carbon source (50 g/L)</td><td>Consumed carbon source (g/L)</td><td>2,3-Butanediol (g/L)</td><td>Lactate (g/L)</td><td>Acetate (g/L)</td><td>Acetoin (g/L)</td><td>Ethanol (g/L)</td><td>Biomass (g/L)</td><td>2,3-Butanediol yield (g/g)</td></tr><tr><td rowspan="5">KG1</td><td>Glucose</td><td>49.29 ± 0.65</td><td>16.76 ± 0.22</td><td>3.62 ± 0.21</td><td>4.52 ± 0.45</td><td>1.73 ± 0.09</td><td>2.67 ± 0.16</td><td>4.80 ± 0.32</td><td>0.34</td></tr><tr><td>Lactose</td><td>49.39 ± 0.59</td><td>16.28 ± 0.13</td><td>2.95 ± 0.15</td><td>2.98 ± 0.28</td><td>3.26 ± 0.11</td><td>4.16 ± 0.32</td><td>2.80 ± 0.43</td><td>0.33</td></tr><tr><td>Fructose</td><td>44.84 ± 0.61</td><td>14.41 ± 0.16</td><td>2.27 ± 0.12</td><td>2.85 ± 0.33</td><td>2.46 ± 0.13</td><td>3.22 ± 0.25</td><td>4.06 ± 0.52</td><td>0.32</td></tr><tr><td>Galactose</td><td>34.89 ± 0.48</td><td>10.27 ± 0.11</td><td>3.33 ± 0.15</td><td>2.83 ± 0.32</td><td>1.80 ± 0.10</td><td>2.64 ± 0.28</td><td>3.89 ± 0.18</td><td>0.29</td></tr><tr><td>Maltose</td><td>49.20 ± 0.51</td><td>17.30 ± 0.21</td><td>2.03 ± 0.14</td><td>2.79 ± 0.16</td><td>3.56 ± 0.12</td><td>4.45 ± 0.45</td><td>3.87 ± 0.21</td><td>0.35</td></tr><tr><td rowspan="5">Δ<i>adhE</i></td><td>Glucose</td><td>49.27 ± 0.42</td><td>23.65 ± 0.25</td><td>1.35 ± 0.09</td><td>2.05 ± 0.12</td><td>0.60 ± 0.04</td><td>0.52 ± 0.04</td><td>3.95 ± 0.52</td><td>0.48</td></tr><tr><td>Lactose</td><td>17.76 ± 0.25</td><td>8.76 ± 0.12</td><td>1.61 ± 0.11</td><td>3.85 ± 0.42</td><td>2.01 ± 0.08</td><td>0.36 ± 0.06</td><td>1.76 ± 0.35</td><td>0.49</td></tr><tr><td>Fructose</td><td>49.47 ± 0.52</td><td>21.40 ± 0.24</td><td>1.48 ± 0.13</td><td>1.58 ± 0.12</td><td>0.83 ± 0.06</td><td>0.94 ± 0.02</td><td>3.25 ± 0.28</td><td>0.43</td></tr><tr><td>Galactose</td><td>36.35 ± 0.42</td><td>14.05 ± 0.42</td><td>0.73 ± 0.07</td><td>1.96 ± 0.09</td><td>3.70 ± 0.21</td><td>0.65 ± 0.03</td><td>2.99 ± 0.42</td><td>0.39</td></tr><tr><td>Maltose</td><td>49.49 ± 0.47</td><td>18.18 ± 0.23</td><td>2.96 ± 0.10</td><td>1.27 ± 0.08</td><td>4.58 ± 0.24</td><td>0.91 ± 0.08</td><td>4.27 ± 0.25</td><td>0.36</td></tr><tr><td rowspan="4">Δ<i>pta</i></td><td>Glucose</td><td>49.27 ± 0.54</td><td>20.20 ± 0.62</td><td>0.77 ± 0.09</td><td>3.15 ± 0.11</td><td>2.31 ± 0.15</td><td>1.69 ± 0.32</td><td>3.40 ± 0.52</td><td>0.41</td></tr><tr><td>Lactose</td><td>10.10 ± 0.25</td><td>2.98 ± 0.11</td><td>0.96 ± 0.07</td><td>2.01 ± 0.10</td><td>_</td><td>0.30 ± 0.02</td><td>1.01 ± 0.46</td><td>0.30</td></tr><tr><td>Fructose</td><td>49.51 ± 0.55</td><td>18.36 ± 0.32</td><td>1.01 ± 0.10</td><td>2.20 ± 0.09</td><td>2.81 ± 0.11</td><td>1.87 ± 0.14</td><td>2.96 ± 0.26</td><td>0.37</td></tr><tr><td>Galactose</td><td>39.49 ± 0.23</td><td>11.88 ± 0.12</td><td>0.19 ± 0.06</td><td>1.98 ± 0.12</td><td>1.56 ± 0.14</td><td>1.29 ± 0.21</td><td>3.27 ± 0.43</td><td>0.30</td></tr><tr><td> </td><td>Maltose</td><td>40.28 ± 0.54</td><td>14.57 ± 0.24</td><td>4.68 ± 0.08</td><td>2.50 ± 0.14</td><td>1.91 ± 0.12</td><td>3.26 ± 0.33</td><td>3.74 ± 0.44</td><td>0.36</td></tr></table>
|
9d72954e7a027e1b8efd2f20cc8a52f4067f723ccb768001d2c4ad96a3a0ca24.png
|
simple
|
<table><tr><td>Intake</td><td>All dysphagic patients (<i>N</i> = 120)</td><td>Spinal onset dysphagic patients (<i>N</i> = 64)</td><td>Bulbar onset dysphagic patients (<i>N</i> = 56)</td><td><i>p</i></td></tr><tr><td>Normal</td><td>8 (7)</td><td>7 (11)</td><td>1 (2)</td><td>ns</td></tr><tr><td>Postural</td><td>31 (26)</td><td>20 (31)</td><td>11 (20)</td><td>ns</td></tr><tr><td>Syrup/nectar</td><td>13 (11)</td><td>12 (19)</td><td>1(2)</td><td>0.007</td></tr><tr><td>Cream</td><td>43 (36)</td><td>22 (34)</td><td>21 (37)</td><td>ns</td></tr><tr><td>Percutaneous endoscopic gastrostomy</td><td>25 (20)</td><td>3 (5)</td><td>22 (39)</td><td>0.0001</td></tr></table>
|
7a0fc322eebcd1dcc85806766694baa6fd547f790659a5532093757a1bdcb797.png
|
simple
|
<table><tr><td> Frequency (%) questions</td><td>Most often</td><td>sometimes</td><td>Not often</td><td>never</td><td>No answer</td></tr><tr><td>How often are you giving oral health education to school (nurseries) children?</td><td>48 (19.7)</td><td>70 (44.6)</td><td>19 (12.1)</td><td>20 (12.7)</td><td>—</td></tr><tr><td>How do you supervise fluoride mouth wash programme in school?</td><td>31 (19.7)</td><td>54 (34.4)</td><td>20 (12.7)</td><td>52 (33.2)</td><td>10 (6)</td></tr><tr><td>Are you examining mouth and teeth of pregnant women?</td><td>59 (37.6)</td><td>35 (22.3)</td><td>17 (10.8)</td><td>46 (29.3)</td><td>—</td></tr><tr><td>How do you refer the patients to dentist or oral hygienist?</td><td>76 (48.4)</td><td>37 (23.6)</td><td>19 (12.1)</td><td>25 (15.9)</td><td>—</td></tr><tr><td></td><td>yes</td><td>no</td><td>No answer</td><td></td><td></td></tr><tr><td>Have you had any partnership with parents regarding oral health?</td><td>45 (28.7)</td><td>112 (71.3)</td><td>—</td><td></td><td></td></tr><tr><td>Have you had any partnership with other health sector regarding oral health?</td><td>24 (15.3)</td><td>133 (84.7)</td><td>—</td><td></td><td></td></tr><tr><td>Do you know about the water fluoride content of your area?</td><td>26 (16.6)</td><td>107 (68.1)</td><td>24 (15.3)</td><td></td><td></td></tr><tr><td>Do you have any information about oral health status (DMFT/CPITN) of the population under your care?</td><td>55 (35)</td><td>102 (65)</td><td>—</td><td></td><td></td></tr><tr><td>Do you complete the annual oral health report form?</td><td>76 (30.2)</td><td>81 (51.6)</td><td>—</td><td></td><td></td></tr></table>
|
62ba7190502bb253183aee959b1a85279f46b1816ef4573a72c302484255684d.png
|
simple
|
<table><tr><td>Type of study</td><td>Scale of analysis</td><td>Data sources</td><td>Interviewee profiles</td><td>No. of interviewees</td></tr><tr><td>History of free care</td><td>National</td><td>Scientific literature, administrative archives and print media, in-depth semi-structured interviews</td><td>Health, agriculture and education (decision-makers, technicians, implementers)</td><td>n = 28</td></tr><tr><td>Fee exemptions for malaria (prevention, treatment)</td><td>District (Hauts-Bassins region)</td><td>Scientific literature, routine data, in-depth semi-structured interviews, group discussions</td><td>Decision-makers, local actors (NGOs, associations) and healthcare providers</td><td>n = 63</td></tr><tr><td>Antiretroviral drug exemptions for children and adults</td><td>Regional (Centre and Hauts-Bassins regions)</td><td>Scientific literature, routine data, semi-structured interviews</td><td>Institutional decision-makers, local actors (NGOs, associations), healthcare providers, service users</td><td>n = 30</td></tr></table>
|
9ce1535b5d1f1e50aaddc6822eff7279f87618be9d0a93aeb7ed1cab085a1a82.png
|
simple
|
<table><tr><td></td><td>Raw data</td><td></td><td>Clean data</td></tr><tr><td>Number of reads</td><td>300,582</td><td></td><td>23,498</td></tr><tr><td>Number of nucleotides (bp)</td><td>673,594,247</td><td></td><td>20,685,462</td></tr><tr><td>Longest read length (bp)</td><td>11,914</td><td></td><td>2,261</td></tr><tr><td>Mean read length (bp)</td><td>2,241</td><td></td><td>880</td></tr><tr><td>Genome coverage %</td><td></td><td>100%</td><td></td></tr><tr><td>Average depth of coverage</td><td></td><td>132×</td><td></td></tr><tr><td>Number of contigs</td><td></td><td>1</td><td></td></tr><tr><td>Whole cp genome length (bp)</td><td></td><td>156,749</td><td></td></tr><tr><td>Run time</td><td></td><td>45 min×2</td><td></td></tr><tr><td>Total DNA requirements (ng)</td><td></td><td>700</td><td></td></tr></table>
|
5eb8372b0f377eea31653f6ddac26fa31f525cda9f2db5cbf5359515c6081aa5.png
|
simple
|
<table><tr><td>Apicomplexan species </td><td>Positive training set </td><td>Negative training set </td></tr><tr><td><i>B. bovis </i></td><td>18 </td><td>30 </td></tr><tr><td><i>B. microti </i></td><td>23 </td><td>22 </td></tr><tr><td><i>C. hominis </i></td><td>1 </td><td>28 </td></tr><tr><td><i>C. muris </i></td><td>0 </td><td>34 </td></tr><tr><td><i>C. parvum </i></td><td>2 </td><td>33 </td></tr><tr><td><i>E. tenella </i></td><td>30 </td><td>143 </td></tr><tr><td><i>N. caninum </i></td><td>21 </td><td>77 </td></tr><tr><td><i>P. berghei </i></td><td>49 </td><td>94 </td></tr><tr><td><i>P. chabaudi </i></td><td>51 </td><td>98 </td></tr><tr><td><i>P. cynomolgi </i></td><td>31 </td><td>90 </td></tr><tr><td><i>P. falciparum </i></td><td>51 </td><td>132 </td></tr><tr><td><i>P. knowlesi </i></td><td>48 </td><td>90 </td></tr><tr><td><i>P. vivax </i></td><td>51 </td><td>101 </td></tr><tr><td><i>P. yoelii </i></td><td>41 </td><td>87 </td></tr><tr><td><i>T. annulata </i></td><td>23 </td><td>41 </td></tr><tr><td><i>T. parva </i></td><td>25</td><td>61 </td></tr><tr><td><i>T. gondii </i></td><td> 42 </td><td>86 </td></tr></table>
|
99b65e141ee1931e09fe73a54a1412f21e70d01cf5bc27fef16b3df63b04fecc.png
|
simple
|
<table><tr><td>Variables</td><td>N</td><td>Pre-intervention</td><td>Post intervention</td><td>p-value</td></tr><tr><td>TUG (sec)</td><td>37</td><td>9.35 (7.16;12.62)</td><td>8.34 (6.27;11.12)</td><td><0.01</td></tr><tr><td>FTSST (sec)</td><td>37</td><td>16.61 (12.50;20.18)</td><td>12.94 (10.07;15.82)</td><td><0.01</td></tr><tr><td>Total CCQ score</td><td>37</td><td>3.6 (3.2;4.3)</td><td>3.3 (2.5;3.6)</td><td>0.039</td></tr></table>
|
6696bfce8f8f371ac6401c4c51ae2a32b4aed39d3577428def710ae6d2f58169.png
|
complex
|
<table><tr><td rowspan="2">Compound</td><td rowspan="2">Spiked concentration (<i>μ</i>g/mL)</td><td colspan="2">Intraday </td><td colspan="2">Interday </td></tr><tr><td>Detected concentration (<i>μ</i>g/mL)</td><td>RSD<sup>a</sup> (%)</td><td>Detected concentration (<i>μ</i>g/mL)</td><td>RSD (%)</td></tr><tr><td rowspan="3">Gallic acid </td><td>5</td><td>5.03 </td><td>2.57 </td><td>5.30 </td><td>1.77 </td></tr><tr><td>10</td><td>9.64 </td><td>1.80 </td><td>9.59 </td><td>2.02 </td></tr><tr><td>20</td><td>20.17 </td><td>0.42 </td><td>20.13 </td><td>0.58 </td></tr><tr><td rowspan="3">Ellagic acid</td><td>5</td><td>5.34 </td><td>0.78 </td><td>5.45 </td><td>2.80 </td></tr><tr><td>10</td><td>9.67 </td><td>2.14 </td><td>9.88 </td><td>2.26 </td></tr><tr><td>15</td><td>15.11 </td><td>0.95 </td><td>14.93 </td><td>1.27 </td></tr><tr><td rowspan="3">Eugenol </td><td>10</td><td>10.52 </td><td>0.83 </td><td>10.39 </td><td>0.36 </td></tr><tr><td>25</td><td>25.09 </td><td>0.28 </td><td>25.16 </td><td>0.14 </td></tr><tr><td>40</td><td>39.81 </td><td>0.12 </td><td>39.81 </td><td>0.08 </td></tr></table>
|
3c46bbc6b0140e7d4e2eeaab89181c5eebba8044c03338b80eb9c75159a8a35f.png
|
complex
|
<table><tr><td> </td><td>With hardiness n (%)</td><td>No hardiness n (%)</td><td>Total</td><td><i>p </i>value</td></tr><tr><td>With burnout,</td><td>40</td><td>101</td><td>141</td><td rowspan="2"> </td></tr><tr><td>n (%)</td><td>(7.02%)</td><td>(17.72%)</td><td>(24.74%)</td></tr><tr><td>No burnout,</td><td><i>85</i></td><td>344</td><td>429</td><td rowspan="2"> </td></tr><tr><td>n (%)</td><td><i>(14.91%)</i></td><td>(60.35%)</td><td>(75.26%)</td></tr><tr><td>Total,</td><td>125</td><td>445</td><td>570</td><td rowspan="2">0.033</td></tr><tr><td>n (%)</td><td>(21.93%)</td><td>(78.07%)</td><td>(100.00%)</td></tr></table>
|
6d2bca1261ec90e5e7b4c360394f1dbe2cfd81209641856565743a966a20e6cc.png
|
complex
|
<table><tr><td></td><td colspan="2">Naïve</td><td colspan="2">GBT</td></tr><tr><td></td><td>Train Acc</td><td>Test Acc</td><td>Train Acc</td><td>Test Acc</td></tr><tr><td>AP</td><td>97.56 (0.70)</td><td>96.00 (5.62)</td><td>97.56 (0.70)</td><td>96.00 (5.62)</td></tr><tr><td>OVR</td><td>97.85 (0.82)</td><td>96.67 (5.67)</td><td>97.85 (0.82)</td><td>96.67 (5.67)</td></tr><tr><td>Dense</td><td>67.56 (2.88)</td><td>68.00 (16.27)</td><td>97.70 (0.74)</td><td>96.00 (6.44)</td></tr><tr><td>Sparse</td><td>66.67 (1.16)</td><td>66.67 (10.42)</td><td>97.78 (0.92)</td><td>95.33 (5.49)</td></tr></table>
|
89f2eaff48d48a3d2b8f8b35f56097f2e957064d8cd62e30a71e8417f13e6ae4.png
|
complex
|
<table><tr><td>Total</td><td>High-Blimp-1</td><td>Low-Blimp-1</td><td><i>P</i> value</td></tr><tr><td>(<i>n</i> = 24)</td><td>(<i>n</i> = 13)</td><td>(<i>n</i> = 11)</td><td></td></tr><tr><td colspan="4">Age, years</td></tr><tr><td> Median</td><td>61</td><td>59</td><td>0.797</td></tr><tr><td> Range</td><td>23–75</td><td>24–77</td><td></td></tr><tr><td colspan="4">Gender</td></tr><tr><td> Male</td><td>6</td><td>4</td><td>0.628</td></tr><tr><td> Female</td><td>7</td><td>7</td><td></td></tr><tr><td colspan="4">WBC, × 10<sup>9</sup>/l</td></tr><tr><td> Median</td><td>82.9</td><td>24.9</td><td>0.033</td></tr><tr><td> Range</td><td>5.8–364.6</td><td>5.1–87</td><td></td></tr><tr><td colspan="4">PB blast, %</td></tr><tr><td> Median</td><td>68</td><td>73</td><td>0.721</td></tr><tr><td> Range</td><td>1.9–93.8</td><td>18–90.8</td><td></td></tr><tr><td colspan="4">Absolute blast counts, × 10<sup>9</sup>/l</td></tr><tr><td> Median</td><td>41</td><td>16</td><td>0.026</td></tr><tr><td> Range</td><td>0.1–342</td><td>3–47</td><td></td></tr><tr><td colspan="4">BM blast, %</td></tr><tr><td> Median</td><td>60</td><td>64.5</td><td>0.626</td></tr><tr><td> Range</td><td>1.5–88</td><td>34.5–79</td><td></td></tr><tr><td colspan="4">Cytogenetics<sup>a</sup></td></tr><tr><td> Adverse</td><td>6</td><td>6</td><td>0.799</td></tr><tr><td> Intermediate</td><td>5</td><td>4</td><td></td></tr><tr><td> Favorable</td><td>1</td><td>1</td><td></td></tr></table>
|
7d6812b8726f015ac0ebb18f59941c1bc8ce2e83f503690ac2f6dc879aa02e60.png
|
complex
|
<table><tr><td></td><td colspan="2">MZ twins(n = 126; 63 twin pairs)</td><td colspan="2">DZ twins(n = 76; 38 twin pairs)</td></tr><tr><td></td><td>r value</td><td>95% CI</td><td>r value</td><td>95% CI</td></tr><tr><td>Weight</td><td>0.881</td><td>0.800-0.931</td><td>0.437</td><td>0.077-0.737</td></tr><tr><td>Waist circumference</td><td>0.865</td><td>0.763-0.935</td><td>0.510</td><td>0.052-0.781</td></tr><tr><td>Systolic blood pressure</td><td>0.598</td><td>0.426-0.731</td><td>0.055</td><td>-0.524-0.576</td></tr><tr><td>Diastolic blood pressure</td><td>0.608</td><td>0.444-0.728</td><td>0.147</td><td>-0.321-0.648</td></tr><tr><td>Serum total cholesterol</td><td>0.445</td><td>0.259-0.633</td><td>0.640</td><td>0.363-0.845</td></tr><tr><td>Serum HDL-cholesterol</td><td>0.840</td><td>0.626-0.895</td><td>0.658</td><td>-0.293-0.798</td></tr><tr><td>Serum triglycerides</td><td>0.527</td><td>0.281-0.707</td><td>0.349</td><td>-0.023-0.625</td></tr><tr><td>Fasting blood glucose</td><td>0.523</td><td>0.453-0.804</td><td>0.545</td><td>0.068-0.744</td></tr><tr><td>Fasting insulin</td><td>0.513</td><td>0.292-0.725</td><td>0.492</td><td>0.209-0.716</td></tr><tr><td>Serum creatinine</td><td>0.639</td><td>0.479-0.784</td><td>0.159</td><td>-0.065-0.434</td></tr><tr><td>Serum uric acid</td><td>0.691</td><td>0.542-0.799</td><td>0.629</td><td>0.453-0.772</td></tr><tr><td>Fibrinogen</td><td>0.663</td><td>0.499-0.791</td><td>0.322</td><td>0.024-0.639</td></tr><tr><td>Serum homocysteine</td><td>0.681</td><td>0.505-0.781</td><td>0.838</td><td>0.582-0.948</td></tr><tr><td>Serum C-reactive protein</td><td>0.683</td><td>0.460-0.851</td><td>0.138</td><td>-0.199-0.555</td></tr></table>
|
9a60a3e64651d8f8d811376cea91408088f4c39809a6c519db3b698a53c086cd.png
|
complex
|
<table><tr><td colspan="2">Variable</td><td><i>n</i> or <i>M</i></td><td>% or <i>SD</i></td></tr><tr><td colspan="2">Time Since Loss (months)</td><td>6.25</td><td>2.36</td></tr><tr><td colspan="2">Severity of PGD<sup>a</sup></td><td>23.33</td><td>10.27</td></tr><tr><td colspan="2">Age (years)</td><td>44.30</td><td>16.07</td></tr><tr><td>Gender</td><td>Female</td><td>123</td><td>71.9%</td></tr><tr><td> </td><td>Male</td><td>47</td><td>27.5%</td></tr><tr><td>Education</td><td>Less than High School</td><td>1</td><td>0.6%</td></tr><tr><td> </td><td>High School</td><td>35</td><td>20.5%</td></tr><tr><td> </td><td>College/Undergraduate Degree</td><td>92</td><td>53.8%</td></tr><tr><td> </td><td>Graduate Degree</td><td>31</td><td>18.1%</td></tr><tr><td> </td><td>Professional Degree</td><td>9</td><td>5.3%</td></tr><tr><td rowspan="2">Relationship to the Deceased</td><td>Grandparent</td><td>22</td><td>12.9%</td></tr><tr><td>Spouse</td><td>36</td><td>21.1%</td></tr><tr><td> </td><td>Child</td><td>6</td><td>3.5%</td></tr><tr><td> </td><td>Sibling</td><td>12</td><td>7%</td></tr><tr><td rowspan="2"> </td><td>Parent</td><td>59</td><td>34.5%</td></tr><tr><td>Friend</td><td>18</td><td>10.5%</td></tr><tr><td> </td><td>Ex-Spouse/Partner</td><td>3</td><td>1.8%</td></tr><tr><td> </td><td>Other</td><td>14</td><td>8.2%</td></tr><tr><td>Cause of Death</td><td>Suicide</td><td>12</td><td>7.0%</td></tr><tr><td> </td><td>Accident</td><td>7</td><td>4.1%</td></tr><tr><td> </td><td>Illness</td><td>109</td><td>63.7%</td></tr><tr><td> </td><td>Natural Sudden</td><td>35</td><td>20.5%</td></tr><tr><td> </td><td>Other</td><td>7</td><td>4.1%</td></tr></table>
|
e4443294be67d6b3250fd404d91b451ebbe053dad2e23593e729f82f439f48c5.png
|
simple
|
<table><tr><td></td><td></td><td>CEPS</td><td>CEPM</td><td>P value</td><td>CEPS</td><td>CEPM</td><td>P value</td></tr><tr><td>19</td><td></td><td>PPM (82)</td><td>PPM (19)</td><td></td><td>No PPM (19)</td><td>No PPM (11)</td><td></td></tr><tr><td></td><td>PG max (mmHg)</td><td>36,97 ± 12,29</td><td>34,65 ± 7,45</td><td>0,45</td><td>38,05 ± 7,99</td><td>29,36 ± 7,31</td><td>0,006</td></tr><tr><td></td><td>PG mean (mmHg)</td><td>20,65 ± 7,86</td><td>18,69 ± 4,54</td><td>0,34</td><td>21,47 ± 5,36</td><td>14,60 ± 2,84</td><td>0,0001</td></tr><tr><td></td><td>DVI</td><td>0,39 ± 0,08</td><td>0,49 ± 0,13</td><td>0,007</td><td>0,53 ± 0,12</td><td>0,59 ± 0,08</td><td>0,17</td></tr><tr><td></td><td>EOAi (cm2/m2)</td><td>0,58 ± 0,12</td><td>0,71 ± 0,39</td><td>0,17</td><td>1,13 ± 0,44</td><td>1,03 ± 0,40</td><td>0,55</td></tr><tr><td>21</td><td></td><td>PPM (49)</td><td>PPM (19)</td><td></td><td>No PPM (27)</td><td>No PPM (24)</td><td></td></tr><tr><td></td><td>PG max (mmHg)</td><td>31,79 ± 8,72</td><td>31,15 ± 12,78</td><td>0,81</td><td>29,56 ± 9,20</td><td>28,42 ± 10,95</td><td>0,69</td></tr><tr><td></td><td>PG mean (mmHg)</td><td>17,43 ± 5,09</td><td>17,36 ± 6,24</td><td>0,96</td><td>15,81 ± 5,64</td><td>15,95 ± 5,52</td><td>0,93</td></tr><tr><td></td><td>DVI</td><td>0,42 ± 0,09</td><td>0,59 ± 0,47</td><td>0,017</td><td>0,59 ± 0,18</td><td>0,60 ± 0,26</td><td>0,89</td></tr><tr><td></td><td>EOAi (cm2/m2)</td><td>0,65 ± 0,11</td><td>0,65 ± 0,18</td><td>0,99</td><td>1,04 ± 0,19</td><td>1,03 ± 0,28</td><td>0,85</td></tr><tr><td>23</td><td></td><td>PPM (32)</td><td>PPM (9)</td><td></td><td>No PPM (26)</td><td>No PPM (15)</td><td></td></tr><tr><td></td><td>PG max (mmHg)</td><td>27,86 ± 12,86</td><td>22,11 ± 7,04</td><td>0,09</td><td>26,46 ± 11,22</td><td>24,28 ± 7,61</td><td>0,52</td></tr><tr><td></td><td>PG mean (mmHg)</td><td>14,97 ± 6,99</td><td>12, 00 ± 4,80</td><td>0,24</td><td>12,92 ± 4,50</td><td>13,36 ± 4,53</td><td>0,77</td></tr><tr><td></td><td>DVI</td><td>0,40 ± 0,07</td><td>0,63 ± 0,45</td><td>0,16</td><td>0,51 ± 0,9</td><td>0,52 ± 0,12</td><td>0,67</td></tr><tr><td></td><td>EOAi (cm2/m2)</td><td>0,71 ± 0,11</td><td>0,85 ± 0,43</td><td>0,37</td><td>1,16 ± 0,20</td><td>1,03 ± 0,21</td><td>0,095</td></tr><tr><td>25</td><td></td><td>PPM (8)</td><td>PPM (2)</td><td></td><td>No PPM (11)</td><td>No PPM (11)</td><td></td></tr><tr><td></td><td>PG max (mmHg)</td><td>28,25 ± 10,82</td><td>36,00 ± 9,89</td><td>0,39</td><td>23,90 ± 6,52</td><td>20, 55 ± 8,38</td><td>0,34</td></tr><tr><td></td><td>PG mean (mmHg)</td><td>14,63 ± 5,55</td><td>18,00 ± 4,24</td><td>0,45</td><td>12,80 ± 4,10</td><td>10,90 ± 4,31</td><td>0,33</td></tr><tr><td></td><td>DVI</td><td>0,32 ± 0,15</td><td>0,44 ± 0,11</td><td>0,31</td><td>0,49 ± 0,06</td><td>0,57 ± 0,13</td><td>0,15</td></tr><tr><td></td><td>EOAi (cm2/m2)</td><td>0,63 ± 0,13</td><td>0,68</td><td>0,73</td><td>0,85 ± 0,41</td><td>1,29 ± 0,40</td><td>0,063</td></tr></table>
|
022659dd13c088e0f7b1448ca36ec97787fb71610ef0febf7d6ed06067275607.png
|
simple
|
<table><tr><td>Stage</td><td>Role names</td><td>Questionable</td></tr><tr><td>1</td><td>17 (4.03%)</td><td>0</td></tr><tr><td>2</td><td>230 (54.5%)</td><td>84</td></tr><tr><td>3</td><td>30 (7.11%)</td><td>1</td></tr><tr><td>4</td><td>2 (0.47%)</td><td>1</td></tr><tr><td>5</td><td>11 (2.61%)</td><td>0</td></tr><tr><td>No data</td><td>132 (31.28%)</td><td>NA</td></tr></table>
|
fd73575c3e8769251b3986ce00df2d8b6e2adc4e03407a3ce9b383af14b1f0d9.png
|
simple
|
<table><tr><td>Characteristics</td><td>Total (n = 412)</td><td>Men (n = 198)</td><td>Women (n = 214)</td></tr><tr><td>Total steps per day</td><td>8182.4 ± 3537.1</td><td>8448.4 ± 3379.5</td><td>7934.4 ± 3668.7</td></tr><tr><td>Total energy expenditure (kcal/day)</td><td>624.6 ± 275.1</td><td>722.7 ± 298.9*</td><td>531.7 ± 212.9</td></tr><tr><td>Actical total counts (per day)</td><td>186699.7 ± 104354.9</td><td>203739.6 ± 110309.5<sup>ψ</sup></td><td>170724.9 ± 95992.9</td></tr><tr><td>Time in sedentary activity (actical) (min/d)</td><td>1098.1 ± 99.2</td><td>1092.8 ± 99.8</td><td>1103.0 ± 98.6</td></tr><tr><td>Time in light activity (actical) (min/d)</td><td>206.9 ± 59.8</td><td>204.1 ± 59.3</td><td>209.6 ± 60.3</td></tr><tr><td>Time in moderate activity (actical) (min/d)</td><td>131.2 ± 51.7</td><td>138.7 ± 53.3<sup>ψ</sup></td><td>124.1 ± 49.2</td></tr><tr><td>Time in vigorous activity (actical) (min/d)</td><td>3.8 ± 7.8</td><td>4.3 ± 8.6</td><td>3.3 ± 7.0</td></tr><tr><td>Total self reported energy expenditure (MET*hr/wk)</td><td>388.6 ± 74.8</td><td>381.9 ± 77.5</td><td>394.9 ± 71.9</td></tr></table>
|
bc4a43b5f684c9dcf7eef9230a1ab4d6ef574a5abc978fd96bd1da419dd8d759.png
|
simple
|
<table><tr><td>Paramètres</td><td>ε3 (E3/E3)</td><td>ε4 (E4/E3+ E4/E4)</td></tr><tr><td>Nombre de sujets</td><td>31</td><td>9</td></tr><tr><td>Age (années)</td><td>58±7</td><td>59±7</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>26±5</td><td>30±2*</td></tr><tr><td>TA (mm Hg)</td><td>15±3</td><td>14±3</td></tr><tr><td>Cholestérol total (mg/dl)</td><td>278</td><td>300±15</td></tr><tr><td>LDL cholestérol (mg/dl)</td><td>219± 27</td><td>230±25</td></tr><tr><td>Triglycérides (mg/dl)</td><td>120±12*</td><td>210±18*</td></tr><tr><td>Apo B (g/l)</td><td>135±15*</td><td>148±20*</td></tr><tr><td>t.Xt (%)</td><td>17</td><td>20</td></tr><tr><td>MCV (%)</td><td>18</td><td>20</td></tr></table>
|
269e358256999b29b6b54f9e0e7f4bbb25527f1bcdd227a572cfe9a0e71630df.png
|
simple
|
<table><tr><td>No.</td><td>Hospital Level</td><td>Original Supply</td><td>Optimal Supply at Week 1</td><td>Optimal Supply at Week 2</td><td>Optimal Supply at Week 3</td><td>Optimal Supply at Week 4</td></tr><tr><td>1</td><td>2</td><td>74</td><td>45.5</td><td>48.8</td><td>48.8</td><td>51.6</td></tr><tr><td>2</td><td>2</td><td>79</td><td>44.5</td><td>49.4</td><td>48.4</td><td>66.2</td></tr><tr><td>3</td><td>2</td><td>160</td><td>90.0</td><td>126.0</td><td>73.9</td><td>111.9</td></tr><tr><td>4</td><td>1</td><td>106</td><td>148.5</td><td>136.4</td><td>141.8</td><td>142.2</td></tr><tr><td>5</td><td>1</td><td>65</td><td>160.0</td><td>159.5</td><td>160.0</td><td>160.0</td></tr><tr><td>6</td><td>2</td><td>87</td><td>104.5</td><td>73.1</td><td>121.5</td><td>61.0</td></tr><tr><td>7</td><td>2</td><td>152</td><td>130.0</td><td>129.8</td><td>128.6</td><td>130.0</td></tr></table>
|
26dbd4f1c66446199d15001bc8872c1c768a4b92e05eb10c0189bffb569ee9a9.png
|
simple
|
<table><tr><td>Group</td><td>BWC (g)</td><td>TW (g)</td><td>Testosterone (nmol/L)</td><td>TSC (10<sup>4</sup>)</td><td>MF (per 30 min)</td></tr><tr><td>Normal control</td><td>49 ± 16.26</td><td>3.40 ± 0.48</td><td>6.99 ± 3.09<sup><i>∗</i></sup></td><td>47 ± 05.81</td><td>19 ± 1.02<sup><i>∗</i></sup></td></tr><tr><td>Untreated</td><td>39 ± 16.23</td><td>2.76 ± 0.08</td><td>3.01 ± 2.82</td><td>35 ± 07.94</td><td>09 ± 1.00</td></tr><tr><td>Sildenafil (20 mg/kg)</td><td>50 ± 15.44</td><td>3.55 ± 0.41</td><td>14.93 ± 8.34<sup><i>∗∗</i></sup></td><td>37 ± 05.92</td><td>64 ± 1.01<sup><i>∗∗</i></sup></td></tr><tr><td><i>O.p</i> (50 mg/kg)</td><td>65 ± 17.47</td><td>3.33 ± 0.20</td><td>2.12 ± 1.54</td><td>53 ± 20.17</td><td>16 ± 3.09</td></tr><tr><td><i>O.p</i> (250 mg/kg)</td><td>97 ± 12.26<sup><i>∗</i></sup></td><td>3.62 ± 0.62</td><td>6.60 ± 3.51<sup><i>∗</i></sup></td><td>74 ± 10.56<sup><i>∗</i></sup></td><td>18 ± 3.54<sup><i>∗</i></sup></td></tr><tr><td><i>M.p</i> (50 mg/kg)</td><td>44 ± 11.60</td><td>4.21 ± 0.41</td><td>2.58 ± 0.71</td><td>46 ± 2.56</td><td>32 ± 3.11<sup><i>∗∗</i></sup></td></tr><tr><td><i>M.p</i> (250 mg/kg)</td><td>48 ± 13.23</td><td>4.29 ± 0.11</td><td>10.95 ± 3.42<sup><i>∗</i></sup></td><td>49 ± 14.13</td><td>46 ± 1.20<sup><i>∗∗</i></sup></td></tr></table>
|
e3ecb6123b004397c60f1ca1b7733cece3903e69ce3ffec0902f1282cbc2733d.png
|
complex
|
<table><tr><td>Outcome</td><td></td><td colspan="2">Rank obtained</td><td colspan="2">Percentage of responders</td><td colspan="7">Priority</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="3">Post</td><td colspan="3">Pre</td><td>Chi</td></tr><tr><td></td><td></td><td>Post</td><td>Pre</td><td>Post</td><td>Pre</td><td>P1</td><td>P2</td><td>P3</td><td>P1</td><td>P2</td><td>P3</td><td>P</td></tr><tr><td>Aesthetics</td><td>Aes</td><td>1</td><td>3</td><td>100%</td><td>89%</td><td>78%</td><td>19%</td><td>3%</td><td>58%</td><td>26%</td><td>5%</td><td><0.01</td></tr><tr><td>Quality of life</td><td>QoL</td><td>2</td><td>4</td><td>91%</td><td>74%</td><td>75%</td><td>6%</td><td>9%</td><td>63%</td><td>21%</td><td>0%</td><td><0.01</td></tr><tr><td>Disability</td><td>Dis</td><td>3</td><td>11</td><td>91%</td><td>63%</td><td>69%</td><td>6%</td><td>16%</td><td>47%</td><td>11%</td><td>5%</td><td><0.01</td></tr><tr><td>Back Pain</td><td>BP</td><td>4</td><td>7</td><td>87%</td><td>68%</td><td>63%</td><td>13%</td><td>13%</td><td>58%</td><td>16%</td><td>11%</td><td><0.01</td></tr><tr><td>Psychological well-being</td><td>PWB</td><td>5</td><td></td><td>84%</td><td></td><td>66%</td><td>13%</td><td>6%</td><td>79%</td><td>5%</td><td>0%</td><td></td></tr><tr><td>Progression in adulthood</td><td>PiA</td><td>6</td><td>2</td><td>84%</td><td>84%</td><td>56%</td><td>28%</td><td>0%</td><td>74%</td><td>5%</td><td>16%</td><td><0.01</td></tr><tr><td>Breathing function</td><td>BF</td><td>7</td><td>1</td><td>84%</td><td>95%</td><td>44%</td><td>25%</td><td>16%</td><td>63%</td><td>16%</td><td>5%</td><td><0.01</td></tr><tr><td>Scoliosis Cobb degrees</td><td>SCD</td><td>8</td><td>5</td><td>84%</td><td>84%</td><td>44%</td><td>34%</td><td>6%</td><td>58%</td><td>11%</td><td>21%</td><td><0.01</td></tr><tr><td>Needs of further treatments in adulthood</td><td>NTA</td><td>9</td><td>6</td><td>81%</td><td>89%</td><td>53%</td><td>22%</td><td>6%</td><td>53%</td><td>21%</td><td>0%</td><td><0.01</td></tr><tr><td>Rib hump</td><td>RH</td><td>10</td><td>8</td><td>78%</td><td>84%</td><td>59%</td><td>13%</td><td>6%</td><td>42%</td><td>26%</td><td>0%</td><td><0.01</td></tr><tr><td>Self control of posture</td><td></td><td>11</td><td></td><td>75%</td><td></td><td>41%</td><td>25%</td><td>9%</td><td></td><td></td><td></td><td></td></tr><tr><td>Perdriolle degrees</td><td>PD</td><td>12</td><td>9</td><td>75%</td><td>84%</td><td>16%</td><td>50%</td><td>9%</td><td>47%</td><td>11%</td><td>11%</td><td><0.01</td></tr><tr><td>Knowledge and understanding of scoliosis</td><td></td><td>13</td><td></td><td>72%</td><td></td><td>44%</td><td>16%</td><td>13%</td><td></td><td></td><td></td><td></td></tr><tr><td>Movement of the vertebral column</td><td></td><td>14</td><td></td><td>72%</td><td></td><td>38%</td><td>25%</td><td>9%</td><td></td><td></td><td></td><td></td></tr><tr><td>Kypho-lordosis Cobb degrees</td><td>KLD</td><td>15</td><td>10</td><td>72%</td><td>68%</td><td>31%</td><td>34%</td><td>6%</td><td>58%</td><td>26%</td><td>5%</td><td><0.01</td></tr><tr><td>Balance</td><td></td><td>16</td><td></td><td>69%</td><td></td><td>44%</td><td>19%</td><td>6%</td><td></td><td></td><td></td><td></td></tr><tr><td>Body motor awareness and learning skills</td><td></td><td>17</td><td></td><td>69%</td><td></td><td>9%</td><td>34%</td><td>25%</td><td></td><td></td><td></td><td></td></tr><tr><td>Sensory motor integration of the corrective pattern</td><td></td><td>18</td><td></td><td>62%</td><td></td><td>41%</td><td>16%</td><td>6%</td><td></td><td></td><td></td><td></td></tr><tr><td>Improved processing of vestibular input</td><td></td><td>19</td><td></td><td>59%</td><td></td><td>6%</td><td>31%</td><td>22%</td><td></td><td></td><td></td><td></td></tr><tr><td>Equality of weight bearing</td><td></td><td>20</td><td></td><td>56%</td><td></td><td>22%</td><td>19%</td><td>16%</td><td></td><td></td><td></td><td></td></tr><tr><td>Exercise efficiency</td><td></td><td>21</td><td></td><td>56%</td><td></td><td>22%</td><td>28%</td><td>6%</td><td></td><td></td><td></td><td></td></tr></table>
|
bffb9341954df00beb2c39fc3d96098a9b41944eeac50b78d2752883b8323e67.png
|
simple
|
<table><tr><td> </td><td>Normal controls</td><td>2-kidneys-1-clip model of hypertension</td><td>1-kidney-1-clip model of hypertension</td><td>P</td></tr><tr><td>Heart rate (bpm)</td><td>455.3 ± 60.8</td><td>472.5 ± 54.9</td><td>463.6 ± 55.4</td><td>ns</td></tr><tr><td>Systolic blood pressure - baseline (mmHg)</td><td>100.9 ± 5.5</td><td>144.8 ± 13.0</td><td>152.3 ± 16.6</td><td><0.0001</td></tr><tr><td>Diastolic blood pressure - baseline (mmHg)</td><td>76.7 ± 4.3</td><td>106.4 ± 12.7</td><td>109.2 ± 8.7</td><td>0.0001</td></tr><tr><td>Heart rate – after atropine (bpm)</td><td>559.8 ± 58.1</td><td>575.9 ± 82.5</td><td>604.4 ± 55.4</td><td>ns</td></tr><tr><td>Systolic blood pressure - after atropine (mmHg)</td><td>108.9 ± 6.6</td><td>152.7 ± 16.1</td><td>151.2 ± 15.3</td><td><0.0001</td></tr><tr><td>Diastolic blood pressure - after atropine (mmHg)</td><td>85.9 ± 6.0</td><td>116.0 ± 11.9</td><td>111.2 ± 8.4</td><td><0.0001</td></tr><tr><td>Heart rate – after metoprolol (bpm)</td><td>463.0 ± 74.0</td><td>513.8 ± 67.6</td><td>479.3 ± 49.4</td><td>ns</td></tr><tr><td>Systolic blood pressure - after metoprolol (mmHg)</td><td>100.2 ± 10.8</td><td>155.1 ± 14.9</td><td>151.1 ± 15.3</td><td><0.0001</td></tr><tr><td>Diastolic blood pressure - after metoprolol (mmHg)</td><td>77.3 ± 9.2</td><td>114.1 ± 13.4</td><td>111.4 ± 10.5</td><td><0.0001</td></tr></table>
|
ef72ca1f2f8f1ca59fe9dd79b0f3afc202d3d9ae05788fc4f962eb2d71a7943f.png
|
simple
|
<table><tr><td>GEO</td><td>Tissue type</td><td>Test sample size (n vs. c)</td><td>Sig genes DN</td><td>Reference</td></tr><tr><td>GSE18520</td><td>Ovary</td><td>10 vs. 53</td><td>79</td><td>[66]</td></tr><tr><td>GSE14407</td><td>Ovary</td><td>12 vs. 12</td><td>109</td><td>[67]</td></tr><tr><td>GSE764</td><td>Uterus</td><td>4 vs. 7 benign</td><td>0</td><td>Unpublished</td></tr><tr><td>GSE764</td><td>Uterus</td><td>4 vs. 8 malignant</td><td>2</td><td>Unpublished</td></tr><tr><td>GSE15471</td><td>Pancreas</td><td>39 vs. 39</td><td>120</td><td>[68]</td></tr><tr><td>GSE23878</td><td>Colon</td><td>24 vs. 35</td><td>74</td><td>Unpublished</td></tr></table>
|
5ddf90fdb446acce2fa87ac0a9295e6faeac98bb8de07eb1b75f147b0bc32d18.png
|
simple
|
<table><tr><td> </td><td>Animals</td><td>−7</td><td>−4</td><td>−1</td><td>+1</td><td>+2</td><td>+3</td><td>+4</td><td>+7</td><td>+8</td><td>+10</td><td>+11</td><td>+14</td></tr><tr><td> </td><td> </td><td>d a.i.</td><td>d a.i.</td><td>h a.i.</td><td>dpi</td><td>dpi</td><td>dpi</td><td>dpi</td><td>dpi</td><td>dpi</td><td>dpi</td><td>dpi</td><td>dpi</td></tr><tr><td>PFT</td><td><i>C. psittaci</i></td><td>n = 18</td><td>n = 18</td><td> </td><td> </td><td> </td><td>n = 18</td><td>n = 15</td><td>n = 12</td><td>n = 9</td><td>n = 9</td><td>n = 6</td><td>n = 6</td></tr><tr><td> </td><td>Controls</td><td>n = 18</td><td>n = 18</td><td> </td><td> </td><td> </td><td>n = 18</td><td>n = 15</td><td>n = 12</td><td>n = 9</td><td>n = 9</td><td>n = 6</td><td>n = 6</td></tr><tr><td>Blood</td><td><i>C. psittaci</i></td><td> </td><td> </td><td>n = 21</td><td>n = 21</td><td>n = 21</td><td>n = 18</td><td>n = 15</td><td>n = 12</td><td> </td><td>n = 9</td><td> </td><td>n = 6</td></tr><tr><td> </td><td>Controls</td><td> </td><td> </td><td>n = 21</td><td>n = 21</td><td>n = 21</td><td>n = 18</td><td>n = 15</td><td>n = 12</td><td> </td><td>n = 9</td><td> </td><td>n = 6</td></tr></table>
|
e3db74941da55ca210ba56bf24d16bbe7904535acf98997f6dc843bbc5a4938f.png
|
complex
|
<table><tr><td rowspan="3">Variable</td><td>Adopted children (<i>N</i> = 18)</td><td>Parents (<i>N</i> = 26)</td><td rowspan="3"><i>P</i><sup>a</sup></td></tr><tr><td>Mean (SD) [range]</td><td>Mean (SD) [range]</td></tr><tr><td>Age (years)</td><td>14.0 (4.1) [7.9 to 20.0]</td><td>49.0 (5.7) [40.0 to 65.0]</td><td><0.001</td></tr><tr><td>Height (cm)</td><td>157.7 (16.4) [130.0 to 180.0]</td><td>167.2 (10.6) [150.0 to 183.0]</td><td>0.021</td></tr><tr><td>Weight (kg)</td><td>50.4 (15.4) [28.0 to 81.0]</td><td>80.5 (16.6) [48.0 to 120.0]</td><td><0.001</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>19.8 (3.1) [13.2 to 26.6]</td><td>28.5 (4.1) [20.7 to 38.3]</td><td><0.001</td></tr><tr><td>PAI</td><td>4.8 (1.4) [3.1 to 5.8]</td><td>4.0 (1.2) [3.5 to 5.5]</td><td>n.s.</td></tr><tr><td>Smoking index</td><td>50 (0.0) [50 to 50] (N 1)</td><td>237.5 (152.3) [75 to 525] (N 8)</td><td>n.s.</td></tr><tr><td>Sleep duration (h)</td><td>8.3 (1.9) [5 to 10]</td><td>7.1 (1.3) [6 to 10]</td><td>0.011</td></tr><tr><td>Fractures (No.)</td><td>2.0 (1.4) [1 to 3]</td><td>1.2 (0.5) [1 to 2]</td><td>n.s.</td></tr><tr><td>Spine BMD Z score</td><td>1.4 (1.1) [−1.4 to 2.8]</td><td>−0.1 (0.9) [−2.3 to 1.7]</td><td><0.001</td></tr><tr><td>Total femur BMD Z score</td><td>0.9 (1.0) [−2.1 to 2.3]</td><td>0.5 (0.8) [−1.1 to 2.4]</td><td>n.s.</td></tr><tr><td>Radius 1/3 BMD Z score</td><td>−0.8 (0.9) [−2.4 to 1.5]</td><td>−0.0 (0.9) [−1.6 to 2.3]</td><td>0.015</td></tr><tr><td>Energy (kcal)</td><td>3177.1 (1070.0) [1369.1 to 5401.2]</td><td>2170.5 (950.3) [833.5 to 4246.5]</td><td>0.008</td></tr><tr><td>Protein (g/1000 kcal)</td><td>33.8 (5.5) [25.8 to 45.6]</td><td>39.2 (5.8) [30.4 to 50.4]</td><td>0.011</td></tr><tr><td>Fat (g/1000 kcal)</td><td>37.0 (6.9) [23.2 to 46.0]</td><td>36.6 (3.8) [29.8 to 45.2]</td><td>n.s.</td></tr><tr><td>Carbohydrate (g/1000 kcal)</td><td>136.7 (20.1) [106.9 to 174.2]</td><td>129.0 (16.6) [81.1 to 156.8]</td><td>n.s.</td></tr><tr><td>Dietary fiber (g/1000 kcal)</td><td>10.1 (3.5) [6.2 to 19.6]</td><td>11.3 (2.3) [6.5 to 19.1]</td><td>n.s.</td></tr><tr><td>Calcium (mg/1000 kcal)</td><td>395.3 (99.7) [276.4 to 593.9]</td><td>356.8 (118.3) [201.9 to 599.3]</td><td>n.s.</td></tr><tr><td>Vitamin D (IU/1000 kcal)</td><td>27.8 (10.2) [15.3 to 47.4]</td><td>33.3 (15.0) [16.1 to 73.9]</td><td>n.s.</td></tr></table>
|
75d3504fad26205a3447c5896119498b1f6e9ce7191f167f034e2664790bed9c.png
|
simple
|
<table><tr><td>Study</td><td>Subject (number)</td><td>Design</td><td>Particles</td><td>Results</td></tr><tr><td>Gong et al [26]</td><td>Healthy volunteers (12)Patients with mild asthma (12)</td><td>Crossover</td><td>Filtered air, Fine CAPS (174 μg/m<sup>3</sup>)</td><td>CAPS induced modest and similar increases in parasympathetic stimulation of HRV in both groups</td></tr><tr><td>Gong et al [42]</td><td>Healthy elderly, age (6)Elderly patients with COPD (13)</td><td>Crossover</td><td>Filtered air, Fine CAPS (200 μg/m<sup>3</sup>)</td><td>Decrease in HRV in healthy elderly but not in COPD patients</td></tr><tr><td>Frampton et al [40]</td><td>Healthy volunteers (40), Patients with asthma (16)</td><td>Crossover</td><td>Filtered airUltrafine carbon particles (10, 25 and 50 μg/m<sup>3</sup>)</td><td>In healthy subjects, reduced CD54 and CD18 on monocytes; decreased CD18 and CD49d on granulocytes; decreased CD25 in blood monocytes, basophils, and eosinophils; increased lymphocyte expression of CD25.In asthma, reduced CD11b on monocytes and eosinophils, CD54 on granulocytes, the percentage of CD4+ T cells, basophils, and eosinophils</td></tr><tr><td>Piatropaoli et al [41]</td><td>Healthy volunteers (40), Patients with asthma (16)</td><td>Crossover</td><td>Filtered airUltrafine carbon particles (10, 25 and 50 μg/m<sup>3</sup>)</td><td>No changes in airway eNO and total cell count/differentials in induced sputum; Increased percentage macrophages in the sputum of asthmatics;No changes in IL-6 and IL-8 in the sputum</td></tr><tr><td>Gong et al [67]</td><td>Healthy volunteers (4)Patients with mild asthma (12)</td><td>Crossover</td><td>Filtered air Coarse CAPS (157 μg/m<sup>3</sup>)</td><td>Decrease HR and PNN50 4 hours post-exposure</td></tr><tr><td>Stenfors et al [43]</td><td>Healthy volunteers (25)Patients with mild asthma (15)</td><td>Single-blind randomized crossover</td><td>Filtered airDiesel exhaust (PM10, 108 μg/m<sup>3</sup>)</td><td>Increased neutrophils, IL-8 and IL-6 in BAL fluid and P-selectin and VCAM-1 in bronchial biopsy, no difference between normal and asthmatics</td></tr><tr><td>Gong et al [44]</td><td>Healthy volunteers (14)Patients with mild asthma (17)</td><td>Crossover</td><td>Filtered airUltrafine CAPS (100 μg/m<sup>3 </sup>or 145,000/cm<sup>3 </sup>particle counts</td><td>Decreased O2sat, FEV1 and low frequency power; no differences between normal and asthmatics</td></tr></table>
|
d61e0833880a138451b3b7a75f198f6b05cc0c7b5a09883953f2e69949dbd6e1.png
|
simple
|
<table><tr><td>Specialty</td><td>No. of clinics</td><td>No. ofpatients</td><td>% of total costrepresented by pharmacy cost(mean ± sd)</td><td>Correlation between costs including and excluding pharmacy costs<sup>1)</sup></td></tr><tr><td>General clinics</td><td>4,695</td><td>3,807,917</td><td>32.04 ± 23.84</td><td>0.99</td></tr><tr><td>Internal medicine</td><td>3,611</td><td>4,852,887</td><td>38.23 ± 25.23</td><td>0.87</td></tr><tr><td>Pediatrics</td><td>2,128</td><td>2,333,778</td><td>26.18 ± 19.80</td><td>0.99</td></tr><tr><td>Otorhinolaryngology</td><td>1,737</td><td>2,561,254</td><td>24.10 ± 15.40</td><td>0.99</td></tr><tr><td>Orthopedic surgery</td><td>1,725</td><td>1,585,045</td><td>20.23 ± 21.56</td><td>0.99</td></tr><tr><td>Obstetrics & gynecology</td><td>1,604</td><td>873,524</td><td>21.09 ± 20.82</td><td>0.98</td></tr><tr><td>Ophthalmology</td><td>1,207</td><td>1,515,235</td><td>23.38 ± 17.31</td><td>0.97</td></tr><tr><td>General surgery</td><td>1,193</td><td>794,618</td><td>27.65 ± 23.32</td><td>0.97</td></tr><tr><td>Family medicine</td><td>1,055</td><td>1,009,541</td><td>34.11 ± 23.20</td><td>0.95</td></tr><tr><td>Urology</td><td>888</td><td>581,503</td><td>30.82 ± 23.46</td><td>0.90</td></tr><tr><td>Dermatology</td><td>803</td><td>779,600</td><td>29.02 ± 21.96</td><td>0.93</td></tr><tr><td>Psychiatry</td><td>708</td><td>308,835</td><td>19.00 ± 27.05</td><td>0.99</td></tr><tr><td>Anesthesiology</td><td>588</td><td>296,653</td><td>28.90 ± 25.95</td><td>0.99</td></tr><tr><td>Neurosurgery</td><td>362</td><td>298,801</td><td>27.49 ± 25.29</td><td>0.99</td></tr><tr><td>Rehabilitation medicine</td><td>276</td><td>158,182</td><td>27.17 ± 26.74</td><td>0.99</td></tr><tr><td>Diagnostic radiology</td><td>244</td><td>156,622</td><td>10.61 ± 21.37</td><td>0.96</td></tr><tr><td>Neurology</td><td>132</td><td>104,304</td><td>41.56 ± 28.60</td><td>0.92</td></tr><tr><td>Thoracic surgery</td><td>82</td><td>64,099</td><td>31.97 ± 23.83</td><td>0.97</td></tr><tr><td>Plastic surgery</td><td>74</td><td>6,251</td><td>13.22 ± 20.15</td><td>0.98</td></tr><tr><td>Total</td><td>23,112</td><td>22,088,649</td><td>29.76 ± 23.80</td><td>0.95</td></tr></table>
|
24a0c8a703fdba21a9b49ac908c320352d2f25a4d5db2d0904add2d8dd7bf285.png
|
simple
|
<table><tr><td>EPDnew database</td><td>Source data: type, reference or source repository</td><td># of libraries</td><td>total tags (millions)</td></tr><tr><td><i>H. sapiens</i></td><td>CAGE from ENCODE/RIKEN, downloaded from UCSC genome browser database (12)</td><td>148</td><td>3841</td></tr><tr><td><i>M. musculus</i></td><td>CAGE from FANTOM5 (http://fantom.gsc.riken.jp/5/))</td><td>339</td><td>6236</td></tr><tr><td><i>D. melanogaster</i></td><td>CAGE from modENCODE (ftp://data.modencode.org/) TSS-seq from Machibase (13)</td><td>57</td><td>646</td></tr><tr><td><i>D. rerio</i></td><td>CAGE from Nepal <i>et al</i>. (14), downloaded from SRA (8), ID SRA055273</td><td>12</td><td>65</td></tr><tr><td><i>C. elegans</i></td><td>GRO-cap from Kruesi <i>et al.</i> (15)</td><td>8</td><td>236</td></tr></table>
|
d2da277d7ca1856427182d89c88c397a2556d11af1fe1053fdc97a811c755c0e.png
|
complex
|
<table><tr><td rowspan="2">Socio-demographic factors</td><td rowspan="2"></td><td colspan="2">STHs infection status</td><td rowspan="2">Total</td><td rowspan="2">X<sup>2</sup></td><td rowspan="2">P-value</td></tr><tr><td>Negative</td><td>Positive</td></tr><tr><td rowspan="2">Age</td><td>6–10</td><td>156 (81.7%)</td><td>35 (18.3%)</td><td>191 (100.0%)</td><td rowspan="2">0.49</td><td rowspan="2">0.12</td></tr><tr><td>11–15</td><td>102 (81.0%)</td><td>24 (19.0%)</td><td>126 (100.0%)</td></tr><tr><td rowspan="2">Gender</td><td>Girl</td><td>145 (78.4%)</td><td>40 (21.6%)</td><td>185 (100.0%)</td><td rowspan="2">0.068</td><td rowspan="2">0.031</td></tr><tr><td>Boy</td><td>113 (85.6%)</td><td>19 (14.4%)</td><td>132 (100.0%)</td></tr><tr><td rowspan="4">Family size</td><td>1 parent and child</td><td>4 (80.0%)</td><td>1 (20.0%)</td><td>5 (100.0%)</td><td rowspan="4">0.03</td><td rowspan="4">0.0</td></tr><tr><td>1 parent and 2 children</td><td>15 (88.2%)</td><td>2 (11.8%)</td><td>17 (100.0%)</td></tr><tr><td>2 parents and 2 children</td><td>40 (88.9%)</td><td>5 (11.1%)</td><td>45 (100.0%)</td></tr><tr><td>2 parents & > 2 children</td><td>193 (79.4%)</td><td>50 (20.6%)</td><td>243 (100.0%)</td></tr><tr><td rowspan="2">Latrine available</td><td>Yes</td><td>216((83.7%)</td><td>42 (16.3%)</td><td>258 (100.0%)</td><td rowspan="2">0.09</td><td rowspan="2">0.05</td></tr><tr><td>No</td><td>36 (67.9%)</td><td>17 (32.1%)</td><td>53 (100.0%)</td></tr><tr><td rowspan="3">Type of latrine</td><td>Ventilated improved</td><td>50 (92.6%)</td><td>4 (7.4%)</td><td>54 (100.0%)</td><td rowspan="3">0.036</td><td rowspan="3">–</td></tr><tr><td>Traditional pit latrine</td><td>152 (79.6%)</td><td>39 (20.4%)</td><td>191 (100.0%)</td></tr><tr><td>Water flash</td><td>13 (100.0%)</td><td>0(.0%)</td><td>13 (100.0%)</td></tr><tr><td rowspan="2">Finger nail trimming</td><td>Yes</td><td>115 (85.8%)</td><td>19 (14.2%)</td><td>134 (100.0%)</td><td rowspan="2">.039</td><td rowspan="2">.024</td></tr><tr><td>No</td><td>31 (72.1%)</td><td>12 (27.9%)</td><td>43 (100.0%)</td></tr></table>
|
6bda3ec767de0c97a1a706c073791d0b48b9cf5939a3d1ecd143878ebb31a977.png
|
simple
|
<table><tr><td>Putative virus integration-harboring regions<sup>a</sup></td><td>SNPs</td><td>Insertions</td><td>Deletions</td></tr><tr><td>Chr3:140,567,185-140,575,795</td><td>26</td><td>6</td><td>2</td></tr><tr><td>Chr6:33,823,990-33,832,089</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Chr18:102,747-110,847</td><td>178</td><td>5</td><td>9</td></tr></table>
|
2e31636d8afaf6c39b0913819e7964ad4dac829722ac4d2f41aa96c537fc2538.png
|
complex
|
<table><tr><td> </td><td>Dependent variable</td><td><i>P</i></td><td>OR</td><td>95% CI</td></tr><tr><td> </td><td>AIH-1</td><td> </td><td> </td><td> </td></tr><tr><td>Model 1</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td rowspan="2"> <i>HLA-DRB1</i><sup><i>∗</i></sup></td><td>Different from 03 and/or 13</td><td rowspan="2"><0.001</td><td rowspan="2">8.28</td><td rowspan="2">3.46–19.82</td></tr><tr><td>03 and/or 13</td></tr><tr><td rowspan="2"> <i>IL13</i> rs20541</td><td>AG plus GG</td><td rowspan="2">0.002</td><td rowspan="2">9.45</td><td rowspan="2">2.28–39.18</td></tr><tr><td>AA</td></tr><tr><td rowspan="2"> <i>IL4RA</i> rs1805011</td><td>AG plus GG</td><td rowspan="2">0.001</td><td rowspan="2">3.72</td><td rowspan="2">1.78–7.77</td></tr><tr><td>AA</td></tr><tr><td> </td><td>IL5 rs2069812</td><td> </td><td> </td><td> </td></tr><tr><td>Model 2</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td rowspan="2"> Treatment suspension</td><td>Yes<sup>a</sup></td><td rowspan="2">0.004</td><td rowspan="2">6.41</td><td rowspan="2">1.83–22.44</td></tr><tr><td>No</td></tr><tr><td> </td><td>IgE levels</td><td> </td><td> </td><td> </td></tr><tr><td>Model 3</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td rowspan="2"> <i>IL4</i> rs2227284</td><td>TT and GT</td><td rowspan="2">0.022</td><td rowspan="2">7.42</td><td rowspan="2">1.33–41.34</td></tr><tr><td>GG</td></tr></table>
|
4869e04ab4f3327e47f2053206a5d3b6c03e3a8a57dcbb91888f49f3531d338e.png
|
complex
|
<table><tr><td>Model</td><td>Insight</td><td>Author, weblink</td></tr><tr><td colspan="3">TECHNIQUES TO STUDY METABOLIC ADAPTATION IN <i>SALMONELLA</i></td></tr><tr><td rowspan="2"><i>S. Typhimurium metabolite profiling for different (nutrient poor, virulence induced) environments and genome-scale metabolite model</i></td><td rowspan="2">→Central carbon metabolism strongly altered (depletion in glycerol catabolism (glycerol, glycerol 3-phosphate, dihydroxyacetone phosphate, and pyruvate), increased glucose. Synthesis and uptake of polyamines (may protect <i>Salmonella</i> against osmotic stress inside host cells).</td><td>Kim et al., 2013</td></tr><tr><td>doi: 10.1039/C3MB25598K</td></tr><tr><td rowspan="2"><i>Metabolic model and microbiology, metabolite measurements; for survival (unrelated to growth): “maintenance requirements” and “costs” (to resist host) are calculated as ATP expenditure</i>.</td><td rowspan="2">→ Accumulation of metabolites in the infected gut (lactose, galactinol, melibiose, and raffinose) <i>Salmonella</i> and murine host lack necessary enzymes → used by Bacteroidetes and other commensals (glycosidases).</td><td>Deatherage Kaiser et al., 2013</td></tr><tr><td>PMID: 22168414</td></tr><tr><td></td><td>→ Model predicted hundreds of virulence phenotypes with 90% accuracy.</td><td></td></tr><tr><td></td><td>→ Costs become very high under excess nutrient availability</td><td></td></tr><tr><td>Model</td><td>Result</td><td>Author, weblink</td></tr><tr><td colspan="3">METABOLIC MODELING TECHNIQUES</td></tr><tr><td rowspan="2"><i>Hypothesis of nutrient-limitation during infection</i></td><td rowspan="2">→ Inactivation of <i>Salmonella</i> enzyme → metabolic bottleneck → overexpression of another enzyme.</td><td>Steeb et al., 2013</td></tr><tr><td>PMID: 23633950</td></tr><tr><td rowspan="2"><i>Deletion effects, e.g., calculations for</i> Δ<i>ppc</i></td><td rowspan="2">→ No compensatory flux via the glyoxylate shunt.</td><td>Fong et al., 2013</td></tr><tr><td>PMID: 23432746</td></tr><tr><td>Model</td><td>Result</td><td>Author, weblink</td></tr><tr><td colspan="3">MODELING REGULATION OF <i>SALMONELLA</i> METABOLISM</td></tr><tr><td rowspan="2"><i>Boolean modeling of genes in SPI1, SPI2, and T6SS Integrated: osmolarity, glucose, iron, calcium and magnesium concentrations, growth phase-dependent stationary phase factors</i>.</td><td rowspan="2">→ Description of pathogenicity island cross-talk (e.g., SPI2-secreted proteins low → activation of T6SS). → Antagonistic cross-talk (e.g., <i>SsrAB</i> to <i>SciS; MviA</i> to <i>RcsB</i>).</td><td>Das et al. (2013)</td></tr><tr><td>doi: 10.1186/1757-4749-5-28</td></tr><tr><td rowspan="2"><i>Spatiotemporal distribution of ROS in neutrophils, macrophages carrying Salmonella and in vivo expression of ROS defense enzymes (KatG, SodAB, and host NADPH oxidase)</i>.</td><td>→ (a) Neutrophils: lethal concentrations of hydrogen peroxide</td><td>Burton et al. (2014)</td></tr><tr><td>→ (b) Macrophages: only sub-lethal ROS concentration during infection</td><td>PMID: 24439899</td></tr></table>
|
dfb7cd8051746b57bd3d23697e3e59504978a4b7fdca46a6a735d86cf634f8bc.png
|
simple
|
<table><tr><td>Booklet themes</td><td>Principal professionala</td></tr><tr><td>Aging</td><td>PT</td></tr><tr><td>Physical activity helps keep you physically fit</td><td>PT</td></tr><tr><td>Food is a prerequisite for health</td><td>PT</td></tr><tr><td>You can take care of problems with your health</td><td>RN</td></tr><tr><td>How to use medicine</td><td>RN</td></tr><tr><td>Coping with everyday life</td><td>OT</td></tr><tr><td>You do not need to feel insecure</td><td>OT</td></tr><tr><td>Technology in everyday life</td><td>OT</td></tr><tr><td>Will I lose my memory?</td><td>OT</td></tr><tr><td>Life events and quality of life during aging</td><td>SW</td></tr><tr><td>Anyone who needs help can get help</td><td>SW</td></tr></table>
|
483664cf500676aae342a9c9e1b82ba491ef45a3a03dd87ac2596cd4d18dd64a.png
|
complex
|
<table><tr><td>Subgroup</td><td>Group</td><td>No. of AS</td><td>Person-years</td><td>IR</td><td>IRR (95% CI)</td><td><i>P</i> value</td></tr><tr><td colspan="7">By age</td></tr><tr><td rowspan="3"> < 40 years</td><td>Control subjects</td><td>11</td><td>86,359</td><td>12.7</td><td>1 (reference)</td><td></td></tr><tr><td>All uveitis</td><td>32</td><td>15,430</td><td>207.4</td><td>17.64 (8.87–35.09)</td><td>< 0.001</td></tr><tr><td>Recurrent uveitis</td><td>12</td><td>2461</td><td>487.5</td><td>46.78 (19.61–111.61)</td><td>< 0.001</td></tr><tr><td rowspan="3"> 40–59 years</td><td>Control subjects</td><td>16</td><td>87,723</td><td>18.2</td><td>1 (reference)</td><td></td></tr><tr><td>All uveitis</td><td>19</td><td>15,745</td><td>120.7</td><td>6.70 (3.44–13.06)</td><td>< 0.001</td></tr><tr><td>Recurrent uveitis</td><td>8</td><td>2994</td><td>267.2</td><td>15.12 (6.41–35.65)</td><td>< 0.001</td></tr><tr><td rowspan="3"> > 59 years</td><td>Control subjects</td><td>17</td><td>85,785</td><td>19.8</td><td>1 (reference)</td><td></td></tr><tr><td>All uveitis</td><td>6</td><td>15,739</td><td>38.1</td><td>1.90 (0.75–4.81)</td><td>0.178</td></tr><tr><td>Recurrent uveitis</td><td>1</td><td>2119</td><td>47.2</td><td>2.46 (0.33–18.53)</td><td>0.382</td></tr><tr><td colspan="7">By sex</td></tr><tr><td rowspan="3"> Male</td><td>Control subjects</td><td>29</td><td>142,124</td><td>20.4</td><td>1 (reference)</td><td></td></tr><tr><td>All uveitis</td><td>33</td><td>25,678</td><td>128.5</td><td>6.34 (3.84–10.44)</td><td>< 0.001</td></tr><tr><td>Recurrent uveitis</td><td>12</td><td>4224</td><td>284.1</td><td>14.38 (7.28–28.41)</td><td>< 0.001</td></tr><tr><td rowspan="3"> Female</td><td>Control subjects</td><td>15</td><td>117,744</td><td>12.7</td><td>1 (reference)</td><td></td></tr><tr><td>All uveitis</td><td>24</td><td>21,235</td><td>113.0</td><td>9.54 (4.99–18.24)</td><td>< 0.001</td></tr><tr><td>Recurrent uveitis</td><td>9</td><td>3350</td><td>268.7</td><td>23.61 (10.05–55.47)</td><td>< 0.001</td></tr></table>
|
152b3161bb50692eba8c94c2f2d0cc435b7ae89d766c968db0b9b955f8f4f033.png
|
complex
|
<table><tr><td>Gene name</td><td>Cytoband</td><td>Probeset on U133A array</td><td>No. cases with LOH</td><td>No. cases without LOH</td><td>No. SNPs</td><td>Fold change with LOH</td><td>Fold change without LOH</td><td>T-test</td><td>P-value</td></tr><tr><td colspan="10"><i><underline>Table 4.a.: Genes/probes with CN loss (CN = 1)</underline></i></td></tr><tr><td><i>ATXN7</i></td><td>chr3p21.1-p12</td><td>204516_at</td><td>4</td><td>2</td><td>10</td><td>0.574</td><td>0.258</td><td>-8.233</td><td>1.333E-03</td></tr><tr><td><i>CTDSPL</i></td><td>chr3p21.3</td><td>213597_s_at</td><td>3</td><td>3</td><td>13</td><td>0.997</td><td>0.890</td><td>-5.414</td><td>8.188E-03</td></tr><tr><td><i>F2R</i></td><td>chr5q13</td><td>203989_x_at</td><td>3</td><td>2</td><td>4</td><td>6.083</td><td>1.217</td><td>-6.771</td><td>7.275E-03</td></tr><tr><td><i>RAB5A</i></td><td>chr3p24-p22</td><td>209089_at</td><td>5</td><td>2</td><td>6</td><td>0.419</td><td>0.240</td><td>-9.065</td><td>5.698E-04</td></tr><tr><td><i>RAF1</i></td><td>chr3p25</td><td>201244_s_at</td><td>3</td><td>2</td><td>9</td><td>0.555</td><td>0.389</td><td>-24.008</td><td>5.074E-04</td></tr><tr><td><i>SCN10A</i></td><td>chr3p22-p21</td><td>208578_at</td><td>3</td><td>4</td><td>23</td><td>1.806</td><td>0.884</td><td>-4.253</td><td>8.107E-03</td></tr><tr><td colspan="10"><i><underline>Table 4.b.: Genes/probes with CN gain (CN = 3 or 4)</underline></i></td></tr><tr><td><i>ARHGAP5</i></td><td>chr14q12</td><td>217936_at</td><td>2</td><td>5</td><td>1</td><td>1.731</td><td>0.769</td><td>-4.809</td><td>8.159E-03</td></tr><tr><td><i>CYP11B1</i></td><td>chr8q21</td><td>214610_at</td><td>2</td><td>6</td><td>3</td><td>0.915</td><td>1.114</td><td>4.728</td><td>3.469E-03</td></tr><tr><td><i>NFATC4</i></td><td>chr14q11.2</td><td>205897_at</td><td>2</td><td>3</td><td>1</td><td>1.363</td><td>0.903</td><td>-11.692</td><td>2.823E-03</td></tr><tr><td><i>PAX9</i></td><td>chr14q12-q13</td><td>207059_at</td><td>2</td><td>5</td><td>1</td><td>0.898</td><td>0.319</td><td>-5.395</td><td>5.706E-03</td></tr><tr><td><i>PPFIA1</i></td><td>chr11q13.3</td><td>202066_at</td><td>7</td><td>2</td><td>12</td><td>7.524</td><td>2.448</td><td>-3.918</td><td>6.425E-03</td></tr><tr><td><i>TP63</i></td><td>chr3q28</td><td>211834_s_at</td><td>2</td><td>13</td><td>17</td><td>0.901</td><td>1.197</td><td>3.438</td><td>9.809E-03</td></tr><tr><td><i>TP63</i></td><td>chr3q28</td><td>211194_s_at</td><td>2</td><td>13</td><td>18</td><td>0.987</td><td>2.649</td><td>4.008</td><td>3.640E-03</td></tr></table>
|
a8655651ba0379fb14c08067928ff9e65d815aa1d316e81f8161ae2aff204b64.png
|
simple
|
<table><tr><td>Gene symbol/lncRNA</td><td>Degree </td><td>Style </td><td>Type </td></tr><tr><td>Shmt2 </td><td>55 </td><td>Up </td><td>Coding </td></tr><tr><td>NONMMUT069313 </td><td>54 </td><td>Up </td><td>Noncoding</td></tr><tr><td>Vimp</td><td>54 </td><td>Down </td><td>Coding </td></tr><tr><td>NONMMUT068653 </td><td>54 </td><td>Up </td><td>Noncoding</td></tr><tr><td>Asap3 </td><td>53 </td><td>Up </td><td>Coding </td></tr><tr><td>NONMMUT001721 </td><td>53 </td><td>Down </td><td>Noncoding</td></tr><tr><td>NONMMUT067923 </td><td>53 </td><td>Up </td><td>Noncoding</td></tr><tr><td>Flna</td><td>52 </td><td>Up </td><td>Coding </td></tr><tr><td>XR_141418 </td><td>52 </td><td>Down </td><td>Noncoding</td></tr><tr><td>Ganab</td><td>52 </td><td>Down </td><td>Coding </td></tr></table>
|
f4c6268f33a355651aaabe23cd631cb70bbd1a1340f74b9c6c1760bc3665070a.png
|
complex
|
<table><tr><td>Variable</td><td>Cases</td><td>Controls</td><td><i>P</i> value</td></tr><tr><td>Age, mean years</td><td>64.21 ± 18.1</td><td>60.74 ± 21.7</td><td>0.198</td></tr><tr><td>Sex</td><td> </td><td> </td><td> </td></tr><tr><td> Male</td><td>41 (47.1%)</td><td>86 (46.7%)</td><td rowspan="2">0.952</td></tr><tr><td> Female</td><td>46 (59.9%)</td><td>98 (53.3%)</td></tr></table>
|
dd5e65b8db2ee947b239ff7b3b379683271db14994a2b831c89399e8db78d618.png
|
simple
|
<table><tr><td>Phage</td><td>Farm</td><td>Genome Size (bp)</td><td>GC Content (%)</td><td>ORFs (<i>n</i>)</td><td>Terminal Repeat (bp)</td><td>Promoters (<i>n</i>)</td><td>Terminators (<i>n</i>)</td><td>Accession Number</td></tr><tr><td>fPS-7</td><td>3</td><td>38,966</td><td>45.6</td><td>51</td><td>200</td><td>12</td><td>4</td><td>LT961840</td></tr><tr><td>fPS-9</td><td>3</td><td>39,034</td><td>45.6</td><td>52</td><td>200</td><td>13</td><td>5</td><td>LT960606</td></tr><tr><td>fPS-10</td><td>3</td><td>39,179</td><td>45.5</td><td>51</td><td>202</td><td>12</td><td>4</td><td>LT962907</td></tr><tr><td>fPS-16</td><td>3</td><td>39,227</td><td>45.5</td><td>51</td><td>200</td><td>12</td><td>4</td><td>LT962906</td></tr><tr><td>fPS-19</td><td>3</td><td>38,938</td><td>45.6</td><td>51</td><td>200</td><td>12</td><td>4</td><td>LT961838</td></tr><tr><td>fPS-21</td><td>3</td><td>39,180</td><td>45.5</td><td>51</td><td>202</td><td>12</td><td>4</td><td>LT961844</td></tr><tr><td>fPS-26</td><td>5</td><td>38,792</td><td>45.7</td><td>51</td><td>205</td><td>12</td><td>4</td><td>LT961836</td></tr><tr><td>fPS-50</td><td>7</td><td>39,764</td><td>45.5</td><td>50</td><td>224</td><td>12</td><td>4</td><td>LT961843</td></tr><tr><td>fPS-52</td><td>7</td><td>39,888</td><td>45.4</td><td>50</td><td>224</td><td>12</td><td>4</td><td>LT961837</td></tr><tr><td>fPS-53</td><td>7</td><td>40,451</td><td>45.4</td><td>50</td><td>196</td><td>11</td><td>3</td><td>LT962379</td></tr><tr><td>fPS-54-ocr</td><td>7</td><td>40,074</td><td>45.5</td><td>49</td><td>200</td><td>11</td><td>4</td><td>LT962475</td></tr><tr><td>fPS-59</td><td>21</td><td>38,391</td><td>45.7</td><td>47</td><td>190</td><td>11</td><td>4</td><td>LT961845</td></tr><tr><td>fPS-64</td><td>5</td><td>39,326</td><td>45.5</td><td>50</td><td>204</td><td>12</td><td>4</td><td>LT961846</td></tr><tr><td>fPS-85</td><td>26</td><td>40,429</td><td>45.4</td><td>50</td><td>196</td><td>11</td><td>3</td><td>LT962380</td></tr><tr><td>fPS-86</td><td>28</td><td>39,024</td><td>45.6</td><td>51</td><td>215</td><td>12</td><td>4</td><td>LT961842</td></tr><tr><td>fPS-89</td><td>25</td><td>40,405</td><td>45.4</td><td>50</td><td>195</td><td>11</td><td>3</td><td>LT961841</td></tr></table>
|
37212d3dce43955311b2051946c355555b1129e7bfa2a533f585217d5fee995f.png
|
complex
|
<table><tr><td rowspan="2"> </td><td colspan="2">NC</td><td colspan="2">HFD</td></tr><tr><td>Mig-6<sup><i>f/f</i></sup></td><td>Mig-6<sup><i>d/d</i></sup></td><td>Mig-6<sup><i>f/f</i></sup></td><td>Mig-6<sup><i>d/d</i></sup></td></tr><tr><td>Total-cholesterol (mg/dL)</td><td>120.0 ± 7.0</td><td>170.1 ± 18.4<sup><i>∗</i></sup></td><td>107.2 ± 11.0</td><td>319.0 ± 25.7<sup><i>∗∗∗</i>###</sup></td></tr><tr><td>HDL-cholesterol (mg/dL)</td><td>86.5 ± 3.1</td><td>133.8 ± 13.7<sup><i>∗∗</i></sup></td><td>77.4 ± 6.9</td><td>244.6 ± 19.4<sup><i>∗∗∗</i>###</sup></td></tr><tr><td>LDL-cholesterol (mg/dL)</td><td>11.1 ± 1.7</td><td>13.6 ± 2.0</td><td>10.9 ± 1.4</td><td>35.1 ± 3.5<sup><i>∗∗∗</i>###</sup></td></tr><tr><td>TG (mg/dL)</td><td>54.7 ± 7.7</td><td>60.2 ± 9.0</td><td>57.6 ± 7.0</td><td>123.3 ± 17.3<sup><i>∗∗</i>##</sup></td></tr><tr><td>FFA (uEq/dL)</td><td>34.2 ± 2.3</td><td>34.0 ± 2.3</td><td>21.1 ± 1.5<sup>###</sup></td><td>32.3 ± 2.5<sup>##</sup></td></tr></table>
|
bba85e2db4f2a294c6b1239c22c26d62ea8dd41bfc3bb57ebcb6b03819fd53e7.png
|
complex
|
<table><tr><td rowspan="2">Dose scenario</td><td colspan="2">Design</td></tr><tr><td>3 + 3</td><td>CRM</td></tr><tr><td>Scenario 1: (0.00, 0.30, 0.40, 0.60)</td><td>10.1 (3.2)</td><td>12.0 (1.7)</td></tr><tr><td>Scenario 2: (0.05, 0.05, 0.30, 0.30)</td><td>13.3 (3.5)</td><td>11.8 (2.0)</td></tr><tr><td>Scenario 3: (0.05, 0.10, 0.15, 0.30)</td><td>14.4 (3.7)</td><td>11.9 (2.2)</td></tr><tr><td>Scenario 4: (0.00, 0.25, 0.30, 0.45)</td><td>11.3 (3.7)</td><td>12.1 (1.7)</td></tr></table>
|
d5f7f99abf7c60f756c38f89d86ffaf214ea9b3c64b3db20ca7c9f1bc050b6d4.png
|
simple
|
<table><tr><td>Most prevalent colonizing serotype(s)</td><td>Region</td><td>Reference</td></tr><tr><td>Ia, Ib, II, III, V</td><td>North America, United States, Europe</td><td>Johri et al., 2006; Ippolito et al., 2010; Lamagni et al., 2013; Melin and Efstratiou, 2013; Florindo et al., 2014; Fabbrini et al., 2016</td></tr><tr><td>Ia</td><td>Mexico</td><td>Ippolito et al., 2010</td></tr><tr><td>IV, Ia</td><td>United Arab Emirates</td><td>Amin et al., 2002</td></tr><tr><td>V</td><td>Egypt</td><td>Shabayek et al., 2014</td></tr><tr><td>Ia, VI</td><td>Malaysia</td><td>Karunakaran et al., 2009; Dhanoa et al., 2010</td></tr><tr><td>VI, VIII</td><td>Japan</td><td>Lachenauer et al., 1999; Matsubara et al., 2002</td></tr></table>
|
a096b95aeb545802b1424edfb8e1d632221da20ce4c82547d3f5c481464a0501.png
|
simple
|
<table><tr><td>Variable</td><td>Dubti</td><td></td><td></td><td>Amibara</td><td></td><td></td><td></td></tr><tr><td></td><td>Female (%)</td><td>Male (%)</td><td>Total (%)</td><td>Female (%)</td><td>male (%)</td><td>Total (%)</td><td>Total (%)</td></tr><tr><td>TBL is a health problem:</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>49 (35.8)</td><td>66 (30.6)</td><td>115 (32.6)*</td><td>28 (16.2)</td><td>38 (17.6)</td><td>66 (17.0)*</td><td>181 (24.4)</td></tr><tr><td>Rare</td><td>84 (61.3)</td><td>146 (67.6)</td><td>230 (65.2)*</td><td>133 (76.9)</td><td>168 (77.8)</td><td>301 (77.4)*</td><td>531 (71.6)</td></tr><tr><td>No</td><td>4 (2.9)</td><td>4 (1.9)</td><td>8 (2.3)</td><td>12 (6.9)</td><td>10 (4.6)</td><td>22 (5.7)</td><td>30 (4.0)</td></tr><tr><td>Do not know</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td></tr><tr><td>TBL is a public health problem since when:</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Since many years ago</td><td>85 (64.4)</td><td>129 (61.1)</td><td>214 (62.4)*</td><td>156 (96.9)</td><td>196 (95.1)</td><td>352 (95.9)*</td><td>566 (79.7)</td></tr><tr><td>Since recent years</td><td>46 (34.8)</td><td>82 (38.9)</td><td>128 (37.3)*</td><td>3 (1.9)</td><td>9 (4.4)</td><td>12 (3.3)*</td><td>140 (19.7)</td></tr><tr><td>Do not know</td><td>1 (0.8)</td><td>0 (0)</td><td>1 (0.3)</td><td>2 (1.2)</td><td>1 (0.5)</td><td>3 (0.8)</td><td>4 (0.6)</td></tr><tr><td>TBL mostly attacks:</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Male</td><td>10 (7.4)</td><td>31(14.5)</td><td>41(11.7)</td><td>12 (7.0)</td><td>29 (13.4)</td><td>41(10.6)</td><td>82 (11.1)</td></tr><tr><td>Female</td><td>7 (5.1)</td><td>6 (2.8)</td><td>13 (3.7)</td><td>8 (4.7)</td><td>7 (3.2)</td><td>15 (3.9)</td><td>28 (3.8)</td></tr><tr><td>Both</td><td>100 (73.5)</td><td>160 (74.8)</td><td>260 (74.3)</td><td>124 (72.1)</td><td>145 (67.1)</td><td>269 (69.3)</td><td>529 (71.7)</td></tr><tr><td>Do not know</td><td>19 (14.0)</td><td>17 (7.9)</td><td>36 (10.3)</td><td>28 (16.3)</td><td>35 (16.2)</td><td>63 (16.2)</td><td>99 (13.4)</td></tr><tr><td>TBL mostly attacks:</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Under 5 years</td><td>96 (70.1)</td><td>147 (69.0)</td><td>243 (69.4)*</td><td>88 (51.5)</td><td>130 (59.9)</td><td>218 (56.2)*</td><td>461 (62.5)</td></tr><tr><td>Children b/n 5 - 15 years</td><td>119 (86.9)*</td><td>200 (93.9)*</td><td>319 (91.1)*</td><td>104 (60.8)</td><td>139 (64.1)</td><td>243 (62.6)*</td><td>562 (76.2)</td></tr><tr><td>Adult under 60 years</td><td>103 (75.2)</td><td>144 (67.6)</td><td>247 (70.6)*</td><td>146 (85.4)</td><td>173 (79.7)</td><td>319 (82.2)*</td><td>566 (76.7)</td></tr><tr><td>Old person over 60 years</td><td>97 (70.8)</td><td>146 (68.5)</td><td>243 (69.4)*</td><td>141 (82.5)</td><td>170 (78.3)</td><td>311 (80.2)*</td><td>554 (75.1)</td></tr><tr><td>Do not know</td><td>6 (4.4)</td><td>2 (0.9)</td><td>8 (2.3)</td><td>15 (8.8)</td><td>16 (7.4)</td><td>31 (8.0)</td><td>39 (5.3)</td></tr></table>
|
6818fb870e7a94459e95223aef22b393550a7251d0a8b5c1cfcf98933cd52a36.png
|
simple
|
<table><tr><td></td><td>H1</td><td>Mesendoderm</td><td>Trophoblast-like cells</td><td>Mesenchymal stem cells</td><td>Neuronal progenitor cells</td></tr><tr><td>1</td><td>H3K4me2,H3K4me1, H2aK5ac,H3K27ac, H2bK5ac,H3K23ac, H3K9me3,H3K79me1, H3K4ac,H3K9ac, H2bK120ac</td><td>H3K4me2,H3K4me1, H3K27ac,H3K23ac, H3K9ac,H3K18ac</td><td>H2aK5ac,H2bK5ac, H3K27me3,H3K23ac, H3K9me3,H3K79me1, H3K4ac,H3K9ac, H2bK120ac,H3K18ac</td><td>H3K4me2,H3K36me3, H3K27ac,H2bK5ac, H3K23ac,H3K9me3, H3K4ac,H3K9ac, H2bK120ac</td><td>H3K4me1,H3K36me3, H2aK5ac,H3K27ac, H2bK5ac,H3K27me3, H3K23ac,H3K79me1, H3K9ac,H2bK120ac</td></tr><tr><td>2</td><td>H2aK5ac,H2bK5ac, H3K23ac,H3K79me1, H3K4ac,H2bK120ac</td><td>H3K4me2,H3K4me1, H3K27ac,H3K23ac, H3K9ac,H2bK120ac</td><td>H3K4me1,H2bK5ac, H3K27me3,H3K23ac, H3K9me3,H3K79me1, H3K4ac,H3K9ac, H2bK120ac,H3K18ac</td><td>H3K4me2,H3K36me3, H2bK5ac,H3K23ac, H3K4ac,H2bK120ac</td><td>H3K4me1,H3K36me3, H3K27ac,H2bK5ac, H3K27me3,H3K9me3, H3K79me1,H3K9ac, H2bK120ac</td></tr><tr><td>3</td><td>H2bK5ac,H3K27me3, H3K23ac,H3K79me1, H3K4ac,H3K9ac</td><td>H2aK5ac,H2bK5ac, H3K79me1,H3K4ac, H2bK120ac,H3K18ac</td><td>H3K27ac,H2bK5ac, H3K27me3,H3K23ac, H3K9me3,H3K18ac</td><td>H3K36me3,H2aK5ac, H2bK5ac,H3K23ac, H3K9me3,H3K4ac H3K9ac</td><td>H3K4me2,H2aK5ac, H3K23ac,H3K9me3, H3K4ac,H2bK120ac</td></tr><tr><td>4</td><td>H3K4me2,H3K4me1, H2aK5ac,H3K27ac, H2bK5ac,H3K27me3, H3K23ac,H3K79me1, H3K4ac,H3K9ac,H3K18ac</td><td>H3K4me1,H3K36me3, H3K27ac,H3K23ac, H3K79me1,H3K4ac, H3K9ac,H2bK120ac, H3K18ac</td><td>H3K27ac,H2bK5ac, H3K27me3,H3K23ac, H3K9me3,H2bK120ac</td><td>H3K36me3,H2aK5ac, H2bK5ac,H3K23ac, H3K4ac,H3K9ac</td><td>H3K4me2,H2aK5ac, H3K23ac,H3K9me3, H3K9ac,H2bK120ac</td></tr><tr><td>5</td><td>H2bK5ac,H3K27me3, H3K23ac,H3K79me1, H3K4ac,H3K18ac</td><td>H3K27ac,H3K27me3, H3K9me3,H3K4ac, H2bK120ac,H3K18ac</td><td>H3K27ac,H2bK5ac, H3K27me3,H3K23ac, H3K9me3,H3K9ac</td><td>H3K4me2,H3K36me3, H2bK5ac,H3K23ac, H3K9me3,H3K9ac</td><td>H3K27ac,H2bK5ac, H3K27me3,H3K9me3, H3K9ac,H2bK120ac</td></tr><tr><td>6</td><td>H2aK5ac,H2bK5ac, H3K9me3,H3K79me1, H3K4ac,H2bK120ac</td><td>H3K4me2,H3K27ac, H3K9me3,H3K4ac, H2bK120ac,H3K18ac</td><td>H3K27ac,H2bK5ac, H3K27me3,H3K23ac, H3K9me3,H3K79me1</td><td>H3K36me3,H2aK5ac, H2bK5ac,H3K9me3, H3K4ac,H2bK120ac</td><td>H3K27ac,H2bK5ac, H3K27me3,H3K9me3, H3K4ac,H2bK120ac</td></tr><tr><td>7</td><td>H2aK5ac,H2bK5ac, H3K23ac,H3K79me1, H3K4ac,H3K9ac</td><td>H3K4me2,H3K4me1, H3K27ac,H3K27me3, H3K9me3,H3K18ac</td><td>H3K27ac,H2bK5ac, H3K27me3,H3K23ac, H3K9me3,H3K4ac</td><td>H3K4me2,H3K36me3, H2bK5ac,H3K23ac, H3K9me3,H3K4ac</td><td>H3K4me2,H3K4me1, H3K23ac,H3K9me3, H3K9ac,H2bK120ac</td></tr><tr><td>8</td><td>H3K4me2,H2aK5ac, H3K27ac,H2bK5ac, H3K27me3,H3K23ac, H3K9me3,H3K79me1, H3K4ac,H3K9ac,H3K18ac</td><td>H3K4me2,H3K4me1, H3K27ac,H3K27me3, H3K4ac,H3K18ac</td><td>H3K4me2,H3K27ac, H3K27me3,H3K23ac, H3K9me3,H3K9ac</td><td>H3K4me2,H3K36me3, H2bK5ac,H3K23ac, H3K4ac,H3K9ac, H2bK120ac</td><td>H3K4me2,H3K4me1, H3K23ac,H3K9me3, H3K4ac,H2bK120ac</td></tr><tr><td>9</td><td>H3K4me2,H3K4me1, H2aK5ac,H3K27ac, H2bK5ac,H3K23ac, H3K9me3,H3K79me1, H3K4ac,H3K9ac H3K18ac</td><td>H3K4me2,H3K4me1, H3K27ac,H3K27me3, H3K4ac,H2bK120ac</td><td>H3K4me1,H3K27ac, H3K27me3,H3K23ac, H3K9me3,H3K79me1</td><td>H3K4me2,H3K4me1, H3K9me3,H3K4ac, H3K9ac,H2bK120ac</td><td>H3K4me2,H3K4me1, H3K36me3,H2aK5ac, H3K27me3,H3K23ac, H3K79me1,H3K9ac, H2bK120ac</td></tr><tr><td>10</td><td>H2aK5ac,H2bK5ac, H3K9me3,H3K79me1, H3K4ac,H3K9ac</td><td>H3K4me2,H3K27ac, H3K27me3,H3K4ac, H2bK120ac,H3K18ac</td><td>H3K4me1,H3K27ac, H3K27me3,H3K23ac, H3K9me3,H3K79me1</td><td>H3K4me2,H3K36me3, H2bK5ac,H3K23ac, H3K9me3,H2bK120ac</td><td>H3K4me2,H3K4me1, H2aK5ac,H3K27ac, H3K9me3,H3K9ac, H2bK120ac</td></tr></table>
|
583998c164974aa73f9f7901861f89147707d45e085286923cf9b5d75d41bc20.png
|
simple
|
<table><tr><td></td><td>Proteins</td><td>Pfam</td><td>SMART</td><td>GO</td><td>Taxonomy</td><td>Semantic similarity</td><td>Functional similarity</td></tr><tr><td>GOTaxExplorer</td><td>b,f,c</td><td>b,f,c</td><td>b,f,c</td><td>b,f,c</td><td>b,f,c</td><td>b,f,-</td><td>b,f,-</td></tr><tr><td>UniProt</td><td>b,f,c</td><td>b,f,c</td><td>b,f,c</td><td>b,f,c</td><td>b,f,c</td><td>-,-,-</td><td>-,-,-</td></tr><tr><td>Pfam</td><td>b,f,-</td><td>b,f,-</td><td>-,f,-</td><td>-,f,-</td><td>b,f,-</td><td>-,-,-</td><td>-,-,-</td></tr><tr><td>SMART</td><td>b,f,-</td><td>-,f,-</td><td>b,f,-</td><td>b,f,-</td><td>b,f,-</td><td>-,-,-</td><td>-,-,-</td></tr><tr><td>PANTHER*</td><td>b,f,-</td><td>-,-,-</td><td>-,-,-</td><td>b,f,c</td><td>b,f,c</td><td>-,-,-</td><td>-,-,-</td></tr><tr><td>InterPro</td><td>b,f,c</td><td>b,f,c</td><td>b,f,c</td><td>b,f,c</td><td>b,f,c</td><td>-,-,-</td><td>-,-,-</td></tr><tr><td>BioDW</td><td>b,f,-</td><td>-,-,-</td><td>-,-,-</td><td>b,f,-</td><td>-,-,-</td><td>b,f,-</td><td>-,-,-</td></tr><tr><td>GOGraph</td><td>-,-,-</td><td>-,-,-</td><td>-,-,-</td><td>-,-,-</td><td>-,-,-</td><td>b,-,-</td><td>b,-,-</td></tr><tr><td>DynGO</td><td>b,f,-</td><td>-,-,-</td><td>-,-,-</td><td>b,f,-</td><td>-,-,-</td><td>-,-,-</td><td>b,-,-</td></tr><tr><td>GFSST<sup>†</sup></td><td>b,f,-</td><td>-,-,-</td><td>-,-,-</td><td>b,f,-</td><td>-,-,-</td><td>-,-,-</td><td>b,-,-</td></tr></table>
|
dfddc0634b3104887c8902e08f0dc8ba298d634b039db4b76dbd5c9cc54408d7.png
|
simple
|
<table><tr><td>First author</td><td>Year</td><td>Year of recruitment</td><td>Race</td><td>Stage</td><td>Pathological type</td><td>No. of Patients</td><td>HPV + ve<i>N</i> (%)</td><td>Age, y</td><td>Genotype(s)</td><td>DNA method</td><td>Median follow-up period (months)</td><td>Hazardratio</td></tr><tr><td>Iwamasa</td><td>2000</td><td>1993-1995</td><td>Asian</td><td>I-II</td><td>LSCC</td><td>41</td><td>25(61.0)</td><td>69.8(+)/70.8(-)</td><td>6,11,16,18</td><td>PCR</td><td>NA</td><td>SC</td></tr><tr><td>Miyagi</td><td>2001</td><td>1995-1997</td><td>Asian</td><td>I-II</td><td>LA+LSCC</td><td>120</td><td>41(34.2)</td><td>LA: 67.3(+)/66.9(-)LSCC: 66.3(+)/69.7(-)</td><td>6,11,16,18</td><td>PCR</td><td>NA</td><td>SC</td></tr><tr><td>Hsu</td><td>2009</td><td>2000-2006</td><td>Asian</td><td>I</td><td>NSCLC</td><td>171</td><td>17(9.9)</td><td>65.2 (37-83)</td><td>16,18</td><td>IMC</td><td>56.4</td><td>SC</td></tr><tr><td>Wu</td><td>2012</td><td>1998-2014</td><td>Asian</td><td>I-III</td><td>NSCLC</td><td>165</td><td>74(44.8)</td><td>NA</td><td>16,18</td><td>PCR</td><td>59.3</td><td>SC</td></tr><tr><td>Chen</td><td>2013</td><td>2002-2007</td><td>Asian</td><td>I-III</td><td>LC</td><td>319</td><td>91(28.5)</td><td>NA</td><td>16,18</td><td>PCR</td><td>57.6</td><td>SC</td></tr><tr><td>Anantharaman</td><td>2014</td><td>2007-2010</td><td>Caucasian</td><td>NA</td><td>LC</td><td>62</td><td>15(24.2)</td><td>62.1</td><td>21 types*</td><td>PCR</td><td>43.44</td><td>Report</td></tr><tr><td>Chen</td><td>2014</td><td>1993-2014</td><td>Asian</td><td>NA</td><td>NSCLC</td><td>117</td><td>62(53.0)</td><td>NA</td><td>16,18</td><td>PCR</td><td>NA</td><td>Report</td></tr><tr><td>Wang</td><td>2014</td><td>2003-2011</td><td>Asian</td><td>I-IV</td><td>LA</td><td>210</td><td>74(35.2)</td><td>69.5</td><td>16,18</td><td>PCR</td><td>12.6</td><td>Report</td></tr></table>
|
a0775d09e1dcbf952447ff53cc950f12e4779e10f46f0e06ff3c38500e659031.png
|
simple
|
<table><tr><td>Type of Study/Description</td><td>Advantages</td><td>Limitations</td></tr><tr><td>Cell culture – in vitroFood item is placed in cells or other tissues in culture conditions.</td><td>Help determine mechanisms of action.Provide clues for further investigation to define mechanisms responsible for how food components interact with host cells.</td><td>What occurs in cells may be different from what occurs in human body.Not conclusive.</td></tr><tr><td>Animal – in vivoFood item is fed to laboratory animals (e.g. rat, mouse, guinea pig, rabbit). Tests the effects of food on certain diseases, physiological conditions, and behaviors</td><td>Can be tightly controlled for testing the metabolism, specificity, and reproducibility of the effect of a certain food component.Tests the toxicity and safety of food components added to the diet.</td><td>Humans differ from animals in many aspects of their physiology, such as food digestion, nutrient absorption, genetics, lifestyle, etc.Not conclusive.</td></tr><tr><td>Case studiesOne individual’s experience with food or a food component is documented.</td><td>Help determine how certain food/components may affect clinical conditions or disorders in humans.Focus on social, psychological, or medical conditions.Provide clues for further investigation.</td><td>Not scientifically rigorous – only one person’s experience.Not conclusive but is more evidence-building.</td></tr><tr><td>Epidemiological/observationalGroups of subjects, typically living in one geographical area, who have developed a disease or condition are compared with a similar sample of subjects who have not developed the disease.</td><td>Address whether a certain food/component could cause a disease but not whether it did cause a disease.</td><td>Memory recall is often used to assess how a food/component might have affected an individual – long-term memory recall may not be accurate.Regionally biased – differences observed between regions may be related to different dietary of cultural preferences or genetic differences.Not conclusive but is more evidence-building.</td></tr><tr><td>Prospective cohort studiesA large group of individuals with a similar background who are healthy when the study begins are followed over time. Diets are assessed at the beginning, during, and end of the study. Eating habits of those who get a disease are compared to those who do not acquire a disease.</td><td>Provide clues about the risk/benefits of a given diet, food component or lack of an important vitamin/mineral (e.g., development of iron deficiency and neurodevelopmental impairment) over time.</td><td>The controls may not be similar to those who acquire a disease with respect to demographic and health factors.Not conclusive but is more evidence-building.</td></tr><tr><td>Randomized, controlled clinical trial (RCT)Evaluates the efficacy of a specific nutritional intervention (e.g., food/component) within a population. Subjects with similar backgrounds are randomly allocated to receive either the test item or placebo.</td><td>Represents the “gold standard” for clinical trial methodology.Randomization minimizes allocation bias by balancing both known and unknown social and health factors.Sample sizes are often large to detect subtle differences in treatments, diet or food component when they exist.Provides most conclusive evidence.</td><td>Unethical to randomize breastfed infants into an infant formula feeding group.</td></tr><tr><td>Meta-analysisReview of the existing scientific literature. Pooled data from several studies are subjected to a statistical meta-analysis.</td><td>Meta-analysis of trials provides a more precise estimate of the treatment effect because of the increased sample size and statistical power.Results can be generalized to a larger population.Inconsistency of results across studies can be quantified and analyzed.</td><td>The validity of the meta-analysis depends on the quality of the systematic review and studies included in the analysis.If confounding variables are not controlled for in the primary studies, there will be potential bias in the meta-analysis (e.g., differing definitions of breastfeeding).</td></tr></table>
|
2e1e540dd80be0ff45b21bd88d5ed5cd13dc534e62e4ac0dbf1b03f9977bb982.png
|
complex
|
<table><tr><td> </td><td colspan="5"><i>Reliability</i></td></tr><tr><td>Study characteristics</td><td># of data points K</td><td>Total sample size N</td><td>Sample-weighted mean reliability (SD)</td><td>95nnnnn CI</td><td>PVA<sub>SE</sub></td></tr><tr><td>EDI total</td><td>2</td><td>471</td><td>.81 (.06)</td><td>.72 - .90</td><td>12.68%</td></tr><tr><td>EDI body dissatisfaction subscale</td><td>3</td><td>256</td><td>.77 (.14)</td><td>.62 - .92</td><td>10.66%</td></tr><tr><td>EDI drive for thinness subscale</td><td>4</td><td>715</td><td>.60 (.15)</td><td>.45 - .75</td><td>10.07%</td></tr><tr><td>EDI bulimia subscale</td><td>4</td><td>715</td><td>.64 (.12)</td><td>.53 - .76</td><td>14.12%</td></tr><tr><td>EAT-26</td><td>4</td><td>920</td><td>.87 (.02)</td><td>.85 - .88</td><td>100.00%</td></tr></table>
|
c67b6fcebe4cc77531e461f81cee286cac270671303007ff8d6a104e67c22989.png
|
simple
|
<table><tr><td></td><td></td><td></td><td></td><td>p/q<sup>a</sup></td><td>p/q<sup>b</sup></td></tr><tr><td>rs16861210</td><td>GG (224)</td><td>GA (12)</td><td>AA (1)</td><td></td><td></td></tr><tr><td>All</td><td>7.76 (7.32-8.22)</td><td>10.27 (8.29-12.45)</td><td>11.79 (5.33-20.77)</td><td>0.029/0.032</td><td>0.143/0.495</td></tr><tr><td></td><td>GG (224)</td><td>AA, AG (13)</td><td></td><td></td><td></td></tr><tr><td>All</td><td>7.76 (7.32-8.22)</td><td>10.38 (8.47-12.48)</td><td></td><td>0.008/0.032</td><td>0.201/0.495</td></tr><tr><td>rs17366568</td><td>GG (169)</td><td>GA (59)</td><td>AA (9)</td><td></td><td></td></tr><tr><td>All</td><td>8.40 (7.88-8.94)</td><td>6.90 (6.16-7.69)</td><td>6.44 (6.48-8.48)</td><td>0.003/0.032</td><td>0.893/0.840</td></tr><tr><td></td><td>GG (169)</td><td>AA, AG (68)</td><td></td><td></td><td></td></tr><tr><td>All</td><td>8.40 (7.88-8.49)</td><td>6.84 (6.15-7.58)</td><td></td><td>0.0007/0.032</td><td>0.850/0.840</td></tr><tr><td>rs2241766</td><td>TT (224)</td><td>TG (13)</td><td></td><td></td><td></td></tr><tr><td>All</td><td>7.82 (7.38-8.28)</td><td>9.70 (7.83-11.76)</td><td></td><td>0.056/0.032</td><td>0.020/0.279</td></tr><tr><td>Men<sup>c</sup></td><td>6.45 (5.85-7.08)</td><td>12.54 (8.49-17.37)</td><td></td><td>0.003/0.131</td><td></td></tr><tr><td>Women<sup>d</sup></td><td>8.87 (8.32-9.44)</td><td>9.38 (7.30-11.71)</td><td></td><td>0.660/0.092</td><td></td></tr><tr><td>rs6773957</td><td>GG (104)</td><td>AG (110)</td><td>AA (23)</td><td></td><td></td></tr><tr><td>All</td><td>7.36 (6.74-8.00)</td><td>8.12 (7.51-8.75)</td><td>9.45 (8.05-10.96)</td><td>0.016/0.032</td><td>0.711/0.840</td></tr><tr><td></td><td>GG (104)</td><td>AA, AG (133)</td><td></td><td></td><td></td></tr><tr><td>All</td><td>7.35 (6.73-8.00)</td><td>8.34 (7.77-8.92)</td><td></td><td>0.021/0.032</td><td>0.559/0.840</td></tr><tr><td></td><td>AG, GG (214)</td><td>AA (23)</td><td></td><td></td><td></td></tr><tr><td>All</td><td>7.76 (7.31-8.22)</td><td>9.47 (8.06-10.99)</td><td></td><td>0.022/0.032</td><td>0.772/0.840</td></tr><tr><td>rs2082940</td><td>CC (224)</td><td>CT (13)</td><td></td><td></td><td></td></tr><tr><td>All</td><td>7.82 (7.38-8.28)</td><td>9.70 (7.83-11.76)</td><td></td><td>0.056/0.032</td><td>0.020/0.279</td></tr><tr><td>Men<sup>e</sup></td><td>6.45 (5.85-7.08)</td><td>12.54 (8.49-17.37)</td><td></td><td>0.003/0.131</td><td></td></tr><tr><td>Women<sup>f</sup></td><td>8.87 (8.32-9.44)</td><td>9.38 (7.30-11.71)</td><td></td><td>0.660/0.092</td><td></td></tr></table>
|
236748c400c79103f5b0149c18f70a0b7ebc8c1114f17982e3d121ecc00a6622.png
|
simple
|
<table><tr><td>S. no.</td><td>Inflammatory response/pathologic condition</td><td>Reference</td><td>Treatment dose</td><td>Radiation dose</td><td>Period of course</td><td>Drug type</td></tr><tr><td>1</td><td>Pneumonitis</td><td>(107)</td><td>Adriamycin: 50 mg/m<sup>2</sup> rechallenged for two further cycles with no symptoms with steroid cover</td><td>15 Gy</td><td>2 months</td><td>Steroid</td></tr><tr><td>2</td><td></td><td>(108)</td><td>Adriamycin: 30 mg/m<sup>2</sup></td><td>36 Gy</td><td>3 weeks</td><td>Steroids</td></tr><tr><td>3</td><td></td><td>(108)</td><td>Adriamycin: 30 mg/m<sup>2</sup></td><td>59.4 Gy</td><td>6 weeks</td><td>Steroids</td></tr><tr><td>4</td><td></td><td>(109)</td><td>Paclitaxel: 175 mg/m<sup>2</sup> rechallenged for one further cycle with no recurrence after premedication with steroids</td><td>43.2 Gy</td><td>12 days</td><td>Not specified</td></tr><tr><td>5</td><td></td><td>(110)</td><td>Intrapleural instillation of 30 mg of adriamycin</td><td>36.5 Gy</td><td>1 month</td><td>Steroids and diuretics</td></tr><tr><td>6</td><td></td><td>(111)</td><td>Mn porphyrin, MnTE-2-PyP5<sup>+</sup> (6 mg/kg/24 h)</td><td>28 Gy</td><td>2 weeks</td><td>Antioxidant and redox-modulating Mn porphyrin</td></tr><tr><td>7</td><td></td><td>(112)</td><td>Genistein diet (10 mg/kg) (in combination with radiation)</td><td>10 Gy</td><td>9 fractions of 3.1 Gy over 30 days</td><td>Soy isoflavone</td></tr><tr><td>8</td><td></td><td>(113)</td><td>Omeprazole, esomeprazole, and lansoprazole</td><td>Radiation regimen was reformulated after 50 Gy if the lesion was extended</td><td>7 days</td><td>Proton pump inhibitors</td></tr><tr><td>9</td><td></td><td>(114)</td><td>Pentoxifylline (400 mg orally)</td><td>40–84 Gy</td><td>8 weeks</td><td>Anticytokine</td></tr><tr><td>10</td><td>Stages I–III NSCLC after radiation therapy</td><td>(80, 81)</td><td>Angiotensin-converting enzyme inhibitors (ACEIs)</td><td>60 Gy</td><td>During the entire course of RT (not specified for individual patient)</td><td>ACEIs</td></tr><tr><td>11</td><td>Radiation pneumonitis/radiation-induced fibrosis</td><td>(115)</td><td>Cyclooxygenase-2 inhibitor twice daily</td><td>13.5–14.75 Gy</td><td>40 consecutive days from the day of local thoracic irradiation or 40 or 80 days later</td><td>Celecoxib (an inducible enzyme)</td></tr></table>
|
b744102f83e06053891e42c808e798620d5174f270f45fbb7f6d0064f3bd8ae8.png
|
complex
|
<table><tr><td>Factor</td><td>Items</td><td>Responses</td><td>values</td></tr><tr><td colspan="4">Outcome variables</td></tr><tr><td> Latrine ownership</td><td>Ownership of latrine</td><td>No/Yes for ownership of latrine</td><td>0/1</td></tr><tr><td colspan="4"> Consistent latrine use</td></tr><tr><td colspan="4">Predictor variables</td></tr><tr><td colspan="4">Risk Perception</td></tr><tr><td> Vulnerability</td><td>How high or low are the chances that you contract diarrheal disease when defecating in the open field?</td><td>Five point scale, that ranges from almost Very low, to Very high</td><td>1 to 5</td></tr><tr><td> Severity</td><td>If you have diarrheal disease because of open defecation, how severely would that impact your life?</td><td>Five point scale, that ranges from almost Very low, to Very high</td><td>1 to 5</td></tr><tr><td colspan="4">Attitude (affective)</td></tr><tr><td></td><td colspan="2">How much beneficial/important it is building Five point scale, that ranges from almost Very low, to Very highyour own latrine in the one year</td><td>1 to 5</td></tr><tr><td></td><td>How much beneficial/important it is to defecate using latrine regularly</td><td>Five point scale, that ranges from almost Very low, to Very high</td><td>1 to 5</td></tr><tr><td></td><td>How much do you like to use latrine?</td><td>Five point scale, that ranges from almost Very low, to Very high</td><td>1 to 5</td></tr><tr><td></td><td>How much do you do you enjoy defecating in latrine?</td><td>Five point scale, that ranges from almost Very low, to Very high</td><td>1 to 5</td></tr><tr><td rowspan="3">Self-efficacy (latrine ownership)Injective norm (latrine ownership)</td><td>How much ability you think you have building your own latrine in the next one year</td><td>Five point scale, that ranges from almost Very low, to Very high</td><td>1 to 5</td></tr><tr><td>Most of the people in my village think I should have my own latrine</td><td>Five point scale, that ranges from completely disagree to completely agree</td><td>1 to 5</td></tr><tr><td>People in my village will judge me if I don’t have my own</td><td>Five point scale, that ranges from completely disagree to completely agree</td><td>1 to 5</td></tr><tr><td rowspan="2">Descriptive norm (latrine use)</td><td>Most of the people I know in the community defecate using latrine regularly</td><td>Five point scale, that ranges from completely disagree to completely agree</td><td>1 to 5</td></tr><tr><td>How many of your neighbors use latrine for defecation?</td><td>Five point scale, that ranges from almost nobody to almost all</td><td>1 to 5</td></tr><tr><td></td><td>Using latrine regularly is the right thing to do because everybody does so</td><td>Five point scale, that ranges from completely disagree to completely agree</td><td>1 to 5</td></tr><tr><td rowspan="3">Injunctive norm (latrine use)</td><td>people who are important to me approve /disapprove that you use latrine</td><td>Five point scale, that ranges from completely disagree to completely agree</td><td>1 to 5</td></tr><tr><td>Defecating using latrine is regularly is something that most of the people in my village think</td><td>Five point scale, that ranges from completely disagree to completely agree</td><td>1 to 5</td></tr><tr><td>People in my village will judge me if I defecate in the open field</td><td>Five point scale, that ranges from completely disagree to completely agree</td><td>1 to 5</td></tr><tr><td colspan="4">Cues to action</td></tr><tr><td> Exposure to Health education (HEW)</td><td></td><td>Yes/No</td><td></td></tr><tr><td> Exposure to CLTSH triggering</td><td></td><td>Yes/No</td><td></td></tr></table>
|
5fba015a2f0835e34320dc39684bb4fa0326433b73bc2a3ac9529cb07f3a5050.png
|
simple
|
<table><tr><td> </td><td>Cases</td><td>Controls</td><td>Total</td></tr><tr><td>Number of admissions to rehab facility</td><td>n (%)</td><td>n (%)</td><td>n (%)</td></tr><tr><td>0</td><td>27 (84)</td><td>19 (79)</td><td>46 (82)</td></tr><tr><td>1</td><td>3 (9)</td><td>5 (21)</td><td>8 (14)</td></tr><tr><td>2</td><td>1 (3)</td><td>0 (0)</td><td>1 (2)</td></tr><tr><td>3</td><td>1 (3)</td><td>0 (0)</td><td>1 (2)</td></tr><tr><td>Total</td><td>32 (100)</td><td>24 (100)</td><td>56 (100)</td></tr></table>
|
db43024adfb4f1626c5688105af24f65184b47d0794dd8f919e3e7b913b2de40.png
|
complex
|
<table><tr><td>Variable</td><td>Mean</td><td>Median</td><td>Standard deviation</td><td>Relative standard deviation</td></tr><tr><td colspan="5"><i>Child survey</i></td></tr><tr><td>Percentage of overweight and obese pre-school children (5–6 years) (dependent variable)</td><td>9.31</td><td>8.60</td><td>4.19</td><td>45.02</td></tr><tr><td>Social index (based on parents education and employment status)</td><td>13.97</td><td>14.00</td><td>1.95</td><td>13.97</td></tr><tr><td>Percentage of non-German children</td><td>35.78</td><td>33.40</td><td>22.57</td><td>63.09</td></tr><tr><td>Percentage of non German children with insufficient German language skills</td><td>8.29</td><td>6.50</td><td>8.34</td><td>100.51</td></tr><tr><td>Percentage of children with measles vaccination</td><td>91.15</td><td>92.40</td><td>4.18</td><td>4.59</td></tr><tr><td>Percentage of children with bad dental hygiene</td><td>12.39</td><td>11.20</td><td>7.24</td><td>58.41</td></tr><tr><td>Percentage of children participating in regular medical check-ups</td><td>87.67</td><td>88.00</td><td>4.68</td><td>5.34</td></tr><tr><td>Percentage of children living in household with at least one smoking parent</td><td>36.03</td><td>37.20</td><td>10.72</td><td>29.75</td></tr><tr><td>Percentage of children having their own TV in bedroom</td><td>11.45</td><td>10.10</td><td>7.06</td><td>61.63</td></tr><tr><td>Percentage of children with poor eye-hand coordination</td><td>15.63</td><td>15.40</td><td>6.80</td><td>43.50</td></tr><tr><td>Percentage of German children with poor language skills</td><td>11.85</td><td>9.30</td><td>8.48</td><td>71.61</td></tr><tr><td>Percentage of non-German children with poor language skills</td><td>20.80</td><td>20.70</td><td>13.14</td><td>63.18</td></tr><tr><td>Percentage of children attending Kindergarten</td><td>89.82</td><td>90.20</td><td>5.21</td><td>5.80</td></tr><tr><td colspan="5"><i>Environmental variables and urban characteristics</i></td></tr><tr><td>Percentage of area with vegetation</td><td>0.22</td><td>0.17</td><td>0.16</td><td>71.25</td></tr><tr><td>Area of parks per km<sup>2</sup></td><td>7.1 × 10<sup>−2</sup></td><td>5.5 × 10<sup>−2</sup></td><td>5.2 × 10<sup>−2</sup></td><td>73.23</td></tr><tr><td>Number of parks per km<sup>2</sup></td><td>2.2 × 10<sup>−3</sup></td><td>2.2 × 10<sup>−3</sup></td><td>1.2 × 10<sup>−2</sup></td><td>55.39</td></tr><tr><td>Area of parks per 1000 inhabitants</td><td>15.7 × 10<sup>3</sup></td><td>11.6 × 10<sup>3</sup></td><td>13.9 × 10<sup>−3</sup></td><td>89.21</td></tr><tr><td>Number of parks per 1000 inhabitants</td><td>0.00</td><td>0.00</td><td>0.00</td><td>67.86</td></tr><tr><td>Euclidean distance to parks</td><td>429.16</td><td>330.27</td><td>326.13</td><td>75.99</td></tr><tr><td>Area of playgrounds per km<sup>2</sup></td><td>6.5 × 10<sup>−3</sup></td><td>4.6 × 10<sup>−3</sup></td><td>5.9 × 10<sup>−3</sup></td><td>90.82</td></tr><tr><td>Number of playgrounds per km<sup>2</sup></td><td>3.7 × 10<sup>−3</sup></td><td>2.2 × 10<sup>−3</sup></td><td>3.5 × 10<sup>−3</sup></td><td>95.53</td></tr><tr><td>Area of playgrounds per 1000 inhabitants</td><td>9.1 × 10<sup>2</sup></td><td>8.7 × 10<sup>2</sup></td><td>3.7 × 10<sup>2</sup></td><td>40.43</td></tr><tr><td>Number of playgrounds per 1000 inhabitants</td><td>5.1 × 10<sup>−1</sup></td><td>4.9 × 10<sup>−1</sup></td><td>1.8 × 10<sup>−1</sup></td><td>34.60</td></tr><tr><td>Euclidean distance to playgrounds</td><td>488.96</td><td>359.74</td><td>403.17</td><td>82.45</td></tr><tr><td>Number of fast food restaurants per km<sup>2</sup></td><td>3.8 × 10<sup>−6</sup></td><td>1.5 × 10<sup>−6</sup></td><td>5.0 × 10<sup>−6</sup></td><td>132.29</td></tr><tr><td>Number of fast food restaurants per 1000 inhabitants</td><td>4.3 × 10<sup>−1</sup></td><td>3.6 × 10<sup>−1</sup></td><td>2.8 × 10<sup>−1</sup></td><td>65.05</td></tr><tr><td>Availability of public transport</td><td>1134.74</td><td>868.42</td><td>914.95</td><td>80.63</td></tr><tr><td colspan="5"><i>Walkability</i></td></tr><tr><td>Connectivity</td><td>−0.04</td><td>−0.09</td><td>1.00</td><td>−2377.29</td></tr><tr><td>Entropy</td><td>−0.10</td><td>0.03</td><td>1.00</td><td>−1012.31</td></tr><tr><td>Population density</td><td>−0.03</td><td>−0.34</td><td>1.00</td><td>−3948.53</td></tr></table>
|
f93907c2e223bd1290b4b90e912dfee3892e65acfef471ce17b3b409ca3b4495.png
|
simple
|
<table><tr><td>Device</td><td>Number of Bits</td><td>Sampling Rate (GSPS) </td></tr><tr><td>Texas Instruments ADC12DJ3200</td><td>12</td><td>6.4</td></tr><tr><td>Texas Instruments ADC32RF45</td><td>14</td><td>3.0</td></tr><tr><td>Texas Instruments ADS54J60</td><td>16</td><td>1.0</td></tr><tr><td>Texas Instruments ADS1675</td><td>24</td><td>0.004</td></tr></table>
|
304261b1a716b4b71a901e6105b40854517acfe37bdd0e854ca26ad8231ded60.png
|
simple
|
<table><tr><td></td><td>Value</td></tr><tr><td>Number of patients</td><td>71</td></tr><tr><td>Pathologic lesion, <i>n</i> (%)</td><td></td></tr><tr><td> Yes</td><td>42 (59.2)</td></tr><tr><td> No</td><td>29 (40.8)</td></tr><tr><td>Indication, <i>n</i> (%)</td><td></td></tr><tr><td> Primary staging</td><td>16 (22.5)</td></tr><tr><td> Follow-up/re-staging</td><td>53 (74.6)</td></tr><tr><td> Non-oncological (FUO and aortic aneurysm graft)</td><td>2 (2.8)</td></tr><tr><td>Tumour type, <i>n</i></td><td></td></tr><tr><td> Lymphoma (NHL/HD)</td><td>18 (11/7)</td></tr><tr><td> Lung cancer (proved/suspicious/incidental)</td><td>13 (10/2/1)</td></tr><tr><td> Breast cancer</td><td>9</td></tr><tr><td> Melanoma</td><td>7</td></tr><tr><td> Renal cell</td><td>3</td></tr><tr><td> Oesophagus, larynx, stomach</td><td>2</td></tr><tr><td> Adrenal, anal, colon, fibrosarcoma, follicular thyroid, hypopharynx, nasopharynx, oropharynx, ovarian, paraganglioma, myeloid sarcoma, mesothelioma, rectal, SCC right upper arm</td><td>1</td></tr><tr><td>Under therapy, <i>n</i> (%)</td><td></td></tr><tr><td> Yes</td><td>13 (18.3)</td></tr><tr><td> No</td><td>56 (78.9)</td></tr><tr><td> N/A</td><td>2 (2.8)</td></tr></table>
|
67eac98bdb62955aaee7e80a182d1ff24af49ad3e1855fdcc3cf1d72597ccc13.png
|
simple
|
<table><tr><td>Lipase</td><td>Porcine pancreatic lipase (PPL)</td><td><i>Pseudomonas</i> sp. (PSL)</td><td><i>Pseudomonas fluorescens</i> lipase (Lipase AK, AKL)</td><td><i>Candida cylindracea</i> A.Y. lipase (AYL)</td><td><i>Candida rugosa</i> lipase (CRL)</td><td>Novozyme 435</td></tr><tr><td>Activity (μmol/h/g)</td><td>2.25</td><td>0.67</td><td>1.32</td><td>0.54</td><td>0.27</td><td>1.47</td></tr></table>
|
7678a96f045dcb7038470b92892bb2b8e815bbd7eb3818c5a3be7494fd66e01b.png
|
simple
|
<table><tr><td></td><td>S/L<sup>† </sup>group (n = 72)</td><td>R/H<sup>‡ </sup>group (n = 13)</td><td>Total (n = 85)</td><td><i>p</i></td></tr><tr><td></td><td>number (%) *</td><td>number (%) *</td><td>number (%) *</td><td></td></tr><tr><td>EpidemiologicalData</td><td></td><td></td><td></td><td></td></tr><tr><td> Sex</td><td></td><td></td><td></td><td>0.758</td></tr><tr><td>Male</td><td>44 (61.1)</td><td>9 (69.2)</td><td>53 (62.4)</td><td></td></tr><tr><td>Female</td><td>28 (38.9)</td><td>4 (30.8)</td><td>32 (37.6)</td><td></td></tr><tr><td> Age (mean years ± SEM<sup>§</sup>)</td><td>33.7 ± 1.1</td><td>31.4 ± 1.5</td><td>33.4 ± 0.9</td><td>0.426</td></tr><tr><td> Transmission route</td><td></td><td></td><td></td><td>0.184</td></tr><tr><td>Heterosexual: extramarital</td><td>31 (43.1)</td><td>6 (46.2)</td><td>37 (43.5)</td><td></td></tr><tr><td>Heterosexual: infected-partner</td><td>31 (43.1)</td><td>2 (15.4)</td><td>33 (38.8)</td><td></td></tr><tr><td>Others</td><td>10 (13.9)</td><td>5 (38.5)</td><td>15 (17.6)</td><td></td></tr><tr><td>Clinical Data</td><td></td><td></td><td></td><td></td></tr><tr><td> Common clinical findings</td><td></td><td></td><td></td><td></td></tr><tr><td>Fever of Unknown Origin (FUO)</td><td>27 (37.5)</td><td>6 (46.2)</td><td>33 (38.8)</td><td>0.554</td></tr><tr><td>Acute febrile syndrome</td><td>23 (31.9)</td><td>8 (61.5)</td><td>31 (36.5)</td><td>0.060</td></tr><tr><td>Asymptomatic</td><td>17 (23.6)</td><td>3 (23.1)</td><td>20 (23.5)</td><td>1.000</td></tr><tr><td>Diarrea</td><td>18 (25.0)</td><td>2 (15.4)</td><td>20 (23.5)</td><td>0.724</td></tr><tr><td>Pulmonary TBc</td><td>17 (23.6)</td><td>2 (15.4)</td><td>19 (22.4)</td><td>0.723</td></tr><tr><td>Others</td><td>24 (33.3)</td><td>6 (46.2)</td><td>30 (35.3)</td><td>0.529</td></tr><tr><td> CDC Clinical category<sup>1</sup></td><td></td><td></td><td></td><td>0.342</td></tr><tr><td>A</td><td>27 (37.5)</td><td>4 (30.8)</td><td>31 (36.5)</td><td></td></tr><tr><td>B</td><td>19 (26.4)</td><td>6 (46.2)</td><td>25 (29.4)</td><td></td></tr><tr><td>C</td><td>26 (36.1)</td><td>3 (23.1)</td><td>29 (34.1)</td><td></td></tr><tr><td> CDC CD4 category<sup>2</sup></td><td></td><td></td><td></td><td>0.063</td></tr><tr><td>1</td><td>8(11.1)</td><td>2 (15.4)</td><td>10 (11.8)</td><td></td></tr><tr><td>2</td><td>30(41.7)</td><td>1 (7.7)</td><td>31 (36.5)</td><td></td></tr><tr><td>3</td><td>34(47.2)</td><td>10(76.9)</td><td>44 (51.8)</td><td></td></tr><tr><td> Combined CDC AIDS Category<sup>3</sup></td><td>41 (56.9)</td><td>10(76.9)</td><td>51 (60.0)</td><td>0.227</td></tr><tr><td>Virological Data</td><td></td><td></td><td></td><td></td></tr><tr><td> Genotype</td><td></td><td></td><td></td><td>1.000</td></tr><tr><td>HIV-1C</td><td>72(100)</td><td>13(100)</td><td>85(100)</td><td></td></tr><tr><td> Phenotype</td><td></td><td></td><td></td><td>1.000</td></tr><tr><td>R5</td><td>68 (94.4)</td><td>13(100)</td><td>81 (95.3)</td><td></td></tr><tr><td>×4</td><td>4 (5.6)</td><td>0 (0)</td><td>4 (4.7)</td><td></td></tr><tr><td>p24 Ag titer (pg/ml; mean ± SEM<sup>§</sup>)</td><td>189.0 ± 5.8</td><td>1745.7 ± 64.9</td><td>427.1 ± 62.1</td><td><0.001<sup>¶</sup></td></tr></table>
|
da493b77f09f22c5450a92f6d9e2a21104141fc8d783fff8e981b9db14a6f1ca.png
|
complex
|
<table><tr><td> </td><td>Bias</td><td colspan="2">Limits of agreement</td><td colspan="2">95%-CI</td><td>p-value</td></tr><tr><td> </td><td> </td><td>Lower</td><td>Upper</td><td>Lower</td><td>Upper</td><td> </td></tr><tr><td>GAT2 (S) – GAT1 (S)</td><td>−0.06</td><td>−1.74</td><td>1.63</td><td>−0.235</td><td>0.347</td><td>0.701</td></tr><tr><td>ICP2 (S) – ICP1 (S)</td><td>−0.2</td><td>−3.3</td><td>2.8</td><td>−0.312</td><td>0.745</td><td>0.411</td></tr><tr><td>ICP2 (R) – ICP1 (R)</td><td>−0.2</td><td>−4.4</td><td>4.1</td><td>−0.584</td><td>0.890</td><td>0.676</td></tr><tr><td>TPA2 (S) – TPA1 (S)</td><td>0.1</td><td>−3.3</td><td>3.5</td><td>−0.699</td><td>0.477</td><td>0.703</td></tr><tr><td>TPA2 (R) – TPA1 (R)</td><td>0.0</td><td>−2.7</td><td>2.7</td><td>−0.465</td><td>0.465</td><td>1.000</td></tr><tr><td>MICP (S) – MGAT (S)</td><td>0.8</td><td>−4.6</td><td>6.2</td><td>−0.085</td><td>1.780</td><td>0.074</td></tr><tr><td>MICP (R) – MGAT (S)</td><td>1.7</td><td>−2.9</td><td>6.2</td><td>0.864</td><td>2.439</td><td><0.001</td></tr><tr><td>MTPA (S) – MGAT (S)</td><td>0.5</td><td>−4.1</td><td>5.1</td><td>−0.266</td><td>1.321</td><td>0.1856</td></tr><tr><td>MTPA (R) – MGAT (S)</td><td>2.3</td><td>−3.4</td><td>8.0</td><td>1.319</td><td>3.292</td><td>< 0.001</td></tr><tr><td>MICP (R) – MICP (S)</td><td>0.8</td><td>−4.0</td><td>5.6</td><td>−0.032</td><td>1.640</td><td>0.059</td></tr><tr><td>MTPA (R) – MTPA (S)</td><td>1.8</td><td>−2.8</td><td>6.3</td><td>0.995</td><td>2.560</td><td><0.001</td></tr></table>
|
97f28871fe85baa33d3ed932914c251de8c89f5e71b71278f59ab977155197ef.png
|
complex
|
<table><tr><td> </td><td>Percentage<sub>EBP-K</sub></td><td>Percentage<sub>EBP-A</sub></td><td>Percentage<sub>EBP-P</sub></td><td>Percentage<sub>EBP-F</sub></td></tr><tr><td>Total</td><td>19.21 ± 3.2%</td><td>20.83 ± 2.1%</td><td>48.97 ± 8.6%</td><td>17.82 ± 5.7%</td></tr><tr><td>Gender</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Male</td><td>19.23 ± 2.2%</td><td>20.84 ± 2.8%</td><td>48.96 ± 7.9%</td><td>17.83 ± 1.7%</td></tr><tr><td>Female</td><td>19.18 ± 1.8%</td><td>20.82 ± 2.2%</td><td>48.99 ± 8.4%</td><td>17.88 ± 6.1%</td></tr><tr><td><i>P</i> value</td><td>0.920</td><td>0.200</td><td>0.414</td><td>0.925</td></tr><tr><td colspan="3">Program subtypes</td><td> </td><td> </td></tr><tr><td>Five-year</td><td>19.25 ± 2.8%</td><td>20.82 ± 1.7%</td><td>48.95 ± 7.6%</td><td>17.80 ± 5.4%</td></tr><tr><td>Eight-year</td><td>19.01 ± 3.4%</td><td>20.86 ± 1.1%</td><td>49.11 ± 9.5%</td><td>17.85 ± 4.8%</td></tr><tr><td><i>P</i> value</td><td>0.508</td><td>0.094</td><td>0.528</td><td>0.283</td></tr></table>
|
af6ffc5bafb149de6d545ac779bcc63f4bb25d918752ef6b20e4106af49f1cd0.png
|
complex
|
<table><tr><td rowspan="2" colspan="2">Confusion Matrix</td><td colspan="2">Expert Classification</td></tr><tr><td>Positive</td><td>Negative</td></tr><tr><td rowspan="2">Classifier classification</td><td>Positive</td><td>TP = 19,050</td><td>FP = 3772</td></tr><tr><td>Negative</td><td>FN = 950</td><td>TN = 76,228</td></tr></table>
|
fe044bfc04fae10e611ebcb0f6339148c0220cc4ab8895ed90e44b083c7872e1.png
|
complex
|
<table><tr><td>Associated risk factors</td><td>BAB</td><td>PAB</td><td>VAB</td></tr><tr><td colspan="4"><underline>Individual factors</underline></td></tr><tr><td>Age (years) 85 and over</td><td></td><td>+</td><td></td></tr><tr><td>Male gender</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Functionally independent</td><td></td><td></td><td>+</td></tr><tr><td>Mild-moderate or severe cognitive impairment</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Sleep disturbance</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Psychologically distressed</td><td>+</td><td>+</td><td></td></tr><tr><td colspan="4"><underline>Environmental factors</underline></td></tr><tr><td>Use of benzodiazepine drugs</td><td></td><td></td><td>+</td></tr><tr><td>Use of neuroleptic drugs</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Use of physical restraints</td><td>+</td><td></td><td></td></tr></table>
|
5c52410451d9acc534b8be1825e8480f7cb68a60129b653a13c725e87de308b1.png
|
simple
|
<table><tr><td></td><td>Increase</td><td>Decrease</td><td>No response</td><td>Total</td></tr><tr><td>Normal</td><td>11 (58%)</td><td>5 (26%)</td><td>3 (16%)</td><td>19 (100%)</td></tr><tr><td>Lesioned</td><td>19 (68%)</td><td>4 (14%)</td><td>5 (18%)</td><td>28 (100%)</td></tr></table>
|
b7e0af7725b4665602b1e50aaec1a8a0ced4a67d790de023023030efe127141a.png
|
simple
|
<table><tr><td></td><td>N</td><td>Yes (%)</td></tr><tr><td>“Access to his/her diabetes EMR via a web portal ...”</td><td>128</td><td></td></tr><tr><td> stimulates the self-management and self-correcting behaviour of the patient</td><td></td><td>75.8</td></tr><tr><td> improves communication during consultation with a well prepared patient</td><td></td><td>44.5</td></tr><tr><td> results in saving time</td><td></td><td>21.9</td></tr><tr><td> results in deceased workload</td><td></td><td>10.9</td></tr><tr><td>“I write the medical information...”</td><td>128</td><td></td></tr><tr><td> as I always did</td><td></td><td>63.3</td></tr><tr><td> in an easier language than before</td><td></td><td>37.5</td></tr><tr><td> with less information than before</td><td></td><td>7.8</td></tr><tr><td>“I think that patients who use the patient portal...”</td><td>122</td><td></td></tr><tr><td> have an increased frequency of visits</td><td></td><td>2.5</td></tr><tr><td> have an unchanged frequency of visits</td><td></td><td>80.3</td></tr><tr><td> have a decreased frequency of visits</td><td></td><td>17.2</td></tr><tr><td>“How do you feel about patients sending you an e-message?”</td><td>128</td><td></td></tr><tr><td> (very) positive</td><td></td><td>65.6</td></tr><tr><td> neutral</td><td></td><td>28.1</td></tr><tr><td> (very) negative</td><td></td><td>6.3</td></tr><tr><td>“How many e-messages do you receive per week?”</td><td>124</td><td></td></tr><tr><td> 0 messages</td><td></td><td>33.1</td></tr><tr><td> 1–10 messages</td><td></td><td>59.7</td></tr><tr><td> ≥ 11messages</td><td></td><td>7.3</td></tr><tr><td>“Who usually answers the e-message of patients?”</td><td>80<sup>a</sup></td><td></td></tr><tr><td> the health care provider answers only the messages of his/her own patients</td><td></td><td>31.3</td></tr><tr><td> the physician (GP or internist) answers all messages</td><td></td><td>2.5</td></tr><tr><td> the nurse (nurse practitioner or diabetes nurse) answers all messages</td><td></td><td>66.3</td></tr></table>
|
6b667b854b29f727170959a97a184a6ae0b70e5fe1e6d595a10668dfdc60af49.png
|
simple
|
<table><tr><td></td><td>Hazard ratio for in-hospital death</td><td>95% CI</td><td>p value</td><td>Hazard ratio for death within 1 year</td><td>95% CI</td><td>p value</td></tr><tr><td>Age</td><td></td><td></td><td>0.068</td><td></td><td></td><td>0.005</td></tr><tr><td> 18–64 years</td><td>1</td><td></td><td></td><td>1</td><td></td><td></td></tr><tr><td> ≥65 years</td><td>1.72</td><td>1.0–3.03</td><td></td><td>2.17</td><td>1.27–3.70</td><td></td></tr><tr><td>Sex</td><td></td><td></td><td>0.426</td><td></td><td></td><td>0.707</td></tr><tr><td> Female</td><td>1</td><td></td><td></td><td>1</td><td></td><td></td></tr><tr><td> Male</td><td>1.32</td><td>0.67–2.60</td><td></td><td>1.12</td><td>0.61–2.10</td><td></td></tr><tr><td>Etiology</td><td></td><td></td><td>0.060<sup>b</sup></td><td></td><td></td><td>0.066<sup>b</sup></td></tr><tr><td> <i>Staphylococcus aureus</i></td><td>1</td><td></td><td></td><td>1</td><td></td><td></td></tr><tr><td> CoNS<sup>c</sup></td><td>0.87</td><td>0.33–2.26</td><td></td><td>0.93</td><td>0.36–2.40</td><td></td></tr><tr><td> Viridans streptococci</td><td>0.90</td><td>0.40–2.03</td><td></td><td>0.85</td><td>0.40–1.81</td><td></td></tr><tr><td> <i>Enterococcus faecalis</i></td><td>0.36</td><td>0.08–1.57</td><td></td><td>0.55</td><td>0.16–1.90</td><td></td></tr><tr><td> <i>Streptococcus pneumoniae</i></td><td>2.37</td><td>0.85–6.59</td><td></td><td>2.58</td><td>0.94–7.09</td><td></td></tr><tr><td> Other pathogens</td><td>0.35</td><td>0.08–1.54</td><td></td><td>0.31</td><td>0.07–1.36</td><td></td></tr><tr><td> Culture negative</td><td>0.42</td><td>0.17–1.05</td><td></td><td>0.51</td><td>0.23–1.13</td><td></td></tr><tr><td>Affected valves</td><td></td><td></td><td><0.001<sup>b</sup></td><td></td><td></td><td><0.001<sup>b</sup></td></tr><tr><td> Prosthetic</td><td>1</td><td></td><td></td><td>1</td><td></td><td></td></tr><tr><td> Aortic</td><td>1.13</td><td>0.48–2.65</td><td></td><td>1.01</td><td>0.46–2.19</td><td></td></tr><tr><td> Mitral</td><td>0.45</td><td>0.16–1.31</td><td></td><td>0.60</td><td>0.24–1.47</td><td></td></tr><tr><td> Tricuspid</td><td>1.04</td><td>0.22–4.88</td><td></td><td>0.73</td><td>0.16–3.35</td><td></td></tr><tr><td> Two native valves</td><td>3.55</td><td>1.49–8.47</td><td></td><td>3.75</td><td>1 68–8.34</td><td></td></tr><tr><td>Echocardiography</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Major Criterion</td><td></td><td></td><td>0.346</td><td></td><td></td><td>0.015</td></tr><tr><td>No</td><td>1</td><td></td><td></td><td>1</td><td></td><td></td></tr><tr><td>Yes</td><td>1.43</td><td>0. 68–3.00</td><td></td><td>2.44</td><td>0.19–5.0</td><td></td></tr><tr><td> Vegetation</td><td></td><td></td><td>0.102</td><td></td><td></td><td>0.005</td></tr><tr><td>No</td><td>1.</td><td></td><td></td><td>1</td><td></td><td></td></tr><tr><td>Yes</td><td>1.81</td><td>0.90–3.68</td><td></td><td>2.62</td><td>1.35–5.09</td><td></td></tr><tr><td>Neurological complications<sup>d</sup></td><td></td><td></td><td>0.009</td><td></td><td></td><td>0.003</td></tr><tr><td>No</td><td>1</td><td></td><td></td><td>1</td><td></td><td></td></tr><tr><td>Yes</td><td>2.17</td><td>1.21–3.90</td><td></td><td>2.30</td><td>1.34–3.96</td><td></td></tr><tr><td>Peripheral emboli<sup>d</sup></td><td></td><td></td><td>0.036</td><td></td><td></td><td>0.016</td></tr><tr><td>No</td><td>1</td><td></td><td></td><td>1</td><td></td><td></td></tr><tr><td>Yes</td><td>1.86</td><td>1.04–3.33</td><td></td><td>1.95</td><td>1.14–3.35</td><td></td></tr><tr><td>Heart failure<sup>d</sup></td><td></td><td></td><td><0.001</td><td></td><td></td><td><0.001</td></tr><tr><td>No</td><td>1</td><td></td><td></td><td>1</td><td></td><td></td></tr><tr><td>Yes</td><td>5.98</td><td>2.35–15.17</td><td></td><td>7.62</td><td>3.26–17.83</td><td></td></tr><tr><td>Serum CRP on admission</td><td></td><td></td><td>0.008</td><td></td><td></td><td><0.001</td></tr><tr><td> < 100 mg/l</td><td>1</td><td></td><td></td><td>1</td><td></td><td></td></tr><tr><td> ≥100 mg/l</td><td>2.92</td><td>1.33–6.40</td><td></td><td>3.90</td><td>1.81–8.43</td><td></td></tr></table>
|
4696c0ecb9a03254ff00cc742e001eb0bd5743fbc788e36d36637cbb7caac8e0.png
|
complex
|
<table><tr><td>Socio-demographic characteristics</td><td>Frequency</td><td>Percentage</td></tr><tr><td colspan="3">LGA</td></tr><tr><td> Idemili South</td><td>70</td><td>46.4</td></tr><tr><td> Onitsha South</td><td>81</td><td>53.6</td></tr><tr><td colspan="3">Groups</td></tr><tr><td> Mothers of women who delivered 6 months before study</td><td>79</td><td>52</td></tr><tr><td> Husbands of women who delivered 6 months before study</td><td>72</td><td>48</td></tr><tr><td colspan="3">Marital status</td></tr><tr><td> Married</td><td>147</td><td>97.4</td></tr><tr><td> Widowed</td><td>4</td><td>2.6</td></tr><tr><td colspan="3">Educational level</td></tr><tr><td> No formal education</td><td>6</td><td>4</td></tr><tr><td> Primary</td><td>55</td><td>36.4</td></tr><tr><td> Secondary</td><td>75</td><td>49.7</td></tr><tr><td> Post-secondary</td><td>15</td><td>9.9</td></tr><tr><td colspan="3">Occupation</td></tr><tr><td> Unemployed</td><td>42</td><td>28</td></tr><tr><td> Civil servant</td><td>44</td><td>29</td></tr><tr><td> Trader</td><td>45</td><td>30</td></tr><tr><td> Artisan</td><td>20</td><td>13</td></tr><tr><td colspan="3">Age group</td></tr><tr><td> 35-39</td><td>24</td><td>15.9</td></tr><tr><td> 40-44</td><td>29</td><td>19.2</td></tr><tr><td> 45-49</td><td>36</td><td>23.8</td></tr><tr><td> 50-54</td><td>26</td><td>17.2</td></tr><tr><td> 55+</td><td>36</td><td>23.8</td></tr></table>
|
e8e1b93df04f2238bdc278f5c88afdbd5fc0186111a2fcdeebbfd867d0378686.png
|
complex
|
<table><tr><td rowspan="2">Variables</td><td>LVEF ≤ 25%</td><td>LVEF > 25%</td><td rowspan="2"><i>P</i> values</td></tr><tr><td>115 patients</td><td>821 patients</td></tr><tr><td>Braden score</td><td>14.4 ± 2.6</td><td>14.8 ± 2.6</td><td>0.121</td></tr><tr><td>Total Glasgow coma score</td><td>12.1 ± 3.9</td><td>12.5 ± 3.6</td><td>0.345</td></tr><tr><td>Heart rate (beats/minute)</td><td>88.6 ± 17.8</td><td>84.2 ± 19.2</td><td>0.021</td></tr><tr><td>Diastolic NBP (mmHg)</td><td>59.2 ± 12.0</td><td>60.8 ± 13.6</td><td>0.249</td></tr><tr><td>Systolic NBP (mmHg)</td><td>110.2 ± 16.9</td><td>120.1 ± 20.2</td><td><0.001</td></tr><tr><td>Respiratory rate (breaths/minute)</td><td>21.0 ± 4.8</td><td>19.2 ± 4.6</td><td><0.001</td></tr><tr><td>Oxygen saturation (%)</td><td>96.8 ± 3.9</td><td>97.2 ± 2.9</td><td>0.278</td></tr><tr><td>Temperature (°C)</td><td>36.6 ± 0.8</td><td>36.7 ± 0.8</td><td>0.474</td></tr><tr><td>Blood urea nitrogen (mg/dL)</td><td>37.6 ± 26.4</td><td>28.9 ± 22.3</td><td><0.001</td></tr><tr><td>Carbon dioxide (mmol/L)</td><td>22.9 ± 5.0</td><td>23.4 ± 5.0</td><td>0.266</td></tr><tr><td>Glucose (mg/dL)</td><td>172.2 ± 78.1</td><td>151.9 ± 65.7</td><td>0.003</td></tr><tr><td>Hemoglobin (mmol/L)</td><td>11.9 ± 2.4</td><td>11.4 ± 2.0</td><td>0.032</td></tr><tr><td>Platelets (×10<sup>3</sup> cells/<i>μ</i>L)</td><td>244.2 ± 112.5</td><td>235.2 ± 108.3</td><td>0.408</td></tr><tr><td>Potassium (mmol/L)</td><td>4.3 ± 0.6</td><td>4.2 ± 0.7</td><td>0.050</td></tr><tr><td>Sodium (mmol/L)</td><td>137.8 ± 5.2</td><td>138.5 ± 4.7</td><td>0.139</td></tr><tr><td>White blood cells (×10<sup>3</sup> cells/<i>μ</i>L)</td><td>12.7 ± 5.6</td><td>12.8 ± 8.3</td><td>0.971</td></tr><tr><td>Age (years)</td><td>70.6 ± 15.1</td><td>67.3 ± 16.4</td><td>0.045</td></tr><tr><td>Weight on admission (kg)</td><td>77.1 ± 18.6</td><td>83.0 ± 25.7</td><td>0.018</td></tr><tr><td>SAPS I score on admission</td><td>13.9 ± 5.9</td><td>13.4 ± 5.5</td><td>0.428</td></tr><tr><td>SOFA score on admission</td><td>6.3 ± 4.2</td><td>5.4 ± 4.3</td><td>0.036</td></tr><tr><td>Males (%)</td><td>74 (64.4)</td><td>432 (52.6)</td><td>0.018</td></tr></table>
|
06839781a09e07e1023846a316ec5fa8c695404f4e62298e92578bb4d8b06408.png
|
simple
|
<table><tr><td>Compound</td><td>Catechol</td><td>Phenol</td><td>Total</td></tr><tr><td>Yield [% w/w]</td><td>5.7 ± 0.1</td><td>3.9 ± 0.1</td><td>9.6 ± 0.3</td></tr><tr><td>Content (mM)</td><td>101</td><td>25</td><td>126</td></tr></table>
|
484212df70bf6a176cc2f21821e0de384b858ea2388378cf7b6da85f20b3870f.png
|
complex
|
<table><tr><td>SUV</td><td>Myocardium</td><td>Muscle</td></tr><tr><td colspan="3">SUV 7.5 min p.i.</td></tr><tr><td>TGwt</td><td>9.6 ± 2.2</td><td>0.5 ± 0.1</td></tr><tr><td>TGwt insulin</td><td>16.9 ± 2.8*</td><td>0.8 ± 0.2*</td></tr><tr><td>TGmut</td><td>5.8 ± 1.6**</td><td>0.7 ± 0.1</td></tr><tr><td>TGmut insulin</td><td>6.4 ± 1.4</td><td>1.1 ± 0.5*</td></tr><tr><td colspan="3">SUV 60 min p.i.</td></tr><tr><td>TGwt</td><td>20.4 ± 3.3</td><td>0.7 ± 0.2</td></tr><tr><td>TGwt insulin</td><td>21.8 ± 4.3</td><td>1.1 ± 0.2*</td></tr><tr><td>TGmut</td><td>12.6 ± 4.1</td><td>1.0 ± 0.2</td></tr><tr><td>TGmut insulin</td><td>7.2 ± 2.6*</td><td>1.5 ± 0.6*</td></tr></table>
|
0b644d22bdd765f7709f5a8ab316323ba44897fdc94b88ace869e17f0aa399b5.png
|
complex
|
<table><tr><td>Gene</td><td>OMIM accession number</td><td>SNP</td><td>Ancestral alleles</td><td>Type</td><td>MAF</td><td>p-value</td><td>p-value adjusted</td><td>Beta</td><td>SE</td><td>Trait</td></tr><tr><td rowspan="2"><i>AGTR 1</i></td><td rowspan="2">*106165</td><td rowspan="2">rs5186</td><td rowspan="2">A</td><td rowspan="2">3’UTR</td><td rowspan="2">28.933</td><td>8.34×10<sup>-04</sup></td><td>0.027</td><td>−0.051</td><td>0.032</td><td>SBP</td></tr><tr><td>6.96×10<sup>-03</sup></td><td>0.041</td><td>−0.045</td><td>0.051</td><td>DBP</td></tr><tr><td rowspan="2"><i>CSF2</i></td><td rowspan="2">*138960</td><td rowspan="2">rs25882</td><td rowspan="2">T</td><td rowspan="2">Exonic</td><td rowspan="2">25.596</td><td>4.67×10<sup>-06</sup></td><td>3.83×10<sup>-04</sup></td><td>0.124</td><td>0.030</td><td>SBP</td></tr><tr><td>7.25×10<sup>-07</sup></td><td>5.94×10<sup>-05</sup></td><td>0.148</td><td>0.048</td><td>DBP</td></tr><tr><td rowspan="3"><i>F7</i></td><td rowspan="3">227500</td><td rowspan="2">rs5742910</td><td rowspan="2">NA</td><td rowspan="2">Upstream</td><td rowspan="2">15.024</td><td>3.72×10<sup>-04</sup></td><td>0.030</td><td>−0.028</td><td>0.041</td><td>SBP</td></tr><tr><td>3.34×10<sup>-04</sup></td><td>0.027</td><td>−0.042</td><td>0.065</td><td>DBP</td></tr><tr><td>rs6046</td><td>C</td><td>Exonic</td><td>12.874</td><td>5.33×10<sup>-04</sup></td><td>0.044</td><td>−0.028</td><td>0.044</td><td>SBP</td></tr><tr><td rowspan="2"><i>IL1B</i></td><td rowspan="2">*147720</td><td rowspan="2">rs1143634</td><td rowspan="2">C</td><td rowspan="2">Exonic</td><td rowspan="2">19.397</td><td>4.21×10<sup>-04</sup></td><td>0.035</td><td>−0.044</td><td>0.035</td><td>SBP</td></tr><tr><td>5.92×10<sup>-04</sup></td><td>0.049</td><td>−0.052</td><td>0.056</td><td>DBP</td></tr><tr><td rowspan="2"><i>LDLR</i></td><td rowspan="2">606945</td><td rowspan="2">rs5742911</td><td rowspan="2">A</td><td rowspan="2">3’UTR</td><td rowspan="2">32.308</td><td>4.31×10<sup>-04</sup></td><td>0.035</td><td>0.06</td><td>0.029</td><td>SBP</td></tr><tr><td>1.17×10<sup>-04</sup></td><td>0.010</td><td>0.071</td><td>0.047</td><td>DBP</td></tr><tr><td><i>LPL</i></td><td>609708</td><td>rs1800590</td><td>G</td><td>5’UTR</td><td>2.586</td><td>3.46×10<sup>-04</sup></td><td>0.028</td><td>0.076</td><td>0.088</td><td>SBP</td></tr><tr><td rowspan="2"><i>TGFB1</i></td><td rowspan="2">*190180</td><td rowspan="2">rs1800469</td><td rowspan="2">C</td><td rowspan="2">Upstream</td><td rowspan="2">29.048</td><td>4.44×10<sup>-04</sup></td><td>0.036</td><td>−0.026</td><td>0.030</td><td>SBP</td></tr><tr><td>9.77×10<sup>-06</sup></td><td>8.02×10<sup>-04</sup></td><td>−0.038</td><td>0.047</td><td>DBP</td></tr><tr><td><i>VDR</i></td><td>*601769</td><td>rs2228570</td><td>T</td><td>Exonic</td><td>40.139</td><td>1.16×10<sup>-05</sup></td><td>9.48×10<sup>-04</sup></td><td>−0.012</td><td>0.028</td><td>SBP</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>6.02×10<sup>-06</sup></td><td>4.93×10<sup>-04</sup></td><td>−0.009</td><td>0.045</td><td>DBP</td></tr></table>
|
0e0600de91b572780d631a90b75e7512ede9fc49ebc2192a8b3ec040402d5d90.png
|
simple
|
<table><tr><td></td><td>Baseline</td><td>1 month</td><td>3 months</td><td>6 months</td><td>12 months</td></tr><tr><td>S100A12</td><td>0.78***/0.75***</td><td>0.68***/0.65***</td><td>0.35/0.27</td><td>0.55*/0.45*</td><td>0.43/0.43</td></tr><tr><td>ESR</td><td>0.37/0.48*</td><td>0.36/0.35</td><td>0.45*/0.42</td><td>0.32/0.33</td><td>0.35/0.40</td></tr><tr><td>CRP</td><td>0.33/0.34</td><td>0.04/0.11</td><td>0.49*/0.35</td><td>0.59**/0.43</td><td>0.57**/0.55*</td></tr></table>
|
a1454ad859d06946ea00fe44f14ed9869ec7826a882a4d0b6b590abb77ef5d74.png
|
complex
|
<table><tr><td></td><td colspan="5">CHILD</td></tr><tr><td>Educational level</td><td>Underweight(%)</td><td>Normalweight(%)</td><td>Overweight(%)</td><td>Obese(%)</td><td>TotalNo. (%)</td></tr><tr><td>MOTHER</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> <i>Low</i></td><td>0.8</td><td>69.1</td><td>20.8</td><td>9.3</td><td>534 (100)</td></tr><tr><td> <i>Medium</i></td><td>0.6</td><td>70.0</td><td>21.9</td><td>7.5</td><td>837 (100)</td></tr><tr><td> <i>High</i></td><td>0.5</td><td>69.8</td><td>23.9</td><td>5.8</td><td>298 (100)</td></tr><tr><td>Total No.</td><td>11</td><td>1147</td><td>371</td><td>140</td><td>1669 (100)</td></tr><tr><td>Chi square for trend</td><td>p = 0.76</td><td>p = 0.93</td><td>p = 0.59</td><td>p = 0.15</td><td></td></tr><tr><td>Kendall's τ<sub>b</sub></td><td></td><td></td><td></td><td></td><td>p = 0.19</td></tr></table>
|
913890611ebcfc6991291c5b3a00c0381e4b4f31e798be819924b5b025dff983.png
|
complex
|
<table><tr><td rowspan="2">Patient no.</td><td colspan="2">FOXP3</td><td colspan="2">OX40</td><td colspan="2">CD123</td><td colspan="2">DC-LAMP</td></tr><tr><td>SLN</td><td>NSLN</td><td>SLN</td><td>NSLN</td><td>SLN</td><td>NSLN</td><td>SLN</td><td>NSLN</td></tr><tr><td>1</td><td>1958</td><td>957</td><td>193</td><td>65</td><td>232</td><td>280</td><td>818</td><td>660</td></tr><tr><td>2</td><td>1925</td><td>1477</td><td>119</td><td>192</td><td>1450</td><td>621</td><td>957</td><td>648</td></tr><tr><td>3</td><td>2205</td><td>1060</td><td>15</td><td>60</td><td>222</td><td>214</td><td>573</td><td>1038</td></tr><tr><td>4</td><td>1562</td><td>1450</td><td>117</td><td>29</td><td>938</td><td>242</td><td>592</td><td>657</td></tr><tr><td>5</td><td>2123</td><td>2086</td><td>245</td><td>192</td><td>1154</td><td>566</td><td>1059</td><td>384</td></tr><tr><td>6</td><td>2814</td><td>1747</td><td>61</td><td>33</td><td>244</td><td>225</td><td>925</td><td>744</td></tr><tr><td>7</td><td>1768</td><td>1633</td><td>54</td><td>60</td><td>395</td><td>1040</td><td>1171</td><td>989</td></tr></table>
|
a11234a1bc234f5282010ce4f0cd2d59bd662514445c34fa93c81b3c8f922e1b.png
|
simple
|
<table><tr><td></td><td>Sham (<i>n</i> = 6)</td><td>2nd PO week (<i>n</i> = 3)</td><td>4th PO week (<i>n</i> = 4)</td><td>6th PO week (<i>n</i> = 5)</td></tr><tr><td>Albumin (g/dL)</td><td>2.5 ± 0</td><td>BDL: 2.4 ± 0.37BDL + AM: 2.85 ± 0.07</td><td>BDL: 1.88 ± 0.5<sup>∗</sup>BDL + AM: 2.9 ± 0<sup>†</sup></td><td>BDL: 1.99 ± 0.17BDL + AM: 3.33 ± 0.36<sup>‡†</sup></td></tr><tr><td>ALT (U/L)</td><td>70 ± 7.07</td><td>BDL: 79.75 ± 17.99BDL + AM: 106 ± 0</td><td>BDL: 124.6 ± 58.8BDL + AM: 76 ± 7.07</td><td>BDL: 79 ± 46.16BDL + AM: 56.71 ± 35.5</td></tr><tr><td>Alkaline phosphatase (U/L)</td><td>573 ± 99</td><td>BDL: 420 ± 84BDL + AM: 324 ± 0</td><td>BDL: 635.6 ± 197.53BDL + AM: 419 ± 56.57</td><td>BDL: 421 ± 172.52BDL + AM: 278 ± 171</td></tr><tr><td>GGT (U/L)</td><td>0 ± 0</td><td>BDL: 24.75 ± 28.93BDL + AM: 79 ± 0</td><td>BDL: 35.8 ± 21.29BDL + AM: 13.5 ± 19.09</td><td>BDL: 33 ± 27.4BDL + AM: 1.86 ± 3.49<sup>††</sup></td></tr><tr><td>Bilirubin (mg/dL)</td><td>0.1 ± 0</td><td>BDL: 2.73 ± 2.86BDL + AM: 10.7 ± 5.23</td><td>BDL: 2.84 ± 1.68<sup>∗</sup>BDL + AM: 2.65 ± 3.61</td><td>BDL: 4.23 ± 1.12BDL + AM: 2.39 ± 2.50</td></tr></table>
|
58befc6cca7d66b96d1c91cc8495a2cb44d41792b8be54e1b13219cb65bb07fc.png
|
simple
|
<table><tr><td>Item</td><td>Points</td><td>Definition</td></tr><tr><td>Pain</td><td>25</td><td>No pain</td></tr><tr><td></td><td>20</td><td>Mild, occasional</td></tr><tr><td></td><td>15</td><td>Moderate (tolerable)</td></tr><tr><td></td><td>0</td><td>Severe, intolerable</td></tr><tr><td>Return to sport (work) at 6 months</td><td>25</td><td>Return without protection</td></tr><tr><td></td><td>20</td><td>Return with protection</td></tr><tr><td></td><td>15</td><td>Restricted return to sport, only exercises</td></tr><tr><td></td><td>0</td><td>Unable to return to sport</td></tr><tr><td>Range of motion</td><td>25</td><td>90-100% (normal)</td></tr><tr><td></td><td>20</td><td>80-89%</td></tr><tr><td></td><td>15</td><td>70-70%</td></tr><tr><td></td><td>0</td><td>50-69%</td></tr><tr><td>Grip strength</td><td>25</td><td>90-100% (normal)</td></tr><tr><td></td><td>15</td><td>80-89%</td></tr><tr><td></td><td>10</td><td>70-70%</td></tr><tr><td></td><td>0</td><td>50-69%</td></tr></table>
|
6831e0b6edd533fbb0ab491c0026da57fa9c5c1706730f9d11358fd68938a2da.png
|
complex
|
<table><tr><td rowspan="3">Test</td><td colspan="10">Channel</td><td rowspan="3">Average</td></tr><tr><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>7</td><td>8</td><td>9</td><td>10</td></tr><tr><td>A</td><td>0.240</td><td>0.423</td><td>0.325</td><td>0.726</td><td>0.681</td><td>0.682</td><td>0.701</td><td>0.663</td><td>0.681</td><td>0.246</td><td>0.537</td></tr><tr><td>B</td><td>0.548</td><td>0.697</td><td>0.307</td><td>0.612</td><td>0.537</td><td>0.429</td><td>0.629</td><td>0.711</td><td>0.715</td><td>0.618</td><td>0.580</td></tr><tr><td>C</td><td>0.444</td><td>0.287</td><td>0.299</td><td>0.510</td><td>0.546</td><td>0.425</td><td>0.512</td><td>0.662</td><td>0.674</td><td>0.430</td><td>0.479</td></tr></table>
|
02ec9135410c643f6518fb654437dfe6ab8a099963a2d197c0640d1d864707e9.png
|
simple
|
<table><tr><td> </td><td>Infants (younger than or equal to 1-year old)</td><td>Older patients (older than 1-year old)</td><td><i>P</i> value</td></tr><tr><td>Number of cases</td><td>18</td><td>108</td><td> </td></tr><tr><td>Gender (M/F)</td><td>10/8</td><td>72/36</td><td> </td></tr><tr><td>Age range (median)</td><td>0.66 </td><td>4.8</td><td> </td></tr><tr><td>Histology (%)</td><td> </td><td> </td><td>0.45</td></tr><tr><td> Embryonal</td><td>88.9</td><td>75.9</td><td> </td></tr><tr><td> Alveolar</td><td>11.1</td><td>24.1</td><td> </td></tr><tr><td>Site of origin (%)</td><td> </td><td> </td><td>0.28</td></tr><tr><td> Head and neck (%)</td><td> </td><td> </td><td> </td></tr><tr><td>Parameningeal</td><td>11.1</td><td>30.6</td><td> </td></tr><tr><td>Orbit</td><td>11.1</td><td>7.4</td><td> </td></tr><tr><td>Head and neck (nonpara nonorbit)</td><td>5.6</td><td>13</td><td> </td></tr><tr><td>GU</td><td> </td><td> </td><td> </td></tr><tr><td> Bladder/prostate</td><td>11.1</td><td>12</td><td> </td></tr><tr><td> Nonbladder/nonprostate</td><td>11.1</td><td>7.4</td><td> </td></tr><tr><td> Extremities</td><td>11.1</td><td>11.1</td><td> </td></tr><tr><td> Others</td><td>38.9</td><td>18.5</td><td> </td></tr><tr><td>TNM stage (%)</td><td> </td><td> </td><td> </td></tr><tr><td> N1</td><td>5.6</td><td>38.9</td><td> </td></tr><tr><td> M1</td><td>11.1</td><td>19.4</td><td> </td></tr><tr><td>Size (%)</td><td> </td><td> </td><td>0.928</td></tr><tr><td> >5</td><td>55.6</td><td>57.4</td><td> </td></tr><tr><td> ≤5</td><td>38.9</td><td>33.3</td><td> </td></tr><tr><td> Unknown</td><td>5.5</td><td>9.3</td><td> </td></tr><tr><td>IRS stage (%)</td><td> </td><td> </td><td>0.34</td></tr><tr><td> I</td><td>27.8</td><td>24.6</td><td> </td></tr><tr><td> II</td><td>27.8</td><td>15.1</td><td> </td></tr><tr><td> III</td><td>33.3</td><td>42.1</td><td> </td></tr><tr><td> IV</td><td>11.1</td><td>18.3</td><td> </td></tr><tr><td>Clinical group (%)</td><td> </td><td> </td><td>0.74</td></tr><tr><td> I</td><td>11</td><td>9</td><td> </td></tr><tr><td> II</td><td>6</td><td>4</td><td> </td></tr><tr><td> III</td><td>72</td><td>68</td><td> </td></tr><tr><td> IV</td><td>11</td><td>19</td><td> </td></tr><tr><td>Risk (%)</td><td> </td><td> </td><td>0.64</td></tr><tr><td> Low</td><td>22.2</td><td>15.7</td><td> </td></tr><tr><td> Intermediate</td><td>66.7</td><td>65.7</td><td> </td></tr><tr><td> High</td><td>11.1</td><td>18.6</td><td> </td></tr></table>
|
3c0147343e331ecd8bea2c8d9ce03256e263a348363ec1ece5b20c68603c642a.png
|
complex
|
<table><tr><td rowspan="2">Reexposure Test Result</td><td colspan="2">Hepatocellular Injury</td><td colspan="2">Cholestatic or Mixed Liver Injury</td></tr><tr><td>ALTb</td><td>ALTr</td><td>ALPb</td><td>ALPr</td></tr><tr><td>●Positive</td><td><5N</td><td>≥2ALTb</td><td><2N</td><td>≥2ALPb</td></tr><tr><td>●Negative</td><td><5N</td><td><2ALTb</td><td><2N</td><td><2ALPb</td></tr><tr><td>●Negative</td><td>≥5N</td><td>≥2ALTb</td><td>≥2N</td><td>≥2ALPb</td></tr><tr><td>●Negative</td><td>≥5N</td><td><2ALTb</td><td>≥2N</td><td><2ALPb</td></tr><tr><td>●Uninterpretable</td><td><5N</td><td>n.a.</td><td><2N</td><td>n.a.</td></tr><tr><td>●Uninterpretable</td><td>n.a.</td><td>≥2ALTb</td><td>n.a.</td><td>≥2ALPb</td></tr><tr><td>●Uninterpretable</td><td>n.a.</td><td>n.a.</td><td>n.a.</td><td>n.a.</td></tr></table>
|
97f65c84ab34215bb01f2da05acc18b40db673a354df4477c92f07adebaae17c.png
|
complex
|
<table><tr><td>Ancestry</td><td>Replicate</td><td colspan="2">Descendants of Affected (DA)</td><td colspan="2">Markov blanket of Affected (MBA)</td><td colspan="2">Children of Affected (DA ∩ MBA)</td></tr><tr><td></td><td></td><td>Number of causal SNPs/number of SNPs</td><td><i>P</i>(<i>X</i> ≥ <i>k</i>)</td><td>Number of causal SNPs/number of SNPs</td><td><i>P</i>(<i>X</i> ≥ <i>k</i>)</td><td>Number of causal SNPs/number of SNPs</td><td><i>P</i>(<i>X</i> ≥ <i>k</i>)</td></tr><tr><td>Asian</td><td>1–10</td><td>12/25</td><td>0.0485</td><td>11/45</td><td>0.891</td><td>2/3</td><td>0.228</td></tr><tr><td></td><td>11–20</td><td>2/7</td><td>0.695</td><td>9/36</td><td>0.850</td><td>0/2</td><td>1</td></tr><tr><td></td><td>1–20</td><td>69/182</td><td>0.000467</td><td>15/55</td><td>0.798</td><td>2/7</td><td>0.695</td></tr><tr><td></td><td>21–40</td><td>15/69</td><td>0.983</td><td>24/63</td><td>0.113</td><td>2/4</td><td>0.367</td></tr><tr><td></td><td>1</td><td>77/237</td><td>0.152</td><td>63/221</td><td>0.973</td><td>16/54</td><td>0.658</td></tr><tr><td></td><td>2</td><td>75/235</td><td>0.305</td><td>55/221</td><td>0.999</td><td>17/64</td><td>0.851</td></tr><tr><td></td><td>3</td><td>74/217</td><td>0.0278</td><td>66/190</td><td>0.0355</td><td>22/43</td><td>0.00227</td></tr><tr><td></td><td>4</td><td>76/227</td><td>0.0479</td><td>55/190</td><td>0.894</td><td>11/42</td><td>0.821</td></tr><tr><td></td><td>5</td><td>76/240</td><td>0.371</td><td>66/218</td><td>0.758</td><td>25/68</td><td>0.155</td></tr><tr><td></td><td>6</td><td>74/224</td><td>0.102</td><td>55/191</td><td>0.909</td><td>13/45</td><td>0.694</td></tr><tr><td></td><td>7</td><td>67/203</td><td>0.160</td><td>60/202</td><td>0.826</td><td>16/55</td><td>0.693</td></tr><tr><td></td><td>8</td><td>65/212</td><td>0.663</td><td>66/226</td><td>0.937</td><td>14/61</td><td>0.958</td></tr><tr><td></td><td>9</td><td>73/230</td><td>0.368</td><td>67/226</td><td>0.887</td><td>24/86</td><td>0.816</td></tr><tr><td></td><td>10</td><td>65/204</td><td>0.376</td><td>59/220</td><td>0.998</td><td>15/57</td><td>0.848</td></tr><tr><td>European</td><td>1–10</td><td>34/105</td><td>0.155</td><td>11/46</td><td>0.849</td><td>1/6</td><td>0.874</td></tr><tr><td></td><td>11–20</td><td>6/11</td><td>0.0604</td><td>6/22</td><td>0.655</td><td>2/2</td><td>0.0822</td></tr><tr><td></td><td>1–20</td><td>0/1</td><td>1</td><td>2/16</td><td>0.972</td><td>0/1</td><td>0.711</td></tr><tr><td></td><td>21–40</td><td>35/107</td><td>0.124</td><td>9/34</td><td>0.703</td><td>3/4</td><td>0.0732</td></tr><tr><td>African</td><td>1–10</td><td>10/60</td><td>0.929</td><td>9/47</td><td>0.795</td><td>0/3</td><td>1</td></tr><tr><td></td><td>11–20</td><td>22/99</td><td>0.613</td><td>10/44</td><td>0.566</td><td>0/4</td><td>1</td></tr><tr><td></td><td>1–20</td><td>7/34</td><td>0.695</td><td>11/53</td><td>0.707</td><td>0/4</td><td>1</td></tr><tr><td></td><td>21–40</td><td>2/2</td><td>0.0508</td><td>3/17</td><td>0.786</td><td>1/1</td><td>0.226</td></tr></table>
|
131a9263906960e5625dd454371f9232a3eb18b6a2e6451ff9bd266c3140a9f7.png
|
simple
|
<table><tr><td>Decades</td><td># cites</td><td>Paper</td><td>Domain</td><td>Institution</td><td>Country</td></tr><tr><td>1945 to 1954</td><td>-</td><td>All cited articles only cited once</td><td>-</td><td>-</td><td>-</td></tr><tr><td>1955 to 1964</td><td>9</td><td>Wilkening, E. A. (1952, May). 'Acceptance of improved farm practices in three coastal plains countries.' <i>Technical Bulletin 98. North Carolina Agricultural Experiment Station.</i></td><td>Diffusion of innovation</td><td>University of Chicago</td><td>USA</td></tr><tr><td>1965 to 1974</td><td>36</td><td>Rogers, E.M. (1962). <i>Diffusion of Innovations</i>. First Edition. New York: The Free Press.</td><td>Diffusion of innovation</td><td>Ohio State University, United States</td><td>USA</td></tr><tr><td>1975 to 1984</td><td>70</td><td>Rogers, E.M. & Shoemaker, F.F. (1971). <i>Communication of Innovations: A Cross Cultural Approach.* </i>New York: The Free Press</td><td>Diffusion of innovation</td><td>Stanford University/University of Denver</td><td>USA</td></tr><tr><td>1985 to 1994</td><td>89</td><td>Rogers, E.M. (1983). <i>Diffusion of Innovations. </i>Third Edition. New York: The Free Press.</td><td>Diffusion of innovation</td><td>University of Southern California</td><td>USA</td></tr><tr><td>1995 to 2004</td><td>229</td><td>Evidence-based Medicine Working Group (1992). 'Evidence-based medicine. A new approach to teaching the practice of medicine.' <i>JAMA</i>, 268(17), 2420–2425.</td><td>EBM</td><td>McMaster University</td><td>Canada</td></tr></table>
|
c353a1963377d8bd99cd632421bb40c6dcd68e49420bbfff15911a6af8d15812.png
|
complex
|
<table><tr><td colspan="2">Characteristics</td><td>Death during treatmentN (%)</td><td>Alive throughout treatmentN (%)</td><td>p value</td></tr><tr><td colspan="2">N</td><td>37</td><td>528</td><td></td></tr><tr><td colspan="2">Mean age at diagnosis ± SD</td><td>45.0 ± 16.2</td><td>40.7 ± 13.5</td><td>0.03</td></tr><tr><td colspan="2"> Median (Min-Max)</td><td>41 (22-88)</td><td>38 (18-94)</td><td></td></tr><tr><td colspan="2">Male Gender</td><td>29 (78.4)</td><td>423 (80.1)</td><td>0.95</td></tr><tr><td>Race</td><td>American Indian</td><td>0</td><td>9 (1.7)</td><td>0.99</td></tr><tr><td></td><td>African American/Black</td><td>13 (35.1)</td><td>187 (35.4)</td><td>0.97</td></tr><tr><td></td><td>Asian/Pacific Islander</td><td>1 (2.7)</td><td>10 (1.9)</td><td>0.73</td></tr><tr><td></td><td>White</td><td>23 (62.2)</td><td>322 (61.0)</td><td>Ref</td></tr><tr><td colspan="2">Hispanic ethnicity</td><td>7 (18.9)</td><td>159 (30.1)</td><td>0.16</td></tr><tr><td colspan="2">US born</td><td>31 (83.8)</td><td>364 (68.9)</td><td>0.03</td></tr><tr><td colspan="2">HIV positive</td><td>24 (64.9)</td><td>180 (34.1)</td><td>0.02</td></tr><tr><td colspan="2"> HAART during tuberculosis therapy</td><td>1/24 (4.2)</td><td>27/180 (15.0)</td><td>0.10</td></tr><tr><td colspan="2"> History of opportunistic infection</td><td>21/24 (87.5)</td><td>101/180 (56.1)</td><td>0.01</td></tr><tr><td colspan="2"> CD4 count</td><td></td><td></td><td></td></tr><tr><td colspan="2">≤ 200 cells/μL<sup>1</sup></td><td>17/19 (89.5)</td><td>108/156 (69.2)</td><td>0.14</td></tr><tr><td colspan="2">Median CD4 count at diagnosis (IQR)<sup>1</sup></td><td>68 (34-104)</td><td>105 (47-269)</td><td>0.06</td></tr><tr><td>Received directly observed therapy<sup>2</sup></td><td>Yes</td><td>28 (75.7)</td><td>251 (47.7)</td><td>0.02</td></tr><tr><td></td><td>Partial*</td><td>4 (10.8)</td><td>90 (17.1)</td><td>0.67</td></tr><tr><td></td><td>No</td><td>5 (13.5)</td><td>185 (35.2)</td><td>Ref</td></tr><tr><td colspan="2">Episode of inadequate therapeutic regimen</td><td>25 (67.6)</td><td>161 (30.5)</td><td>0.01</td></tr><tr><td colspan="2">During intensive phase<sup>3</sup></td><td>24 (64.9)</td><td>129/525 (24.6)</td><td>0.001</td></tr><tr><td colspan="2">Median duration of inadequate treatment (days) (IQR) (n = 153)</td><td>23 (6-35)</td><td>18 (9-34)</td><td>0.18</td></tr><tr><td colspan="2">During continuation phase<sup>4</sup></td><td>10/33 (30.3)</td><td>116/523 (22.2)</td><td>0.44</td></tr><tr><td colspan="2">Median duration of inadequate treatment (days) (IQR) (n = 126)</td><td>37 (24-50)</td><td>29 (13-50)</td><td>0.24</td></tr><tr><td colspan="2"> Due to non-adherence</td><td>22 (59.5)</td><td>142 (26.9)</td><td>0.01</td></tr><tr><td colspan="2">During intensive phase<sup>3</sup></td><td>21 (56.8)</td><td>109/525 (20.8)</td><td>0.001</td></tr><tr><td colspan="2">Median duration of inadequate treatment (days) (IQR) (n = 130)</td><td>8 (5-28)</td><td>15 (7-24)</td><td>0.13</td></tr><tr><td colspan="2">During continuation phase<sup>4</sup></td><td>10/33 (30.3)</td><td>108/523 (20.7)</td><td>0.64</td></tr><tr><td colspan="2">Median duration of inadequate treatment (days) (IQR) (n = 118)</td><td>30 (16-50)</td><td>29 (14-53)</td><td>0.11</td></tr><tr><td colspan="2"> Due to adverse reaction<sup>5</sup></td><td>10 (27.0)</td><td>49/527 (9.3)</td><td>0.10</td></tr><tr><td colspan="2">During intensive phase<sup>5</sup></td><td>7 (18.9)</td><td>39/527 (7.4)</td><td>0.21</td></tr><tr><td colspan="2">Median duration of inadequate treatment (days) (IQR) (n = 46)</td><td>29 (8-39)</td><td>14 (6-38)</td><td>0.75</td></tr><tr><td colspan="2">During continuation phase<sup>5</sup></td><td>3 (8.1)</td><td>18/527 (3.4)</td><td>0.98</td></tr><tr><td colspan="2">Median duration of inadequate treatment (days) (IQR) (n = 21)</td><td>25 (1-31)</td><td>14 (7-20)</td><td>0.40</td></tr><tr><td colspan="2">Hospitalized for tuberculosis<sup>6</sup></td><td>29 (78.4)</td><td>253/526 (48.1)</td><td>0.003</td></tr><tr><td colspan="2">Homeless within 1 year of diagnosis<sup>7</sup></td><td>16/27 (59.3)</td><td>138/356 (38.8)</td><td>0.04</td></tr><tr><td colspan="2">Substance abuse at diagnosis</td><td>23 (62.2)</td><td>228 (43.2)</td><td>0.13</td></tr><tr><td colspan="2">Sputum smear positive</td><td>27 (73.0)</td><td>233 (44.1)</td><td>0.004</td></tr><tr><td colspan="2">Sputum culture positive</td><td>34 (91.9)</td><td>471 (89.2)</td><td>0.62</td></tr><tr><td colspan="2">Extrapulmonary disease in addition to pulmonary disease</td><td>18 (48.7)</td><td>143 (27.1)</td><td>0.13</td></tr><tr><td colspan="2">Cavitary disease</td><td>4 (10.8)</td><td>129 (24.4)</td><td>0.12</td></tr><tr><td colspan="2">Any prior medical condition</td><td>25 (67.6)</td><td>288 (54.6)</td><td>0.13</td></tr></table>
|
4daa7fb7117986621ba1bc341b2f6aef18940db9e61612f8290085962d6aa83d.png
|
complex
|
<table><tr><td colspan="2">Variable</td><td>Alive</td><td>Dead of Disease</td><td>Dead other Causes</td><td>p-value</td></tr><tr><td colspan="2">Surgical Approach, n (%)</td><td></td><td></td><td></td><td><0.0001</td></tr><tr><td></td><td>Adrenalectomy</td><td>374 (88.6)</td><td>437 (63.8)</td><td>111 (67.7)</td><td></td></tr><tr><td></td><td>None</td><td>36 (8.5)</td><td>212 (30.9)</td><td>41 (25.0)</td><td></td></tr><tr><td></td><td>Other</td><td>11 (2.6)</td><td>30 (4.4)</td><td>9 (5.5)</td><td></td></tr><tr><td colspan="2">Laterality, n (%)</td><td></td><td></td><td></td><td>0.08</td></tr><tr><td></td><td>Left</td><td>222 (52.6)</td><td>347 (50.7)</td><td>96 (58.5)</td><td></td></tr><tr><td></td><td>Right</td><td>190 (45.0)</td><td>300 (43.8)</td><td>61 (37.2)</td><td></td></tr><tr><td></td><td>Bilateral</td><td>1 (0.3)</td><td>8 (1.1)</td><td>1 (0.6)</td><td></td></tr><tr><td colspan="2">T Classification, n (%)</td><td></td><td></td><td></td><td><0.0001</td></tr><tr><td></td><td>TX</td><td>39 (9.3)</td><td>82 (12.0)</td><td>30 (18.3)</td><td></td></tr><tr><td></td><td>T0</td><td>1 (0.2)</td><td>0</td><td>0</td><td></td></tr><tr><td></td><td>T1</td><td>32 (7.6)</td><td>10 (1.5)</td><td>14 (8.5)</td><td></td></tr><tr><td></td><td>T2</td><td>228 (54.0)</td><td>192 (28.0)</td><td>57 (34.8)</td><td></td></tr><tr><td></td><td>T3</td><td>68 (16.1)</td><td>91 (13.3)</td><td>18 (11.0)</td><td></td></tr><tr><td></td><td>T4</td><td>47 (11.1)</td><td>136 (19.8)</td><td>31 (18.9)</td><td></td></tr><tr><td colspan="2">N Classification, n (%)</td><td></td><td></td><td></td><td><0.0001</td></tr><tr><td></td><td>NX</td><td>79 (18.7)</td><td>244 (35.6)</td><td>58 (35.4)</td><td></td></tr><tr><td></td><td>N0</td><td>332 (78.7)</td><td>356 (52.0)</td><td>89 (54.2)</td><td></td></tr><tr><td></td><td>N1</td><td>11 (2.6)</td><td>85 (12.4)</td><td>17 (10.4)</td><td></td></tr><tr><td colspan="2">Metastasis, n (%)</td><td>7 (1.7)</td><td>174 (25.4)</td><td>14 (8.5)</td><td><0.0001</td></tr><tr><td colspan="2">SEER Stage, n (%)</td><td></td><td></td><td></td><td><0.0001</td></tr><tr><td></td><td>Localized</td><td>274 (64.9)</td><td>205 (29.9)</td><td>77 (46.9)</td><td></td></tr><tr><td></td><td>Regional</td><td>106 (25.1)</td><td>206 (30.1)</td><td>40 (24.4)</td><td></td></tr><tr><td></td><td>Distant</td><td>20 (4.8)</td><td>216 (31.5)</td><td>28 (17.1)</td><td></td></tr><tr><td></td><td>Unstaged</td><td>22 (5.2)</td><td>58 (8.5)</td><td>19 (11.6)</td><td></td></tr><tr><td colspan="2">Median Survival, months (IQR)</td><td>53 (17, 112)</td><td>9 (3, 24)</td><td>10 (1, 51)</td><td><0.0001</td></tr></table>
|
3024ee6c7c8540be87349725cc2eec4fd7ebd27688e12e8037ca5905d4555549.png
|
simple
|
<table><tr><td></td><td><i>n</i> (%)</td><td>Positive CAPs</td><td>Positive SPTs</td><td><i>n</i> (%)</td><td><i>n</i> (%)</td></tr><tr><td>Distribution of food allergies</td><td>All patients (<i>n</i> = 496)</td><td>N (min‐max, median) (<i>n</i> = 496)</td><td>N (range wheal, median) (<i>n</i> = 496)</td><td>Mueller 0–2 (<i>n</i> = 238)</td><td>Mueller 3–4 (<i>n</i> = 258)</td></tr><tr><td>List of 10 out of 14 major food allergens<sup>1</sup></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Cow's milk</td><td>34 (7%)</td><td>31 (0.40–101, 2.02)</td><td>11 (1–4, 2)</td><td>12 (5%)</td><td>22 (9%)</td></tr><tr><td>Hen's egg</td><td>29 (6%)</td><td>26 (0.40–101, 2.38)</td><td>11 (1–4, 2)</td><td>14 (6%)</td><td>15 (5%)</td></tr><tr><td>Peanut</td><td>191 (39%)</td><td>114 (0.39–101, 4.32)</td><td>136 (1–5, 2)</td><td>75 (32%)</td><td>116 (45%)</td></tr><tr><td>Tree nuts</td><td>283 (57%)</td><td></td><td></td><td></td><td></td></tr><tr><td>Hazelnut</td><td>212 (43%)</td><td>127 (0.36–100, 6.64)</td><td>156 (1–4, 2)</td><td>93 (39%)</td><td>119 (46%)</td></tr><tr><td>Almond</td><td>125 (25%)</td><td>30 (0.4–5.70, 1.69)</td><td>105 (1–4, 2)</td><td>61 (26%)</td><td>64 (25%)</td></tr><tr><td>Walnut</td><td>115 (23%)</td><td>48 (0.4–45.10, 1.95)</td><td>84 (1–4, 2)</td><td>48 (20%)</td><td>67 (26%)</td></tr><tr><td>Brazil nut</td><td>9 (2%)</td><td>9 (0.73–42, 2.68)</td><td>Not determined</td><td>0</td><td>9 (4%)</td></tr><tr><td>Pistachio</td><td>24 (5%)</td><td>24 (0.4–100, 1.44)</td><td>Not determined</td><td>6 (3%)</td><td>18 (7%)</td></tr><tr><td>Cashew nut</td><td>41 (8%)</td><td>28 (0.39–57, 3.55)</td><td>23 (1–4, 2)</td><td>11 (5%)</td><td>30 (12%)</td></tr><tr><td>Fish<sup>2</sup></td><td>4 (1%)</td><td></td><td></td><td>3 (1%)</td><td>1 (0.4%)</td></tr><tr><td>Cod</td><td></td><td>3 (0.5–10.90, 6.30)</td><td>2 (2–4, 3)</td><td></td><td></td></tr><tr><td>Crustaceans<sup>2</sup></td><td>29 (6%)</td><td></td><td></td><td>9 (4%)</td><td>20 (8%)</td></tr><tr><td>Shrimp</td><td></td><td>21 (0.4–61, 2.23)</td><td>16 (1–4, 2)</td><td></td><td></td></tr><tr><td>Lobster</td><td></td><td>14 (0.36–55, 2.12)</td><td>5 (1–3, 2)</td><td></td><td></td></tr><tr><td>Crab</td><td></td><td>13 (0.39–52, 1.70)</td><td>6 (1–3, 1)</td><td></td><td></td></tr><tr><td>Sesame</td><td>33 (7%)</td><td>22 (0.5–82, 4.85)</td><td>22 (1–4, 2)</td><td>9 (4%)</td><td>24 (9%)</td></tr><tr><td>Soy</td><td>46 (9%)</td><td>25 (0.4–12.7, 1.14)</td><td>33 (1–4, 2)</td><td>14 (6%)</td><td>32 (12%)</td></tr><tr><td>Lupin</td><td>2 (0.4%)</td><td>2 (3.86–19.90, 11.88)</td><td>Not determined</td><td>1 (0.4%)</td><td>1 (0.4%)</td></tr><tr><td>Celery</td><td>36 (7%)</td><td>4 (0.5–4.87, 2.33)</td><td>34 (1–4, 2)</td><td>16 (7%)</td><td>20 (8%)</td></tr><tr><td>Other allergens, not belonging to the major allergens</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Fruit (all)<sup>3</sup></td><td>338 (68%)</td><td></td><td></td><td>175 (74%)</td><td>163 (63%)</td></tr><tr><td>Fruit (top 3)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Apple</td><td>270 (54%)</td><td>154 (0.38–58.10, 3.73)</td><td>215 (1–5, 3)</td><td></td><td></td></tr><tr><td>Kiwi</td><td>171 (35%)</td><td>45 (0.36–31.10, 1.20)</td><td>147 (1–5, 3)</td><td></td><td></td></tr><tr><td>Peach</td><td>124 (25%)</td><td>40 (0.44–70.20, 2.60)</td><td>110 (1–2, 2)</td><td></td><td></td></tr><tr><td>Vegetables (all)<sup>3</sup>, <sup>4</sup></td><td>154 (31%)</td><td></td><td></td><td>72 (30%)</td><td>82 (32%)</td></tr><tr><td>Vegetables (top 3)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Tomato</td><td>82 (17%)</td><td>20 (0.4–26.10, 1.55)</td><td>73 (1–4, 2)</td><td></td><td></td></tr><tr><td>Carrot</td><td>73 (15%)</td><td>17 (0.82–45,2.78)</td><td>67 (1–4, 2)</td><td></td><td></td></tr><tr><td>Paprika</td><td>44 (9%)</td><td>5 (0.40–3.53, 0.71)</td><td>41 (1–3, 2)</td><td></td><td></td></tr><tr><td>Other food allergies</td><td>6 (1%)</td><td></td><td></td><td>1 (0.4%)</td><td>5 (2%)</td></tr><tr><td>Mean number of food allergies<sup>3</sup> (SD, min‐max)</td><td>2.9 (1.87, 1–9)</td><td></td><td></td><td>2.6 (1.74, 1–9)</td><td>3.1 (1.95, 1–9)</td></tr></table>
|
a58dcb29f343830f11a053736e01073d5ba4af6ad9293b024e30efec80e28e4d.png
|
simple
|
<table><tr><td>AQP4 Isoforms</td><td>Cell Type</td><td>Intracellular Localization</td><td>Reference</td></tr><tr><td>AQP4a (M1)</td><td>Astrocytes</td><td>PM</td><td>[85,90,95]</td></tr><tr><td>AQP4c (M23)</td><td>Astrocytes, skeletal muscle, kidney</td><td>PM</td><td>[85,90,95]</td></tr><tr><td>AQP4e (Mz)</td><td>Astrocytes (rat), organ of Corti (rat)</td><td>PM, intracellular vesicles, GA, EC</td><td>[72,89,96]</td></tr><tr><td>AQP4b</td><td>Astrocytes (rat)</td><td>GA</td><td>[89]</td></tr><tr><td>AQP4d</td><td>Astrocytes (rat)</td><td>GA, EC</td><td>[72,89]</td></tr><tr><td>AQP4f</td><td>Astrocytes (rat)</td><td>GA</td><td>[89]</td></tr><tr><td>AQP4-Δ</td><td>Skeletal muscle</td><td>ER, faintly in the PM</td><td>[91]</td></tr></table>
|
01080342c9f9b6d89d6ece9e8ea4f7ba3e4a67c9668c91d8726cd13014202ea3.png
|
simple
|
<table><tr><td>Site</td><td>Invoiced dollar (US$)</td><td>Matching dollar (US$)</td><td>Donated time dollar (US$)</td><td>Total additional investment (US$)</td><td>Ranking<sup>a</sup></td><td>Degree of change</td></tr><tr><td>Site 1</td><td>1.00</td><td>2.91</td><td>2.33</td><td>5.24</td><td>2</td><td>H</td></tr><tr><td>Site 2</td><td>1.00</td><td>3.05</td><td>0.52</td><td>3.57</td><td>5</td><td>H</td></tr><tr><td>Site 3</td><td>1.00</td><td>1.81</td><td>1.10</td><td>2.91</td><td>7</td><td>L</td></tr><tr><td>Site 4</td><td>1.00</td><td>0.84</td><td>0.04</td><td>0.88</td><td>10</td><td>L</td></tr><tr><td>Site 5</td><td>1.00</td><td>1.95</td><td>1.05</td><td>3.00</td><td>6</td><td>L</td></tr><tr><td>Site 6</td><td>1.00</td><td>1.18</td><td>0.05</td><td>1.23</td><td>9</td><td>L</td></tr><tr><td>Site 7</td><td>1.00</td><td>4.25</td><td>0.46</td><td>4.72</td><td>4</td><td>H</td></tr><tr><td>Site 8</td><td>1.00</td><td>6.06</td><td>1.41</td><td>7.47</td><td>1</td><td>H</td></tr><tr><td>Site 9</td><td>1.00</td><td>4.67</td><td>0.42</td><td>5.09</td><td>3</td><td>H</td></tr><tr><td>Site 10</td><td>1.00</td><td>2.35</td><td>0.12</td><td>2.46</td><td>8</td><td>L</td></tr><tr><td>Average, all sites</td><td>1.00</td><td>3.29</td><td>0.85</td><td>4.14</td><td></td><td></td></tr></table>
|
b970f7ebcaaa703c13b76be5539dc6f15a6a6410a7ae0ee1317e6043ef545ae3.png
|
simple
|
<table><tr><td>Year and season</td><td>Mean</td><td>Lower limit (2.50%)</td><td>Median</td><td>Upper limit (97.50%)</td></tr><tr><td><i>2001 - Rainy/Summ</i>er</td><td>0.2286</td><td>0.009099</td><td>0.1516</td><td>0.6998</td></tr><tr><td>2001 - Dry/Winter</td><td>0.7513</td><td>9.63E-04</td><td>0.2329</td><td>5.646</td></tr><tr><td>2002 - Rainy/Summer</td><td>0.03168</td><td>6.83-E-04</td><td>0.0143</td><td>0.1307</td></tr><tr><td><i>2002 - Dry/Winter</i></td><td>0.7903</td><td>0.08158</td><td>0.487</td><td>3.028</td></tr></table>
|
2c2c213c99487c1f52c566430a6d7b738d426613995ff85db3f8fdc562895320.png
|
simple
|
<table><tr><td>Risk Factors</td><td>No. HHV8 Infection/No. Tested (%)</td><td>aORs (95%CI) *</td><td><i>p</i>-values</td></tr><tr><td>Ever injected drugs</td><td></td><td></td><td></td></tr><tr><td>No</td><td>21/145 (14.5)</td><td>1.00</td><td></td></tr><tr><td>Yes</td><td>56/296 (18.9)</td><td>1.50 (0.83–2.69)</td><td>0.181</td></tr><tr><td>Ever sharing syringe</td><td></td><td></td><td></td></tr><tr><td>No</td><td>75/430 (17.4)</td><td>1.00</td><td></td></tr><tr><td>Yes</td><td>2/11 (18.2)</td><td>1.06 (0.20–5.46)</td><td>0.949</td></tr><tr><td>Steady partner</td><td></td><td></td><td></td></tr><tr><td>No</td><td>41/232 (17.7)</td><td>1.00</td><td></td></tr><tr><td>Yes</td><td>36/209 (17.2)</td><td>0.97 (0.55–1.72)</td><td>0.922</td></tr><tr><td>Ever had sex in the past month</td><td></td><td></td><td></td></tr><tr><td>No</td><td>53/288 (18.4)</td><td>1.00</td><td></td></tr><tr><td>Yes</td><td>24/153 (15.7)</td><td>0.85 (0.42–1.71)</td><td>0.650</td></tr><tr><td>Condom use in the last sex intercourse</td><td></td><td></td><td></td></tr><tr><td>Never or no sex</td><td>69/380 (18.2)</td><td>1.00</td><td></td></tr><tr><td>Yes</td><td>8/61 (13.1)</td><td>0.57 (0.21–1.56)</td><td>0.273</td></tr><tr><td>Ever had commercial sex</td><td></td><td></td><td></td></tr><tr><td>No</td><td>69/409 (16.9)</td><td>1.00</td><td></td></tr><tr><td>Yes</td><td>8/32 (25.0)</td><td>6.05 (0.80–45.67)</td><td>0.081</td></tr><tr><td>Frequency of condom use in commercial sex </td><td></td><td></td><td></td></tr><tr><td>Always or no sex</td><td>71/414 (17.1)</td><td>1.00</td><td></td></tr><tr><td>Sometimes</td><td>3/8 (37.5)</td><td>1.59 (0.16–6.12)</td><td>0.120</td></tr><tr><td>Never</td><td>3/19 (15.8)</td><td>0.72 (0.06–8.32)</td><td>0.790</td></tr><tr><td>HIV</td><td></td><td></td><td></td></tr><tr><td>No</td><td>77/439 (17.5)</td><td>-</td><td></td></tr><tr><td>Yes</td><td>0/2 (0.0)</td><td>-</td><td>-</td></tr><tr><td>HCV</td><td></td><td></td><td></td></tr><tr><td>No</td><td>32/170 (18.8)</td><td>1.00</td><td></td></tr><tr><td>Yes</td><td>45/271 (16.6)</td><td>0.82 (0.48–1.41)</td><td>0.476</td></tr><tr><td>Syphilis</td><td></td><td></td><td></td></tr><tr><td>No</td><td>76/429 (17.7)</td><td>1.00</td><td></td></tr><tr><td>Yes</td><td>1/12 (8.3)</td><td>0.50 (0.06–4.09)</td><td>0.519</td></tr></table>
|
b83a71e7f03c1cc9dc61769cc106498b27e9dfad7fefbe29bc2f4a2b3700a71a.png
|
complex
|
<table><tr><td></td><td colspan="3">Prakasam district</td><td colspan="3">Azamgarh district</td></tr><tr><td></td><td>Sex worker</td><td>Casual unpaid partner</td><td>Any partner<sup>#</sup></td><td>Sex worker</td><td>Casual unpaid partner</td><td>Any partner<sup>#</sup></td></tr><tr><td></td><td>%</td><td>%</td><td>%</td><td>%</td><td>%</td><td>%</td></tr><tr><td>Total sample size</td><td>633</td><td>633</td><td>633</td><td>639</td><td>639</td><td>639</td></tr><tr><td>Migrants who never had sex</td><td>75.0</td><td>44.9</td><td>42.0</td><td>75.9</td><td>54.1</td><td>48.8</td></tr><tr><td>Migrants who initiated sex in place of origin</td><td>9.8</td><td>42.5</td><td>43.4</td><td>7.5</td><td>42.7</td><td>43.7</td></tr><tr><td>Migrants who initiated sex in place of destination</td><td>15.2</td><td>12.6</td><td>14.5</td><td>16.6</td><td>3.1</td><td>7.5</td></tr><tr><td>p-value</td><td><0.001</td><td><0.001</td><td><0.001</td><td><0.001</td><td><0.001</td><td><0.001</td></tr><tr><td>Number who initiated sex in place of origin</td><td>62</td><td>269</td><td>275</td><td>48</td><td>273</td><td>279</td></tr><tr><td>Had sex in destination after initiating at place of origin [total]</td><td>59.7</td><td>39.4</td><td>46.9</td><td>49.0</td><td>23.5</td><td>47.7</td></tr><tr><td><i>Had sex in destination only</i></td><td>19.4</td><td>6.7</td><td>6.9</td><td>29.2</td><td>2.6</td><td>9.0</td></tr><tr><td><i>Had sex both in destination and in origin during their migration</i></td><td>40.3</td><td>32.7</td><td>40.0</td><td>18.8</td><td>20.9</td><td>38.7</td></tr><tr><td>Had sex in only origin areas during their migration</td><td>16.1</td><td>39.4</td><td>32.7</td><td>43.8</td><td>53.1</td><td>35.5</td></tr><tr><td>Did not have sex in any area during migration after they first had sex before migration</td><td>24.2</td><td>21.2</td><td>20.4</td><td>8.3</td><td>23.4</td><td>16.9</td></tr><tr><td>Number who initiated sex in place of destination</td><td>96</td><td>80</td><td>92</td><td>106</td><td>20</td><td>48</td></tr><tr><td>Had sex in destination areas only but not in origin</td><td>45.8</td><td>56.3</td><td>54.4</td><td>85.9</td><td>75.0</td><td>79.2</td></tr><tr><td>Had sex in both destination and origin areas</td><td>54.2</td><td>43.8</td><td>45.7</td><td>14.2</td><td>25.0</td><td>20.8</td></tr></table>
|
6349d836717b33b7626b93e3ec63f9626582e0c98ac8521bee9e06fe0fda8e98.png
|
simple
|
<table><tr><td>Calcination temperature (°C)</td><td>Time (min)</td><td>Sheet resistance (mΩ/□)</td></tr><tr><td>400</td><td>30</td><td>7.4</td></tr><tr><td>350</td><td>30</td><td>27.2</td></tr><tr><td>300</td><td>30</td><td>41.3</td></tr><tr><td>300</td><td>60</td><td>40.6</td></tr><tr><td>250</td><td>30</td><td>47.6</td></tr><tr><td>250</td><td>60</td><td>45.4</td></tr><tr><td>200</td><td>30</td><td>–</td></tr><tr><td>Non-calcination</td><td>0</td><td>–</td></tr></table>
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.